The Development of Pot-Economical Strategies for the Synthesis of Natural Products and Analogs by Javed, Salim
The Development of Pot-Economical Strategies  




Submitted to the graduate degree program in the Department of Chemistry and  
the Graduate Faculty of the University of Kansas in partial fulfillment of the 
requirements of the degree of Doctor of Philosophy 
 
________________________________ 








Richard S. Givens 
 
________________________________ 




Helena C. Malinakova 
 
 
September 28th, 2016  
Date Defended 
 ii 
The Dissertation Committee for Salim Javed certifies that this is  
the approved version of the following dissertation: 
 
The Development of Pot-Economical Strategies  






















Department of Chemistry 
University of Kansas, September 28th, 2016 
The development of atom-, redox-, step-, and pot-economical methods for the 
efficient synthesis of medicinal drugs, bioactive natural products and their synthetic 
analogs stands at the forefront of modern day organic synthesis and drug discovery. 
In particular, one-pot sequential operations are of prime importance due to their 
efficiency, versatility, and expediency in constructing advanced intermediates, 
polycyclic scaffolds and bioactive natural products. One-pot sequential protocols 
enable the formation of several bonds and stereocenters in a single reaction vessel, 
and minimize the need for workup and chromatographic procedures between 
intermediary steps, thus saving time and reducing chemical waste generation in 
multistep syntheses of bioactive target molecules.  
Previous studies in our group have focused on the development and utilization 
of one-pot sequential protocols for the synthesis of (–)-tetrahydrolipstatin and 
strictifolione. The focus of this dissertation is the development and implementation of 
one-pot sequential operations for the streamlined syntheses of α,β-unsaturated 
macrocycles, bioactive natural products and their synthetic analogs.  Chapter-1 is a 
literature review focused on recent application of one-pot sequential protocols in 
natural product and drug synthesis. 
 iv 
Chapter-2 is work carried out in the course of this dissertation that is focused 
on the synthesis of functionalized and structurally diverse α,β-unsaturated 14-
membered macrocycles. A series of one-pot sequential protocols was developed for 
the synthesis of novel macrocycles bearing α,β-unsaturated chemotypes. The method 
highlights a phosphate tether-mediated approach to establish asymmetry, and 
consecutive one-pot sequential processes to access the macrocycles with minimal 
purification procedures. This library amenable strategy provided diverse macrocycles 
containing α,β-unsaturated carbon-, sulfur-, or phosphorus-based warheads.  
Chapter-3 outlines our work on a pot-economical total synthesis of antifungal 
natural product Sch-725674 and structural analogs. The approach takes advantage of 
a number of one-pot sequential transformations, including a phosphate tether-
mediated one-pot sequential RCM/CM/ chemoselective hydrogenation protocol, a 
one-pot tosylation/ acrylation sequence, and a one-pot sequential Finkelstein reaction/ 
Boord olefination/ acetonide deprotection procedure to streamline the synthesis route 
by reducing isolation and purification procedures, thus saving time. Overall, an 
asymmetric route has been developed that is efficiently accomplished in seven pots 
from phosphate (S,S)-triene and with minimal purification.  
Chapter 4 describes our ongoing efforts toward the asymmetric total synthesis 
of (–)-13-desmetnyl-lyngbouilloside an unnatural analog of lyngbouilloside. The key 
reactions involved in the synthesis of 13-desmethyl-lyngbouilloside are one-pot 
sequential RCM/CM/ chemoselective hydrogenation, regio- and diastereoselective 
cuprate addition followed by tether removal, Pd-catalyzed reductive allylic 
 v 
transposition, Roskamp homologation, Boeckaman acylketen cyclization, Julia 
olefination and glycosylation. Thus far, we were able to accomplish the synthesis of 
macrolactone core of (–)-13-desmetnyl-lyngbouilloside. Further studies towards the 
completion of the molecule are underway. Chapter 5 is a compilation of the 

















To my parents for loving me and supporting me 





I would like to acknowledge my family members first, my parents and my 
siblings for their unconditional love, true and great support through out this journey. 
Especially my mother, who herself was unable to attend school, but she provided all 
the possible opportunities for me and for my siblings to get better and quality 
education. I would like to acknowledge my wife whose support, love and care helped 
me stay focused during my PhD. I am also very grateful for all the prayers and 
supports of my wife’s family. I would also acknowledge my little, one-year-old 
daughter “Areesha Salim”, who is the constant source of happiness and joy for me in 
stressed times.  
I would like to thank my advisor Prof. Paul R. Hanson for guiding and 
supporting me over the years.  Paul, you have set an example of excellence as a 
research advisor, mentor, instructor, and a role model for me. Your enthusiasm for 
research, and teaching is incredible, although sometimes it was not easy for me to set 
in 6 hours super long meetings four days a week. But at the end of the day, I agree 
that I have learned a lot in those meeting not only regarding my thesis projects, but 
also it was an invaluable source of useful information regarding organic chemistry, 
medicinal chemistry and biology. Thank you for believing in me, encouraging me and 
teaching me not to give up under any circumstances. I am very grateful for all that 
you have done and still doing for me. I would like acknowledging Dr. Yumi for being 
very supportive throughout the years, for her hospitality at thanksgiving, Christmas 
Eve and so many other occasions, making Lawrence home for us. I am also very 
 viii 
grateful to Paul’s parents for treating us as family.  
I would like to take this opportunity to extend my sincere gratitude to my 
committee members, Prof. Jon Tunge, Prof. Helena C. Malinakova and Prof. Berl R. 
Oakley for their help, guidance, cooperation and support.  I would like to thank Prof. 
Rich Givens for his help regarding my Oral proposal and for reviewing and 
corrections in my dissertations. I am also very grateful to all the faculty members in 
the chemistry department for their kind support, guidance and advice. I would like to 
acknowledge and appreciate the help of other research groups in Malott Hall, 
including all of the Tunge group members and Clift group members. I am grateful to 
Justin and Sarah for their help in NMR experiments and data interpretation. I would 
like to acknowledge our front office staffs, Susan, Beth, Beverly, Ruben, Dan and 
Donnie for their help and support.  
I would like to express my special appreciation and thanks to my professors at 
HEJ Research Institute, specially Prof. Fatima Z. Basha and Dr. Anwar Basha, who 
provided me this opportunity to peruse my education in the United States. I greatly 
appreciate their continuous help and support all these past years. I am also very 
grateful to Prof. Shabir Ahamd and Prof. Rasool khan for their moral support and 
encouragement. 
I would like to thank all the former and present Hanson group members for 
providing me their useful feedback regarding my practice talks, oral proposal and 
reviewing my dissertations. I would like to appreciate the cooperation and 
collaboration of Mahipal Bodugam, Jessica Torres and Arghya Ganguly. I would like 
 ix 
to acknowledge Qin Zang (for his guidance and training, when I joined the Hanson 
group), Naeem Asad, Kashif Ali, Jung Ho, Saqib Faisal, Pradip Maity, Maria A. 
Khan, Andie Cassity, Gihan Dissanayake, Corn Ndi, Jay ja (our cricket score board) 
and Viena Thomas for the useful discussion regarding chemistry and experiments in 
the lab. I would like to acknowledge Dr. Patrick Kearney for his help and useful 
feedbacks while I was writing my oral proposal and this dissertation.  
Finally, I would like to acknowledge my friends here in Lawrence, KS, USA 
specially Saqib Faisal and his family, Shah Saud, Danyal Ijaz, Hashim Raza, Adnan 
sab and their families for inviting me at different occasions. I am also very grateful to 
all my friends including Javed Ali, Abbas Hassan, Shah Hassan, Muazzam khan, M. 
Rashid, Asif, Emel khan and M. Alam back in Pakistan for their moral support and 
encouragement through out my Ph.D. 
   
 x 
The development of pot economical strategies for the  
synthesis of natural products and analogs  
 
CONTENTS         Page # 
Title Page             i 
Acceptance Page            ii 
Abstract              iii 
Acknowledgments              vii 
Table of Contents               x 
Abbreviations              xvi 
 
Chapter 1: One-pot Sequential Protocols for the Synthesis of 
Medicinal Compounds, Natural Products and Their Corresponding 
Analogs          1 
 
1.1. Introduction          2 
1.2. Development of one-pot sequential protocols by Clarke and coworkers 5 
1.2.1. Synthesis of functionalized tetrahydropyran-4-ones and substituted 
piperid-4-ones using the Pot, Atom and Step Economy (PASE)  
principle          5 
 
1.3. Application of one-pot sequential protocols for the synthesis of bioactive 
natural products and medicinal drugs by Hayashi and coworkers 6 
 
1.3.1. Synthesis of (–)-oseltamivir via a sequence of three one-pot sequential 
operations        6 
 
1.3.2. One-pot synthesis of ABT–341     9 
1.3.3. Synthesis of (–)-oseltamivir via a one-pot sequential operation 10 
 xi 
1.3.4. Synthesis of prostaglandin A1 and E1 Methyl Esters through a 
sequence of three one-pot sequential operations   11 
 
1.3.5. Synthesis of (–)-horsfiline and (–)-coerulescine alkaloids  13 
1.3.6. One-pot synthesis of (S)-baclofen     14 
1.4. Application of one-pot sequential protocols for the synthesis of 
telcagepant          15 
 
1.5. One-pot sequential protocol in the enantioselective total synthesis of 
epoxyisoprostanes         17 
 
1.6. Application of one-pot, sequential, L-proline catalyzed, a-
amination/propargylation in the synthesis of (–)-epiquinamide  18 
 
1.7. Enantioselective synthesis of (+)-fusarisetin A     19 
1.8. Phosphate tether-mediated one-pot sequential protocols for the synthesis 
of polyol containing bioactive natural products by Hanson and coworkers 
          21 
 
1.8.1. Application of one-pot sequential operation in the total synthesis of 
(–)-tetrahydrolipstatin        22 
 
1.8.2. Application of one-pot sequential RCM/CM/“H2” protocol for the 
syntheses of advanced polyols subunits    23 
 
1.8.3. Asymmetric total synthesis of (+)-strictifolione via three one-pot, 
sequential reactions       24 
 
1.8.4. Syntheses of complex polyol containing scaffolds via one-pot 
sequential RCM/CM/“H2” followed by reductive tether removal 25 
 
1.8.5. Synthesis of macrolactone core of lyngbouilloside   27 
1.8.6. Synthesis of C9–C25 subunit of spirastrellolide B   29 
 xii 
1.8.7. Synthesis of α,β-unsaturated macrocycles via consecutive 4-to-6 one-
pot sequential operations (Chapter-2)     31 
 
1.8.8. Pot-economical approach for the total synthesis of Sch-725674 and 
corresponding analogs (Chapter-3)     32 
 
1.8.9. Synthetic studies towards total synthesis of (–)-13-desmethyl-
lyngbouilloside (Chapter-4)      35 
 
1.9. Conclusion         36 
1.10. Special Acknowledgment       37 
1.11. References Cited        38 
Chapter 2: Modular Synthesis of Novel Macrocycles Bearing α,β-
Unsaturated Chemotypes via a Series of One-pot, Sequential 
Processes          48 
 
2.1. Introduction         49 
2.2. Previous strategies for the syntheses of medium to large-size  
heterocycles         51 
2.2.1. Synthesis of medium- and large-sized rings via Build/Couple/Pair 
(B/C/P) strategy        52 
 
2.2.2. Synthesis of macrolactones and macrolactams via oxidative ring 
expansion strategy       53 
 
2.2.3. A diversity-oriented synthesis of functionalized macrocyclic scaffolds 
via multidimensional coupling strategy     55 
 
2.2.4. Organo- and metal-catalyzed synthesis of drug-like macrocyclic 
scaffolds         56 
 
2.2.5. Synthesis of diverse medium to large-macrocycles via Successive Ring 
Expansion (SuRE) strategy       57 
 xiii 
 
2.3. Results and discussions        58 
2.3.1. Rational design       60 
2.3.2. Synthesis of 14-membered macrolactone 2.3a and  
macrosultone 2.3b       61 
 
2.3.3. Synthesis of 14-membered macrolactam 2.3d and macrosultam 2.3e 
analogs         68 
 
2.3.4. Synthesis of 14-membered macrophostone 2.3c and macrophostam 
2.3f analogs        72 
 
2.4. Conclusion         74 
2.5. Special Acknowledgment       75 
2.6. References Cited        76 
Chapter 3: Pot-Economical Approach for the Total Synthesis of  
Anti-fungal Natural Product Sch-725674 and Corresponding 
Analogs         89 
3.1. Introduction         90 
3.1.1. Sch-725674 and related natural products    91 
3.2. Overview of previous total synthesis of Sch-725674 (3.1f)   92 
3.2.1. Synthesis of sixteen-stereoisomers library of  
Sch-725674 using a fluoros tagging strategy    93 
 
3.2.2. An asymmetric synthesis of macrolactone core of Sch-725674 94 
3.2.3. An enantioselective total synthesis of Sch-725674   96 
3.2.4. An asymmetric total synthesis of Sch-725674   98 
3.2.5. Formal total synthesis of Sch-725674    99 
 xiv 
3.3. Results and discussion       100 
3.3.1. Proposed retrosynthetic analysis of Sch-725674   100 
3.3.2. Forward synthesis of Sch-725674     101 
3.4. A pot-economical approach for the total syntheses of  
Sch-725674 analogs        106 
 
3.4.1. Syntheses of macrolactone 3.1g and macrolactam 3.1h analogs of  
Sch-725674        107 
 
3.4.2. Syntheses of amine substituted macrolactones 3.1i and 3.1j  111  
3.4.3. Synthesis of amine substituted macrolactam 3.1k   112 
3.5. Conclusion          113 
3.6. Special Acknowledgment       113 
3.7. References Cited        114 
Chapter 4: Efforts Towards the Asymmetric Total Synthesis of  
(–)-13-Desmethyl-lyngbouilloside, an Unnatural Analog of 
Lyngbouilloside                120 
4.1. Introduction         121 
4.2. Overview of previous efforts toward the syntheses of (–)-lyngbouilloside 
(4.1a)          123 
 
4.2.1. Stereoselective synthesis of the C1–C13 fragment of (–)-
lyngbouilloside        123 
 
4.2.2. Enantioselective synthesis of the lyngbouilloside macrolactone core
          125 
 
4.2.3. Asymmetric total synthesis of (–)-lyngbouilloside aglycon  127 
 xv 
4.2.4. Phosphate tether-mediated synthesis of macrolactone  
core of (–)-lyngbouilloside              130 
 
4.3. Isolation, biological activity and total synthesis of (–)-lyngbyaloside B 
(4.1d) reported by the Fuwa group      133 
 
4.3.1. Total synthesis of (–)-13-desmethyl-lyngbyaloside B          134 
4.3.2. Total synthesis and biological evaluation of (–)-lyngbyaloside 
B and its analogs               136 
 
4. 4. Results and Discussion       140 
4.4.1. Retrosynthetic analysis of (–)-13-desmethyllynbouilloside (4.1c)  140 
4.4.2. Forward synthesis of (–)-13-desmethyl-lynbouilloside (4.1c)  141 
4.5. Conclusion         145 
4.6. References Cited        147 




aq      aqueous 
AcCl     acetyl chloride 
AcOH     acetic acid 
Bn      benzyl 
BnBr      benzyl bromide 
brsm      based on recovered starting material 
9-BBN     9-Borabicyclo(3.3.1)nonane 
BOPCl     bis(2-oxo-3-oxazolidinyl)phosphonic chloride 
t-BuOH     t-Butanol 
CHCl3     chloroform 
CuI      copper iodide 
cat.      catalytic 
COSY     correlation spectroscopy 
C      carbon 
ClCH2CO2H    dimethylformamide 
Cs2CO3     cesium carbonate 
Cl      chlorine 
NaOAc    sodium acetate 
Fmoc     fluorenylmethyloxycarbonyl chloride 
CsCl     caesium chloride 
Cbz     carboxybenzyl 
 xvii 
CM      cross metathesis 
CuBr      copper bromide 
CuI      copper iodide 
DABCO     1,4-Diazabicyclo[2.2.2]octane 
DBU      1,8-diazabicycloundec-7-ene 
DBAD     Di-tert-butyl azodicarboxylate 
DCM (CH2Cl2)    dichloromethane 
DCE      1,2-Dichloroethane 
DIAD      diisopropyl azodicarboxylate 
DIPEA/Hünig’s base    N,N'-Diisopropylethylamine 
DMAP     4-(dimethylamino)pyridine 
DMF     dimethylformamide 
Me2SO4     dimethylsulfate 
Et      ethyl 
Et2O      diethyl ether 
EtOAc     ethyl acetate 
EDC (EDCI)     1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
G-I      Grubbs’ first generation catalyst 
G-II      Grubbs second-generation catalyst 
GC      gas chromatography 
HG-II      Hoveyda-Grubbs second generation catalyst 
HRMS     high-resolution mass spectrometry 
 xviii 
h      hours 
HCl     hydrochloric acid 
Hz      hertz 
IR      infrared radiation 
i-Bu      isobutyl 
i-Pr      isopropyl 
LiOH      lithium hydroxide 
LiCl     lithium chloride 
LCMS     liquid chromatography–mass spectrometry 
M      molarity 
MeCN     acetonitrile 
H2O2     hydrogen peroxide 
Me      methyl 
MeOH     methanol 
MeI      methyl iodide 
Mmol      millimole(s) 
MOM      methoxymethyl- 
MsCl      methanesulfonyl chloride 
NaHCO3     sodium bicarbonate 
NMO      N-methylmorpholine-N-oxide 
NMR      nuclear magnetic resonance 
NH3     ammonia 
 xix 
NaClO2    sodium chlorite 
NaBH4     sodium borohydride 
NIH      National Institute of Health 
NaH2PO4    monosodim phosphate 
nBuLi      n-butyllithium 
OMe      methoxy 
o-NBSH     o-nitrobenzene sulfonyl hydrazine 
PMB      para-methoxybenzyl 
ppm      parts per million 
Ph      phenyl 
PCy3      tricyclohexylphosphine 
PTSA      p-toluenesulfonic Acid 
K2CO3     potassium carbonate 
RCM      ring closing metathesis 
Rt/RT      room temperature 
sat.      saturated 
NaOtBu     sodium tert-Butoxide 
NaHMDS     sodium hexamethyldisilazide 
NaOH      sodium hydroxide 
Na2SO4     sodium sulfate 
TBACl     tetrabutyl ammonium chloride 
TBAF      tetrabutyl ammonium fluoride 
 xx 
TIPS      triisopropylsilyl- 
TBDPS     tert-butyl(diphenyl)silyl- 
TBS      tert-butyl(dimethyl)silyl- 
TMSCl    trimethylsilyl chloride 
TMSOTf    trimethylsilyl tirfluoromethanesulfonate 
PCC     pyridinium chlorochromate 
Pd(OAc)2    palladium (II) acetate 
Pd(OH)2    palladium hydroxide 
TFA      trifluoroacetic acid 
K3PO4     tripotassium phosphate 
PPh3      triphenylphosphine 
tolSH     toluenethiol 
TLC      thin layer chromatography 
TiCl4     titanium tetrachloride 
EtOH     ethanol 
t-Bu      tert-butyl 
Et3N      triethylamine 
THF      tetrahydrofuran 
2,2-DMP     dimethoxypropane 
PPTS      pyridinium p-toluenesulfonate 
LLS      longest linear sequence 
TSC      total step count 
 xxi 
Yb(OTf)3    ytterbium (II) tirfluoromethanesulfonate  
TOS      target oriented synthesis 
Si      silicon 
IC50      inhibitory concentration at 50% 
Me2Zn     dimethylzinc 
DDQ      2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
Boc      tert-butyloxycarbonyl 
DOS      diversity oriented synthesis 
NBS      N-bromosuccinimide 
NaOAc•3H2O    sodium acetate trihydrate 




















One-pot Sequential Protocols for the Synthesis of  





The development of atom-,1 redox-,2 step-,3 and pot-economical4 strategies to 
access advanced intermediates for the synthesis of medicinal drugs, bioactive natural 
products and analogs stands at the forefront of modern-day synthesis and drug discovery. 
In particular, one-pot reaction protocols are of prime importance due to their efficiency, 
versatility, and expediency in constructing densely functionalized advanced 
intermediates, 5 , 6  polycyclic ring systems 7  and bioactive natural products.4 One-pot 
reaction protocols enable the formation of several bonds and stereocenters in a single 
reaction vessel. These efficient processes reduce the need for workup and 
chromatographic separations between intermediary steps, thus saving time and 
minimizing waste generation in multistep syntheses of bioactive target molecules.8, 9, 10 A 
basic keyword search using Sci-Finder unveils the historic development of one-pot 
reaction protocols over the past few decades. 11  The number of scientific reports 
containing the concept “one-pot reaction” has increased significantly between 1980 and 
2015 (Figure 1.1b). Although, the number of articles containing the concept “one-pot 
reaction” steadily grew between 1980–2000, the last fifteen years (2000–2015) in the 
literature among the synthetic community has seen immense popularity of one-pot 
reaction protocols. Moreover, Hayashi and coworkers have recently developed methods, 
which enhance the number of reactions that can be performed in one-pot protocols, vide 
infra. This work has inspired efforts in this dissertation to develop chemistry aimed at the 
streamlined synthesis of macrocyclic natural products and their corresponding analogs 
via the use of a series of one-pot sequential protocols. 
One-pot reaction protocols are broadly divided into two main categories i.e one-
 3 
pot multicomponent, whereby all components are added at the beginning domino/cascade 
reactions are a subset of this category and one-pot sequential reactions 
(components/reagents are added sequentially). Historically, one-pot processes such as 
Passerini12 and Ugi reactions13 first reported in 1921 and 1959, respectively, have 
dominated the one-pot literature.  
 
Figure 1.1. a) One-pot reaction protocols for the syntheses of natural products and 
medicinal compounds. b) Number of scientific reports containing the keyword “one-pot 
reaction” from 1980–2015. (Data were attained via keyword search using Sci-Finder.)  
Tietze proposed the term “domino reactions” for one-pot processes and defined 





















bonds (usually C–C bonds) under the same reaction conditions without the addition of 
additional reagents and catalysts, and in which the subsequent transformations occur as a 
consequence of the functionality formed in the prior reactions. A 2014 review on the 
concept of domino reactions by Tietze and coworkers (as well as earlier reviews), 
highlights the vast arsenal of tandem and cascade processes that have been developed for 
the total synthesis of natural products and analogs.14 Nicolaou described in his 2006 
review titled “ Cascade Reactions in Total Synthesis” that these descriptions for the one-
pot processes are comparatively interchangeable.15 One-pot reactions (domino/cascade 
reactions) are extensively studied and have been reviewed multiple times in the 
literature.4a-b,12,15,16 The second category known as “one-pot sequential reactions” is 
underexplored and recently started gaining popularity both in the synthetic community 
and in industry.  
In 2007, Clarke and coworkers introduced the concept of combining Pot-, Atom- 
and Step-Economy (PASE) in organic synthesis, which refers to the completion of 
sequential reactions in a single flask without the need for workup and purification 
between steps.17 The authors suggested that PASE syntheses are green in nature as they 
have the potential to (i) reduce the number of synthetic pots, which in turn minimizes the 
number and amount of reagents needed, (ii) reduce the amount of solvents in reactions, 
workup, and chromatographic purifications, and (iii) reduce waste and contaminants 
generated from cleaning equipment and glassware. 
Since 2009, the aforementioned elegant efforts by Hayashi and coworkers have 
been of particular note for the use of consecutive one-pot sequential procedures (i.e a 
series of one-pot protocols) to complete multi-reaction syntheses of (–)-oseltamivir,18 
 5 
Dpp4-selective inhibitor ABT-341, 19  prostaglandin A1 and E1 methyl esters, 20  (–)-
horsfiline, (–) coerulescine21 and (S)-baclofen.22 Inspired by this body of work, Hanson 
and coworkers have utilized the "one-pot paradigm" in a number of phosphate tether-
mediated one-pot sequential protocols for the syntheses of (–)-tetrahydrolipstatin,23 
strictifolione24 and Sch-725674.25  Moreover, they have applied this concept in the 
generation of diverse α,β-unsaturated 14-membered macrocycles bearing carbon-, sulfur- 
and phosphorus-based warheads.26 It is the purpose of this chapter to compile a brief 
account of the recent literature on the use of one-pot sequential protocols for the synthesis 
of advanced intermediates,6,7 medicinal compounds,18,19,20 selected bioactive natural 
products and their corresponding analogs.  
1.2. Development of one-pot sequential protocols by Clarke and coworkers 
1.2.1. Syntheses of functionalized tetrahydropyran-4-ones and substituted piperid-
4-ones using the Pot, Atom and Step Economy (PASE) principle 
In 2007, Clarke and coworkers employed the PASE principle to synthesize a 
series of highly substituted tetrahydropyran-4-ones (THPs) (1.1.4–1.1.6) (Scheme 1.1).17a 
These one-pot sequential processes began with a Lewis acid-catalyzed addition of 
diketene 1.1.1 to an aldehyde in the presence of Schiff base 1.1.2. The resulting 
enantiomerically pure aldol adducts 1.1.3 subsequently underwent Knoevenagel 
condensation with a second aldehyde, followed by an intramolecular Michael reaction in 
the same pot to afford functionalized tetrahydropyran-4-ones(1.1.4). Taken collectively, 
the authors were able to synthesize highly substituted THPs (1.1.4–1.1.6) in moderate to 
good overall yields and good to excellent enantioselectivities (Scheme 1.1). 
 Similarly in 2008, Clarke and coworkers reported the synthesis of highly 
substituted piperid-4-ones 1.1.10 using a one-pot, four-component condensation approach 
 6 
(Scheme 1.1).17d The sequence involved Lewis acid (TiCl4)-catalyzed diketene 1.1.1 
addition to a tosyl imine 1.1.7 to furnish the aldol adduct 1.1.8. The crude product was 
subsequently treated with one equivalent of aldehyde in MeOH to afford a cis/trans-
diastereomeric mixture of substituted piperid-4-ones 1.1.9 in good yield. The mixture of 
diastereomers was efficiently converted to a single diastereomer of piperid-4-ones 1.1.10 
by epimerization under basic conditions. The authors suggested that this robust method 
would enable access to a diverse range of substituted piperid-4-ones 1.1.10 in good yield 
by employing a variety of different coupling partners. 
Scheme 1.1. PASE synthesis of tetrahydropyran-4-one and piperidines. 
 
1.3. Application of one-pot sequential protocols in the synthesis of bioactive 
natural products and medicinal drugs by Hayashi and coworkers 
1.3.1. Synthesis of (–)-oseltamivir via a sequence of three one-pot sequential 
operations 
 In 2009, Hayashi and coworkers reported the synthesis of (–)-oseltamivir utilizing 
three one-pot operations (Scheme 1.2).18 (–)-Oseltamivir phosphate (Tamiflu®) is a 
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 7 
influenza.27 The authors accomplished the synthesis of (–)-oseltamivir using a sequence 
of three one-pot processes requiring only one-purification procedure. The first one-pot 
operation began with an asymmetric organocatalytic Michael addition of aldehyde 1.2.1 
to nitroalkene 1.2.2 using diphenylprolinol silyl ether as a catalyst,28 furnishing the 
adduct 1.2.3 in quantitative yield and high enantioselectivity.  
Scheme 1.2. Synthesis of (–)-oseltamivir via three one-pot operations. 
 
Next, the authors performed a Michael reaction between 1.2.3 and vinylphosphonate 
1.2.4, followed by an intramolecular Horner-Wardsworth-Emmons (HWE) reaction, and 
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cyclohexane 1.2.6 in 70% yield over three reactions in one pot. The tert-butyl ester 1.2.6 
obtained after purification was deprotected with trifluoroacetic acid (TFA), which 
afforded carboxylic acid 1.2.7. 
The crude carboxylic acid was transformed to the corresponding acyl azide 1.2.8 
over a sequence of two reactions in one-pot consisting of addition of oxalyl chloride 
followed by sodium azide in aqueous acetone at 0 ºC. The acyl azide 1.2.8 was 
subsequently converted to amide 1.2.9 via Curtius rearrangement by treating the azide 
1.2.8 with acetic acid and acetic anhydride at room temperature. Next, the nitro group in 
1.2.9 was reduced to an amine (1.2.10) using zinc and TMSCl in EtOH at 70 ºC. Finally, 
the crude product 1.2.10 was treated with K2CO3 to enable the retro-Michael reaction of 
the thiol moiety affording (–)-oseltamivir (1.2.11) in 82% yield.  
The salient features of Hayashi's (–)-oseltamivir synthesis include; i) a single pot 
assembly of a fully functionalized ethylcyclohexenecarboxylate intermediate 1.2.6 with 
required stereochemical configuration, ii) use of a second pot for the deprotection of tert-
butyl ester, as well as transfer of the crude acid 1.2.7 to the next pot without further 
purification, iii) utilization of a sequence of three reactions in the third pot involving 
Curtius rearrangement/reduction of the nitro group to an amine/retro-Michael reaction of 
the thiol, which completed the synthesis of the target molecule. Overall, this efficient 
synthesis comprised of nine reactions, which were performed in a sequence of three one-
pot sequential operations to accomplish the synthesis of (–)-oseltamivir from the 
commercially available nitroalkene 1.2.2 in 57% overall yield. In 2010 and 2011, 
Hayashi and coworkers further streamlined the synthesis of (–)-oseltamivir by developing 
a consecutive two-pot sequence that consisted of eleven reactions with 60% overall yield 
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and only two workup and purification procedures.18b,c  
1.3.2. One-pot synthesis of ABT–341 
 In 2011, Hayashi and coworkers disclosed a one-pot synthesis of ABT-341,19 a 
potent orally bioavailable DPP4-selective inhibitor (Scheme 1.3). Similar to the synthesis 
of (–)-oseltamivir,18 the one-pot synthesis of ABT-341 commenced with an 
enantioselective Michael addition of an acetaldehyde to nitroalkene 1.3.1 in the presence 
of diphenylprolinol silyl ether as an organocatalyst to afford adduct 1.3.2. The resulting 
nitroalkene 1.3.2 underwent a successive Michael addition with vinylphosphonate 1.3.3, 
followed by a Horner–Wadsworth–Emmons reaction (HWE) reaction to afford the 
cyclized product 1.3.4a. The successive reaction for the formation of chiral cyclohexene 
carboxylic acid 1.3.5 was the epimerization of the α position of the nitroalkane, which 
was not proceeding in the presence of Cs2CO3.  
In order to solve this problem, TMSCl was added to the crude reaction mixture, 
which reacted with the solvent (EtOH) to generate HCl. The in situ-generated HCl 
reacted with Cs2CO3 to provide insoluble CsCl. After quenching the Cs2CO3, addition of 
i-Pr2EtN cleanly promoted the isomerization process, which was followed by tert-butyl 
ester deprotection using TFA to afford the cyclohexene carboxylic acid 1.3.5 with the 
desired stereochemistry. The crude carboxylic acid was subjected to o-(benzotriazol-1-
yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate (TBTU)-mediated coupling with 
amine 1.3.6 to furnish amide 1.3.7. The nitro group in amide 1.3.7 was reduced to 
corresponding amine using Zn and AcOH. Overall, the synthesis of ABT-341 was 
completed in 63% yield over a sequence of nine reactions in one-pot.  
 10 
Scheme 1.3. One-pot sequential protocol for the synthesis of ABT-341. 
 
1.3.3. Synthesis of (–)-oseltamivir via a one-pot sequential operation 
As a further refinement of one-pot sequential protocols, Hayashi and coworkers reported 
a one-pot synthesis of (–)-oseltamivir (1.2.11) in 2013.29 This one-pot synthesis of 1.2.11 
commenced with diphenylprolinol silyl ether-mediated asymmetric Michael reaction of 
α-alkoxyaldehyde 1.4.1 with trans-nitroalkene 1.4.2. The rest of the synthesis of (–)-
oseltamivir is a slight modification of the previously reported three-pot synthetic 
sequence by Hayashi and coworkers, which is discussed in detail in section 1.3.1 
(Scheme 1.2). The advantages of the aforementioned one-pot sequential operations are 
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and chromatographic purification was required for the synthesis of 1.2.11. In addition, 
this one-pot procedure demonstrates the power of a carefully designed one-pot sequential 
protocol which enabled the synthesis of a stereochemically complex {(–)-oseltamivir} on 
a gram scale (1.2 g) in 28% overall yield. 
Scheme 1.4. One-pot synthesis of (–)-oseltamivir.  
 
1.3.4. Synthesis of prostaglandin A1 and E1 methyl esters through a sequence of 
three one-pot sequential operations 
Two years later, in 2013 Hayashi and coworkers reported an enantioselective total 
synthesis of prostaglandin A1 (PGA1) (1.5.8) and E1 (PGE1) methyl esters (1.5.9) in 25% 
and 14% overall yield, respectively (Scheme 1.5).20 The forward synthesis began with 
organocatalytic asymmetric Michael addition of aldehyde 1.5.2 to nitroalkene 1.5.1 to 
furnish the aldehyde 1.5.3. The crude product 1.5.3 was subsequently subjected to an 
intramolecular Henry reaction facilitated by i-Pr2EtN,30 which afforded the corresponding 
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of 1.5.4 with alkylphosphonate 1.5.5 in the same pot to afford the desired α,β-unsaturated 
ketone 1.5.6.  
Scheme 1.5. Three-pot synthesis of prostaglandin A1 and E1 methyl esters.  
 
Diastereoselective reduction of the α,β-unsaturated ketone functionality in 1.5.6 
using (–)-diisopinocampheyl chloroborane (DIPCl) afforded the alcohol 1.5.7 in 68% 
yield (dr = 96:4), completing the skeleton of prostaglandin with all the necessary carbon 
atoms. It is noteworthy to mention that protection of hydroxyl group in 1.5.7 was not 
required, thus avoiding additional protection/deprotection reactions. The resulting alcohol 
1.5.7 was subjected to a one-pot sequential dehydration by using acidic alumina and 
double bond isomerization to afford the 2-nitrocyclopentene. The crude 2-
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novel transformation of the nitro group in 1.5.7 to a carbonyl functionality using Nef 
reaction conditions.31 Subsequently, the authors epimerized the α-side chain from cis to 
trans orientation with respect to the ω-side chain in 1.5.7. Without quenching, the 
reaction mixture was neutralized with TMSCl and then a base-mediated epoxidation was 
performed. The resulting epoxy ketone was subsequently treated with Zn and aqueous 
NH4Cl to afford the PGE1 methyl ester (1.5.9) in 14% overall yield.  
In summary the syntheses of both PGA1 (1.5.8) and PGE1 methyl esters (1.5.9) 
were accomplished in three one-pot sequential operations from inexpensive and simple 
starting materials. This short synthetic route involved only three isolations and three 
purification events, which greatly facilitated the syntheses of both the prostaglandin A1 
(1.5.8) and E1 methyl ester and (1.5.9).  
1.3.5. Synthesis of (–)-horsfiline and (–)-coerulescine alkaloids 
The next year, in 2014, Hayashi and coworkers reported the synthesis of  
(–)-horsfiline and (–)-coerulescine alkaloids via three one-pot sequential operations in 
33% and 46% overall yields, respectively (Scheme 1.6).21 The forward synthesis 
commenced with a DBU-catalyzed aldol reaction of commercially available isatin 
derivatives 1.6.1 and 1.6.2 with formaldehyde and was followed by dehydration to afford 
an E/Z mixture of olefins 1.6.5 and 1.6.6 in 90% and 81% yields, respectively. The 
aldehydes 1.6.5 and 1.6.6 were next subjected to an enantioselective conjugate addition 
of nitromethane to furnish the corresponding Michael adducts 1.6.7 and 1.6.8 with all 
quaternary-carbon stereogenic centers. Zn was added to the crude reaction mixture and 
was followed by AcOH and water to reduce the nitro groups in 1.6.7 and 1.6.8 to the 
corresponding amines. The amines subsequently underwent intramolecular reductive 
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amination to afford the pyrrolidinone spirocycles. Next, N-methyl substitution was 
carried out by simple addition of formaldehyde to the crude reaction mixture to afford 
1.6.9 and 1.6.10 in moderate to good yields. Finally, benzyl deprotection with Na/NH3 at 
–78 ºC completed the syntheses of (–)-horsfiline and (–)-coerulescine in a three-pot 
sequence with 33% and 46% overall yields, respectively. 
Scheme 1.6. Thee-pot synthesis of (–)-horsfiline and (–)-coerulescine alkaloids. 
 
1.3.6. One-pot synthesis of (S)-baclofen 
In 2016, Hayashi and coworkers accomplished the synthesis of (S)-baclofen 
(1.7.7) from commercially available starting materials 1.7.1 and 1.7.2 over a sequence of 
four reactions in one-pot (Scheme 1.7).22 The one-pot sequential operation began with 
DBU-catalyzed aldol condensation between p-chlorobenzaldehyde 1.7.1 and 
acetaldehyde 1.7.2, which afforded the corresponding α,β-unsaturated aldehyde 1.7.4 
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4 rxns one-pot
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desired aldehyde 1.7.4 via retro-acetalization and dehydration reactions at 50 ºC. The 
crude product 1.7.4 was subjected to organocatalytic asymmetric Michael reaction at 
room temperature to afford the nitroalkane 1.7.5. Subsequent transformations were 
performed in the same pot: Karus-Pinnick oxidation32 afforded the carboxylic acid 1.7.6 
and Raney Ni reduced the nitro group in 1.7.6, completing the synthesis of (S)-baclofen 
(1.7.7) in 31% yield in one-pot.  
Scheme 1.7. One-pot synthesis of the (S)-baclofen (1.7.7). 
 
1.4. Application of one-pot sequential protocols for the synthesis of telcagepant  
In 2010, researchers at Merck Research Laboratories reported a pot-economical 
synthesis of telcagepant, a CGRP-receptor antagonist33 for the treatment of migraines.34 
The authors accomplished the synthesis of the crucial intermediate 1.8.7 via a three-step 
sequence consisting of two one-pot sequential operations (Scheme 1.8). The first one-pot 
operation involved four reactions to enable the synthesis of aldehyde 1.8.5. The synthesis 
began with 1,2-addition of acrolein to commercially available 1,2-difluorobenzene 1.8.1 
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corresponding cinnamyl alcohol 1.8.3. The crude product 1.8.3 was subsequently 
converted to the corresponding α,β-unsaturated aldehyde 1.8.4 using TEMPO oxidation 
and the resulting aldehyde was subsequently subjected to an asymmetric Michael reaction 
using nitromethane to afford  the aldehyde 1.8.5 in one-pot with 48% overall yield (88% 
av/rxn). Next, the authors subjected the aldehyde 1.8.5 to the Doebner-Knoevenagel 
reaction 35  to afford the homologated enamine 1.8.6, which was isolated as the 
tributylammonium salt 1.8.7 using n-Bu3N and i-PrOAc in 93% yield.  
Scheme 1.8. Pot-economical synthesis of telcagepant. 
 
Upon successful synthesis of the core chiral framework 1.8.7, the authors applied 












































































































telcagepant potassium salt, EtOH solvate (1.8.12)
> 99.8% purity, >99.9%ee
 17 
followed by trifluoroethylation of the resulting crude amine 1.8.8. Subsequent hydrolysis 
of the ester functionality in 1.8.8 furnished carboxylic acid 1.8.9. The crude product 1.8.9 
was cyclized to produce the substituted ε-lactam 1.8.11 in 73% overall yield (dr. 95.5:1). 
The diastereoslectivity of the newly generated centers in 1.8.11 was controlled by 
dynamic epimerization/crystallization. The synthesis of telcagepant (1.8.12) was 
completed according to known literature procedures in a one-pot, two-step reaction 
sequence in 79% yield.34 Throughout the synthesis of this therapeutic agent (telcagepant), 
only three intermediates were isolated, and no chromatographic procedures were 
necessary. 
1.5. One-pot sequential protocol in the enantioselective total synthesis of 
epoxyisoprostanes  
 In 2015, Lu and coworkers developed a pot-economical approach for the 
stereoselective synthesis of epoxyisoprostanes (Scheme 1.9).36 Toward this goal, the 
forward synthesis began with a one-pot sequential organocatalytic Michael reaction of 
methyl acetoacetate 1.9.1 with fumaraldehyde 1.9.2 to afford aldehyde 1.9.3. The crude 
aldehyde was subsequently subjected to Wittig olefination reaction to afford alkene 
fragment 1.9.4 with 72% yield in one-pot. Olefin 1.9.4 was subjected to a second one-pot 
reaction sequence consisting of hydrolysis of the methyl ester in 1.9.4, followed by 
decarboxylation of the resulting β-ketoacid to afford ketone fragment 1.9.5. The acetal 
protecting group in crude 1.9.5 was deprotected using Amberlyst-15 to furnish 
ketoaldehyde 1.9.6 in 77% yield via two reactions in one-pot with 99% ee. The 
ketoaldehyde 1.9.6 was subjected to an intramolecular aldol condensation reaction using 
N-benzylcinchoninium chloride to afford the cyclopentenone 1.9.7 in 30% yield. The 
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resulting enone 1.9.7 was subjected to a one-pot, three-reaction sequence consisting of an 
intermolecular aldol reaction to install the side chain 1.9.8,37 mesylation, and trans-
selective elimination to afford target molecule 1.9.10 in 63 % yield.  
Scheme 1.9. Enantioselective total synthesis of epoxyisoprostanes. 
 
1.6. Application of one-pot sequential L-proline-catalyzed, α-amination 
/propargylation in the synthesis of (–)-epiquinamide 
In 2016, Sudalai and coworkers reported an enantioselective formal total 
synthesis of (–)-epiquinamide (1.10.6) (Scheme 1.10).38 The forward synthesis of 1.10.6 
commenced with monobenzylation of commercially available 1,6-hexanediol 1.10.1 
followed by a selective oxidation of the unprotected alcohol in 1.10.1 using PCC to 
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proline-catalyzed one-pot sequential α-amination/propargylation reaction to afford the 
anti-amino alcohol in 79% yield. The resulting amino alcohol was brominated with NBS 
to furnish alkyne bromide 1.10.3. Intramolecular hydroalkoxylation39 of 1.10.3 using 
AuCl3 as a catalyst in toluene/water afforded γ-butyrolactone 1.10.4 in 78% yield.  The γ-
butyrolactone was treated with Raney Ni and H2 in MeOH, which led to cleavage of the 
N–N bond with simultaneous deprotection of the benzyl group. The resulting free amine 
underwent intramolecular opening of the lactone to generate a stable six-membered 
lactam, which was subsequently mesylated to afford the dimesylated fragment 1.10.5 in 
91% yield. Advanced fragment 1.10.5 was converted to the final natural product (–)-
epiquinamide (1.10.6) as reported in the literature.40 
Scheme 1.10. A formal enantioselective synthesis of (–)-epiquinamide using a one-pot 
sequential α-amination/propargylation sequence. 
 
1.7. Enantioselective synthesis of (+)-fusarisetin A  
In 2016, Zhang and coworkers reported a concise, asymmetric total synthesis of 
(+)-fusarisetin A (1.11.6) (Scheme 1.11).41 Toward this goal, the authors developed a 
one-pot, four-reaction sequence involving intramolecular Diels−Alder (IMDA) 
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reaction/Mukaiyama aldol/desilylation/oxidation, which efficiently afforded the 
tetracyclic core 1.11.5 of the natural product 1.11.6. The forward synthesis of fusarisetin 
A began with the synthesis of intermediate 1.11.1 from known starting material in 3 
linear steps.41 The triene 1.11.1 was subjected to an IMDA reaction using TMSOTf as 
Lewis acid to afford the aldehyde fragment 1.11.2. The crude aldehyde was subsequently 
subjected to a Mukaiyama-aldol reaction to generate tetracyclic compound 1.11.4. 
Without further purification, the tetracyclic compound was converted to lactone 1.11.5 
via a sequential treatment with HF•Py at 0 ºC and PCC at room temperature. Overall, 
tetracyclic lactone intermediate 1.11.5 was obtained in a one-pot process consisting of 
four reactions with 43% overall yield. Purified tetracyclic lactone intermediate 1.11.5 was 
converted to (+)-fusarisetin A after a few additional synthetic transformations.41 
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1.8. Phosphate tether-mediated one-pot sequential protocols for the synthesis of 
polyol containing bioactive natural products by Hanson and coworkers 
 As part of an ongoing program, recent efforts in the Hanson group are devoted to 
the development of one-pot sequential processes for the syntheses of polyol-containing 
intermediates, 1,3-diol-containing bioactive natural products, and their corresponding 
analogs (Figure 1.2).  
 
Figure 1.2. Phosphate tether-mediated one-pot sequential processes for the syntheses of 
bioactive natural products and corresponding analogs. 
To date, one-pot sequential protocols have been successfully employed in the synthesis of 
(–)-tetrahydrolipstatin (1.2a, anti-obesity drug),23 (+)-strictifolione (1.2b, antifungal),24 
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Sch-725674 (1.2d, antifungal) (Figure 1.2).25 More recently, we reported an efficient 
synthesis of the C9–C25 subunit of spirastrellolide B (1.2e)43 and a modular synthesis of 
a diverse range of functionalized novel α,β-unsaturated macrocycles (1.2f–k)26 using 
one-pot sequential operations. In addition, we have implemented one-pot sequential 
operations in the syntheses of simplified analogs of Sch-725674 (1.2l–p) and 13-
desmethyl-lyngbouilloside (1.2q) (Figure 1.2). 
1.8.1. Application of one-pot sequential operations in the total synthesis of (–)-
tetrahydrolipstatin 
 In 2010, Hanson and coworkers reported a concise synthesis of  
(–)-tetrahydrolipstatin (an anti-obesity drug) in 11 linear steps starting from readily 
prepared (S,S)-triene 1.12.144  (Scheme 1.12).23 In this efficient synthesis, the authors 
employed a phosphate tether-mediated one-pot sequential protocol. The sequence 
consisted of ring-closing metathesis, cross metathesis, and chemoselective hydrogenation 
(RCM/CM/“H2”) 6 reactions for the synthesis of bicyclic phosphate 1.12.3 from readily 
prepared (S,S)-triene 1.12.1 and commercially available 1-undecene as a CM partner. 
This one-pot sequence began with an RCM reaction of (S,S)-triene 1.12.1 using HG-II 
catalyst45 (3 mol%) in refluxing CH2Cl2, which afforded the bicyclic phosphate. The 
crude product was subsequently subjected to a CM reaction using the HG-II catalyst (10 
mol%) and 1-undecene CM partner to afford the bicyclic phosphate 1.12.2. Without 
further purification and solvent change, the CM adduct 1.12.2 was subjected to 
chemoselective reduction of the external olefin in 1.12.2 by using o-NBSH and Et3N 
(2mL/1g of o-NBSH). This one-pot three-reaction sequence furnished the bicyclic 
phosphate 1.12.3 in 40% yield (75% av/rxn). The purified bicyclic phosphate 1.12.3 
served as an advanced intermediate for the synthesis of (–)-tetrahydrolipstatin (1.12.4). 
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Scheme 1.12. Application of one-pot sequential RCM/CM/“H2” protocol in the synthesis 
of (–)-tetrahydrolipstatin, 1.2a. 
 
1.8.2. Application of one-pot sequential RCM/CM/“H2” protocol for the syntheses 
of advanced polyols subunits 
To extend the applicability of the aforementioned phosphate tether-mediated one-
pot sequential RCM/CM/“H2” protocol, Hanson and co-workers were focused to 
optimize the reaction conditions for this efficient one-pot process to obtain better yields 
for the final products (Scheme 1.13).6 In this regard, the authors screened different 
solvents, catalysts, additives, and a variety of type I, II and III olefins for CM. After 
investigating various reaction conditions, moderate to good yields of the final products 
1.13.4–1.13.9 were obtained for the one-pot sequential RCM/CM/“H2” operation by 
using HG-II, freshly freeze-degas-thawed (FDT) DCM and DCE as solvents. Overall, 
this one-pot, three-reaction protocol can be utilized to streamline the syntheses of 1,3-
skipped-polyol-containing scaffolds, bioactive natural products, and their corresponding 
analogs.  
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Scheme 1.13. One-pot sequential RCM/CM/hydrogenation. 
 
1.8.3. Asymmetric total synthesis of (+)-strictifolione via three one-pot sequential 
protocols 
In 2014, Hanson and coworkers developed a pot-economical and library amenable 
approach for the asymmetric total synthesis of (+)-strictifolione (1.2b) and a related 
natural product (1.14.9) (Scheme 1.14).24 The forward syntheses of 1.2b and 1.14.9 
began with the synthesis of bicyclic phosphates 1.14.2 and 1.14.6 via one-pot sequential 
RCM/CM/“H2”6 protocol from the corresponding phosphate triester-(R,R)-1.13.1 and -
(S,S)-1.12.7,44 respectively. The bicyclic phosphates 1.14.2 and 1.14.6 were subsequently 
subjected to another one-pot sequential Pd-catalyzed, reductive allylic 
transposition/methylation/tether removal protocol to afford advanced 1,3-anti diol 
fragments 1.14.3 and 1.14.7, respectively. The resulting diols 1.14.3 and 1.14.7 were 
transferred via cannula to the next pot without further purification. The solvent was 





































































followed by addition of the HG-II catalyst. The CM reaction afforded the final natural 
products 1.2b and 1.14.9 in moderate to good yields. Overall, both natural products were 
efficiently accessed in three one-pot sequential operations from readily prepared 
phosphate triesters 1.13.1 and 1.12.1, respectively. 
Scheme 1.14. Three-pot synthesis of (+)-strictifolione and a related natural product. 
 
 
1.8.4. Syntheses of complex polyol containing scaffolds via one-pot sequential 
RCM/CM/“H2” followed by reductive tether removal 
In 2014, Hanson and coworkers developed a divergent, efficient and modular 
approach for the syntheses of polyol-containing scaffolds 1.15.6–1.15.10.5 The key 
reactions involved in the syntheses of these polyols were a phosphate tether-mediated 
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one-pot sequential RCM/CM/“H2” operation and a reductive tether removal (Scheme 
1.15). The divergent aspect of this method was introduced by simply switching of CM 
partners 1.15.2 and 1.15.3 in the cross metathesis reactions to accomplish the syntheses 
of five different polyols subunits 1.15.6–1.15.10 starting from the three coupling partners 
1.15.1, 1.15.2 and 1.15.3. As shown in Scheme 1.15, coupling of mono-chlorophosphate 
(S,S)-1.15.1 with alcohol 1.15.3 furnished the phosphate triester (S,S)-1.15.4.  
Scheme 1.15. Synthesis of stereodiverse polyols via phosphate tether-mediated one-, two-
pot sequential RCM/CM/reduction protocol.  
 
The resulting triene-(S,S)-1.15.4 was further diversified by using two one-pot 
sequential processes: one-pot RCM/CM/“H2” protocol and reductive tether removal to 
afford the tetraol subunit 1.13.6 in 26% yield over two-pots (4 reactions, 71% av/rxn). 
Accordingly, triene 1.15.5 was coupled with alcohol 1.15.2 through a one-pot sequential 
RCM/CM/“H2” operation, followed by reductive tether removal using LiAH4 to generate 
polyol 1.15.7 in 24% yield over two-pots and four reactions (70% average per reaction). 
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In similar fashion, the authors were able to synthesize the polyol subunits 1.15.8–1.15.10 
utilizing a one-pot sequential RCM/CM/“H2” followed by phosphate tether removal. 
1.8.5. Synthesis of macrolactone core of lyngbouilloside 
In 2015, Hanson and coworkers reported a concise synthetic pathway for the 
synthesis of the macrolactone core of the originally assigned structure of lyngbouilloside 
(Scheme 1.16).Error! Bookmark not defined. The key reactions involved in the synthesis of 
macrolactone core 1.16.7 are one-pot sequential RCM/CM/“H2”, Roskamp 
homologation, and Boeckman acylketene cyclization. Toward this goal, CM partner 
1.16.1 was synthesized in 9 steps from commercially available geraniol. Next, the authors 
subjected the (R,R)-triene 1.13.1 and CM partner 1.16.1 to a phosphate tether-mediated 
one-pot sequential RCM/CM/“H2” protocol to afford the bicyclic phosphate 1.16.2 in 
65% yield over three reactions in one-pot.  
With bicyclic phosphate 1.16.2 in hand, the authors performed Pd-catalyzed, 
reductive allylic transposition, followed by methylation of the resulting phosphoric acid, 
and reductive tether removal to afford the 1,3 anti-diol fragment 1.16.3 in 76% yield. The 
free alcohols of 1,3 anti-diol fragment 1.16.3 were silyl-protected using TESOTf and 2,6-
lutidine to generate intermediate 1.16.4 in excellent yield. The terminal olefin in 1.16.4 
was subjected to oxidative cleavage, employing the modified Johnson-Lemieux protocol 
developed by Jin and coworkers,46 to afford the corresponding aldehyde. The crude 
aldehyde with out further purification was subjected to Roskamp homologation47 to 
afford the β-keto ester 1.16.5 in 76% yield over two steps with only one purification 
procedure. PMB-deprotection of the tertiary alcohol in 1.16.5 afforded the cyclization 
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precursor 1.16.6 in 98% yield. The tertiary alcohol 1.16.6 was subjected to Boeckman 
acylketene cyclization conditions48 to accomplish the synthesis of macrolactone core of 
lyngbouilloside in excellent yield. Further studies towards the completion of the molecule 
are underway. 
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1.8.6. Synthesis of C9–C25 subunit of spirastrellolide B 
In 2016, Hanson and coworkers reported an efficient synthesis of C9–C25 subunit 
1.2e of the marine natural product spirastrellolide B (Figure 1.3).Error! Bookmark not defined. 
The key synthetic features include the union of the two key fragments 1.3a and 1.3b via a 
Suzuki-Miyaura coupling reaction. A late-stage one-pot deprotection/cascade 
Achmatowicz rearrangement–spiroketalization sequence to install the key spirocyclic 
intermediate present in the C9–C25 fragment of spirastrellolide B. The synthesis of the 
C9–C16 fragment 1.3b was accomplished via a phosphate tether-mediated one-pot 
sequential RCM, a subsequent hydroboration-oxidation protocol, followed by 
stereoselective transformations in a facile manner. The spirocyclic intermediate was 
further functionalized by employing a Lindlar/NaBH4 reduction protocol to accomplish 
the C9–C25 subunit 1.2e of spirastrellolide B. 
 
Figure 1.3. Retrosynthetic analysis of the C9–C25 subunit of spirastrellolide B. 
The forward synthesis of the C9–C25 subunit 1.2e began with the synthesis of the 
C9–C16 polyol-containing fragment 1.3b (Scheme 1.17), whereby, the triene phosphate 

















































regard, the triene (R,R)-1.13.1 was treated with G-II (3 mol%) and the resulting bicyclic 
phosphate was exposed to BH3•DMS, followed by oxidation with sodium perborate to 
afford alcohol 1.17.1 in 31% yield over three reactions in one pot (56% average per 
reaction, not optimized). Subsequent benzyl protection of the primary alcohol with BnBr 
and Ag2O afforded 1.17.2. The bicyclic phosphate 1.17.2 was treated with in-situ-
generated dimethyl cuprate, followed by reductive removal of the phosphate tether to 
provide diol 1.17.3 and install the C14-methyl group in regio- and diastereoselective 
fashion. Diol 1.17.3 was protected as an acetal to generate 1.17.4 in 87% yield, and 
subsequent cross metathesis of 1.17.4 with commercially available pinacol vinylboronate 
successfully furnished the intermediate 1.3b in quantitative yield (98%). 
The synthesis of C17–C25 fragment 1.3a was accomplished in seven linear steps 
from commercially available (S)-Roche ester. With key fragments 1.3a and 1.3b in hand, 
a Suzuki-Miyaura coupling reaction of bromofuran 1.3a with vinylboronate 1.3b in the 
presence of Pd(PPh3)4 and K3PO4 furnished the coupling product in moderate yield 
(50%). Diimide reduction of the resulting olefinic bond using excess o-NBSH and Et3N 
generated Achmatowicz-cyclization precursor 1.17.5 in 84% yield. With advanced 
intermediate 1.17.5 in hand, acetal deprotection using catalytic camphorsulfonic acid 
(CSA, 10 mol%), followed by cascade Achmatowicz-spiroketalization (m-CPBA, then 
CSA), furnished the required spiroketal-containing diol 1.17.6 in 51% yield over three 
reactions in one pot (80% av/rxn). Global TBS-protection with TBSOTf and 2,6-lutidine, 
followed by C–C double bond reduction with H2 and Lindlar catalyst furnished the 
ketone. Diastereoselective reduction (ds = 88%) of the resultant ketone with NaBH4, 
afforded the C9–C25 fragment of spirastrellolide B (1.2b) in 82% yield over two 
 31 
reactions. 
Scheme 1.17. Efficient synthesis of C9–C25 fragment of spirastrellolide B. 
 
1.8.7. Synthesis of α,β-unsaturated macrocycles via consecutive 4-to-6, one-pot 
sequential operations (Chapter 2) 
 Chapter 2 of this dissertation describes a concise synthesis of novel macrocycles 
possessing α,β-unsaturated chemotypes that employ a series of one-pot sequential 
protocols (Scheme 1.18).26 This efficient and library amenable approach utilizes four to 
six consecutive one-pot sequential processes, highlighting phosphate tether-mediated 
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k in good to excellent yields from readily prepared (R,R)-triene 1.13.1 and CM partner 
1.18.1.49. A notable merit of the method is the application of multiple consecutive pot-
economical operations that significantly avoid workup and purification procedures 
between successive reactions, reducing operational time and waste generation. The 
synthesis of these structurally diverse α,β-unsaturated macrocycles will be discussed in 
detail in chapter-2 of this dissertation. 
Scheme 1.18. Syntheses of α,β-unsaturated macrocycles via a sequence of four-to-six 
one-pot sequential processes. 
 
1.8.8. Pot-economical approach for the total synthesis of Sch-725674 and 
corresponding analogs (Chapter 3) 
Chapter 3 of this dissertation describes a pot economical approach for the 
asymmetric synthesis of antifungal natural product Sch-725674 (Scheme 1.19).25 The key 
structural features of this natural product include a 14-membered ring, an E-configured 
α,β- unsaturated ester, a lipophilic n-pentyl side chain, and a 1,3-anti-diol moiety 



























































This approach takes the advantage of a number of one-pot sequential transformations 
including one-pot sequential RCM/CM/“H2” protocol, a one-pot tosylation/acrylation 
sequence, a one-pot sequential Finkelstein reaction/Boord olefination/acetonide-
deprotection, and final RCM/MOM-deprotection sequence. These one-pot sequential 
operations streamlined the synthesis route by reducing isolation and purification 
procedures, thus saving time. Overall, an asymmetric route has been developed that was 
efficiently accomplished to synthesize Sch-725674 in seven pots from phosphate (S,S)-
triene 1.12.1 and CM partner 1.19.1 with minimal purification procedures.  
Scheme 1.19. Pot-economical, asymmetric syntheses of Sch-725674. 
 
We anticipated that the outlined pot-economical and library amenable approach 
for the synthesis of Sch-725674 can be further exploited for the synthesis of a diverse 
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Sch-725674 (Figure 1.4). The key reactions involved in the synthesis of Sch-725674 
analogs (1.2l–p) were one-pot sequential RCM/CM/“H2”, regio- and diastereoselective 
cuprate addition, one-pot sequential protecting group manipulation, one-pot sequential 
Mitsunobu/reduction/acrylation and a final RCM/deprotection sequence. Employing 
these one-pot sequential protocols, we were able to accomplish the synthesis of five 
structurally diverse analogs (1.2l–p) in a rapid, efficient, and pot-economical manner 
with amine, alcohol and α,β-unsaturated lactone/lactam functionality incorporated in 
them. All five Sch-analogs have been submitted for antifungal and antibacterial screening 
to our collaborators.  
 




















































Total reactions = 12
Purification procedures = 6
workup = 7
Total reactions = 10
Purification procedures = 5
workup = 6
Total reactions = 12
Purification procedures = 5
workup = 6
Total reactions = 12
Purification procedures = 6
workup = 7
Total reactions = 12
Purification procedures = 6
workup = 7
Total reactions = 14









1.8.9. Synthetic studies toward the total synthesis of (–)-13-desmethyl-
lyngbouilloside (Chapter 4) 
 
  Chapter 4 of this dissertation describes the asymmetric total synthesis of (–)-13-
desmethyl-lyngbouilloside, an unnatural analog of lyngbouilloside (Scheme 1.20). The 
forward synthesis of (–)-13-desmethyl-lyngbouilloside commenced with phosphate 
tether-mediated one-pot sequential RCM/CM/ chemoselective hydrogenation to couple 
(S,S)-triene 1.12.1 and CM 1.20.1, followed by regio- and diastereoselective cuprate 
addition to the resulting bicyclic phosphate 1.20.2. The resulting 1,3-anti diol was 
subjected to a one-pot regioselective TIPS-protection, followed by MOM-protection, to 
afford the stereotriad-bearing subunit 1.20.3. With CM partner 1.20.3 in hand, efforts 
were focused on coupling with (R,R)-trien 1.13.1 via an iterative use of one-pot 
sequential RCM/CM/chemoselective hydrogenation, followed by tether removal via Pd-
catalyzed reductive allylic transposition, to furnish the advance fragment 1.20.5. The free 
alcohols in 1,3-anti diol fragment 1.20.5 were protected as benzyl ethers, followed by 
oxidative cleavage of the terminal olefin in 1.20.6 and Roskamp homologation, to afford 
the b-ketoester 1.20.7. TIPS-deprotection using TBAF, followed by Boeckman 
acylketene cyclization to furnish the fully functionalized macrolactone core of (–)-13-




Scheme 1.20. Asymmetric total synthesis of (–)-13-desmethyl-lyngbouilloside 
 
1.9. Conclusion 
In summary, one-pot sequential operations are efficient methods for carrying out 
several bond transformations and stereocenter formations in a single reaction vessel, 
which minimize workup and purification procedures in multistep synthesis to reduce 
chemical waste generation and to save time. Moreover, one-pot sequential protocols are 
not only a useful synthetic method to be adopted for the production of target molecules, 
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but also represent a promising green approach in modern-day organic synthesis. 
Therefore, carefully designed, one-pot sequential reaction protocols are important in 
streamlining the synthesis of target medicinal compounds, bioactive natural products, and 
their corresponding analogs. 
1.10. Special Acknowledgment 
The author acknowledges that portions of this chapter, including the preliminary 
Introduction and Results and Discussion sections are reprinted, in part, or adapted from 
the following publications, with permission from the corresponding publishers: 
(a) Javed, S.; Bodugam, M.; Ganguly, A.; Torres, J.; Hanson, P. R. Modular Synthesis of 
Novel Macrocycles Bearing α,β-Unsaturated Chemotypes via a Series of One-Pot, 
Sequential Protocols. Chem. Eur. J. 2016, 22, 6755–6758. (b) Bodugam, M.; Javed, S.; 
Ganguly, A.; Torres, J.; Hanson, P. R. A Pot-Economical Approach to the Total 
Synthesis of Sch-725674. Org. Lett. 2016, 18, 516–519. (c) Maitra, S.; Bodugam, M.; 
Javed, S. Hanson, P. R. Efficient Synthesis of the C9–C25 Subunit of Spirastrellolide B. 
Org. Lett. 2016, 18, 3094–3097. 
  
 38 
1.11. References Cited 
 
[1] (a) Trost, B. M. The atom economy: a search for synthetic efficiency. Science 
1991, 254, 1471–1477. (b) Trost, B. M. Atom economy - a challenge for organic 
synthesis: homogeneous catalysis leads the way. Angew. Chem. Int. Ed. 1995, 34, 
259–281. 
[2] (a) Young, I. S.; Baran, P. S. Protecting-group-free synthesis as an opportunity for 
invention. Nat. Chem. 2009, 1, 193–205. (b) Hoffmann, R. W. Protecting-group-
free synthesis. Synthesis 2006, 3531–3541. 
[3]  Wender, P. A.; Verma, V. A.; Paxton, T. J.; Pillow, T. H. Function-Oriented 
Synthesis, Step Economy, and Drug Design. Acc. Chem. Res. 2008, 41, 40–49. 
[4] (a) Hong, B. C.; Raja, A.; Sheth, V. M. Asymmetric Synthesis of Natural 
Products and Medicinal Drugs through One-Pot-Reaction Strategies. Synthesis 
2015, 47, 3257–3285. (b) Albrecht, L.; Jiang, H.; Jorgensen, K. A. A Simple 
Recipe for Sophisticated Cocktails: Organocatalytic One-Pot Reactions-Concept, 
Nomenclature, and Future Perspectives. Angew. Chem. Int. Edit. 2011, 50, 8492–
8509. (c) Hayashi, Y. Pot economy and one-pot synthesis. Chem. Sci. 2016, 7, 
866–880. (d) Vaxelaire, C.; Winter, P.; Christmann, M. One-Pot Reactions 
Accelerate the Synthesis of Active Pharmaceutical Ingredients. Angew Chem Int 
Edit 2011, 50, 3605-3607. 
[5] Hanson, P. R.; Jayasinghe, S.; Maitra, S.; Ndi, C. N.; Chegondi, R. A modular 
phosphate tether-mediated divergent strategy to complex polyols. Beilstein J. Org. 
Chem. 2014, 10, 2332–2337. 
[6] Venukadasula, P. K. M.; Chegondi, R.; Suryn, G. M.; Hanson, P. R. A Phosphate 
Tether-Mediated, One-Pot Sequential Ring-Closing Metathesis/Cross-
Metathesis/Chemoselective Hydrogenation Protocol. Org. Lett. 2012, 14, 2634–
2637. 
[7] Liu, C.; Zeng, Z.; Chen, R.; Jiang, X.; Wang, Y.; Zhang, Y. Total Synthesis 




[8]  (a) Ishikawa, H.; Suzuki, T.; Hayashi, Y. High-Yielding Synthesis of the Anti-
Influenza Neuramidase Inhibitor (–)-Oseltamivir by Three “One-Pot” Operations. 
Angew. Chem. Int. Ed. 2009, 48, 1304–1307. (b) Ishikawa,H.; Suzuki, T.; Orita, 
H.; Uchimaru, T.; Hayashi, Y. High-Yielding Synthesis of the Anti-Influenza 
Neuraminidase Inhibitor (–)-Oseltamivir by Two “One-Pot” Sequences Chem. 
Eur. J. 2010, 12616–12626. (c) Ishikawa, H.; Bondzic, B. P.; Hayashi, Y. 
Synthesis of (–)-Oseltamivir by Using a Microreactor in the Curtius 
Rearrangement. Chem. Eur. J. 2011, 6020–6031. 
[9] Ishikawa, H.; Honma, M.; Hayashi, Y. One-Pot High-Yielding Synthesis of the 
DPP4-Selective Inhibitor ABT-341 by a Four-Component Coupling Mediated by 
a Diphenylprolinol Silyl Ether. Angew. Chem. Int. Edit. 2011, 50, 2824–2827. 
[10] Umemiya, S.; Hayashi, Y. Pot Economy in the Synthesis of Prostaglandin A1 and 
E1 Methyl Esters. Angew. Chem. Int. Ed. 2013, 52, 3450. 
[11] Scifinder available at: https://scifinder.cas.org. 
[12] (a) Baker, R. H.; LINN, L. E. The Passerini reaction; optically active anilides. J. 
Am. Chem. Soc. 1948, 70, 3721–3723. (b) Giustiniano, M.; Novellinoa, E.; Tron, 
G. C. Nitrile N-Oxides and Nitrile Imines as New Fuels for the Discovery of 
Novel Isocyanide-Based Multicomponent Reactions. Synthesis 2016 48, 2721–
2731. (c) Rotstein, B. H.; Zaretsky, S.; Rai, V.; Yudin, A. K. Small Heterocycles 
in Multicomponent Reactions. Chem. Rev. 2014, 114, 8323–8359. 
[13] (a) Plant, A.; Thompson, P.; Williams, D. M. Application of the Ugi Reaction for 
the One-Pot Synthesis of Uracil Polyoxin C Analogues. J. Org. Chem. 2009, 74, 
4870–4873. (b) Mossetti, R.; Pirali, T.; Saggiorato D. s.; Tron G. C. Imides: 
forgotten players in the Ugi reaction. One-pot multicomponent synthesis of 
quinazolinones. Chem. Commun. 2011, 47, 6966–6968. (c) Hartung, A.; Seufert, 
F.; Berges, C.; Gessner, V. H.; Holzgrabe U. One-Pot Ugi/Aza-Michael Synthesis 
of Highly Substituted 2,5-Diketopiperazines with Anti-Proliferative Properties. 
Molecules 2012, 17, 14685–14699. (d) Nechaeva, A. A.; Peshkova, A. A.; 
 40 
 
Peshkov, V. A.; Eycken E. V. V. The Application of Multicomponent Ugi and 
Passerini Reactions for the One-Pot Synthesis of Pyrrolones and Butenolides. 
Synthesis 2016, 48, 2280–2286. (e) Su, Y.; Bouma, M. J.; Alcaraz, L.; Stocks, M.; 
Furber, M. Masson, G.; Zhu J. Organocatalytic Enantioselective One-Pot Four-
Component Ugi-Type Multicomponent Reaction for the Synthesis of Epoxy-
tetrahydropyrroloACHTUNGTRENUNG[3,4-b]pyridin-5-ones. Chem. Eur. J. 
2012, 18, 12624–12627. (f) Voit, B. Sequential One-Pot Reactions Using the 
Concept of “Site Isolation” Angew. Chem. Int. Ed. 2006, 45, 4238–4240. 
[14] (a) Sebren, L. J.; Devery, J. J.; Stephenson, C. R. J. Catalytic Radical Domino 
Reactions in Organic Synthesis. Acs Catal. 2014, 4, 703–716. (b) Tietze, L. F. 
Domino Reactions in the Total Synthesis of Natural Products. Domino Reactions 
2014, 579–610. (c) Lutz F. Tietze, F. L. Rackelmann N. Domino reactions in the 
synthesis of heterocyclic natural products and analogs. Pure Appl. Chem. 2004, 
76, 1967–1983. (d) Knoke, M.; de Meijere, A. A versatile access to 1-
cyclopropyl-2-aryl-1,3,5-hexatrienes - Domino Heck-Diels-Alder reactions of 
1,3-dicyclopropyl-1,2-propadiene. Synlett 2003, 195–198. (e) Tietze, L. F., 
Domino reactions in organic synthesis. Chem. Rev. 1996, 96, 115–136. (f) Tietze, 
L. F. Domino Reactions in Organic-Synthesis. Chem. Ind-London 1995, 453–457. 
f) Tietze, L. F.; Bachmann, J.; Wichmann, J.; Burkhardt, O. Domino Reactions in 
Organic-Chemistry - the Knoevenagel Hetero-Diels-Alder Hydrogenation 
Sequence for the Biomimetic Synthesis of Indole Alkaloids Via Strictosidine 
Analogs. Synthesis-Stuttgart 1994, 1185–1194. 
[15] (a) Nicolaou, K. C.; Edmonds D. J.; Bulger. P. G. Cascade Reactions in Total 
Synthesis. Angew. Chem. Int. Ed. 2006, 45, 7134–7186. (b) Nicolaou, K. C.; 
Montagnon T.; Snyder S. A.; Tandem reactions, cascade sequences, and 
biomimetic strategies in total synthesis. Chem. Commun. 2003, 551–564. 
[16] Selected reviews on cascade reactions: (a) Volla, C. M. R.; Atodiresei, I.; 
Rueping, M. Catalytic C–C Bond-Forming Multi-Component Cascade or Domino 
Reactions: Pushing the Boundaries of Complexity in Asymmetric 
Organocatalysis. Chem. Rev. 2014, 114, 2390–2431. (b) Ramachary D. B.; Jain, 
 41 
 
S. Sequential one-pot combination of multi-component and multi-catalysis 
cascade reactions: an emerging technology in organic synthesis. Org. Biomol. 
Chem. 2011, 9, 1277–1300. (c) Grondal, C.; Jeanty M.; Enders, D. 
Organocatalytic cascade reactions as a new tool in total synthesis Nat. Chem. 
2010, 2, 167–178. (d) Denard, C. A.;  Hartwig, J. F.; Zhao, H. Multistep One-Pot 
Reactions Combining Biocatalysts and Chemical Catalysts for Asymmetric 
Synthesis. ACS Catal. 2013, 3, 2856−2864. (e) Mossetti, R.; Pirali, T.; Saggiorato 
D. s.; Tron G. C. Imides: forgotten players in the Ugi reaction. One-pot 
multicomponent synthesis of quinazolinones. Chem. Commun. 2011, 47, 6966–
6968. (f) Dhinakaran, I.; Padmini, V.; Bhuvanesh, N. Chemodivergent, One-Pot, 
Multi-Component Synthesis of Pyrroles and Tetrahydropyridines under Solvent- 
and Catalyst-Free Conditions Using the Grinding Method. ACS Comb. Sci. 2016, 
18, 236−242.  
[17] (a) Clarke, P. A.; Santos, S.; Martin, W. H. C. Combining pot, atom and step 
economy (PASE) in organic synthesis. Synthesis of tetrahydropyran-4-ones. 
Green. Chem. 2007, 9, 438–440. (b) Clarke, P. A.; Zaytzev, A. V.; Whtwoo, A. C. 
Pot, atom and step economic (PASE) synthesis of highly functionalized 
piperidines: a five-component condensation. Tetrahedron Lett. 2007, 48, 5209–
5212. (c) Clarke, P. A.; Zaytsev, A. V.; Whitwood, A. C. Pot, Atom, and Step 
Economic (PASE) Synthesis of Highly Substituted Piperidines: A Five-
Component Condensation. Synthesis-Stuttgart 2008, 3530–3532. (d). Clarke, P. 
A.; Zaytsev, A. V.; Morgan, T. W.; Whitwood, A. C.; Wilson, C. One-pot 
synthesis of functionalized piperid-4-ones: A four-component condensation. Org. 
Lett. 2008, 10, 2877–2880. 
[18]  (a) Ishikawa, H.; Suzuki, T.; Hayashi, Y. High-Yielding Synthesis of the Anti-
Influenza Neuramidase Inhibitor (–)-Oseltamivir by Three “One-Pot” Operations. 
Angew. Chem. Int. Ed. 2009, 48, 1304–1307. (b) Ishikawa,H.; Suzuki, T.; Orita, 
H.; Uchimaru, T.; Hayashi, Y. High-Yielding Synthesis of the Anti-Influenza 
Neuraminidase Inhibitor (–)-Oseltamivir by Two “One-Pot” Sequences Chem. 
Eur. J. 2010, 12616–12626. (c) Ishikawa, H.; Bondzic, B. P.; Hayashi, Y. 
 42 
 
Synthesis of (–)-Oseltamivir by Using a Microreactor in the Curtius 
Rearrangement. Chem. Eur. J. 2011, 6020–6031. 
[19] Ishikawa, H.; Honma, M.; Hayashi, Y. One-Pot High-Yielding Synthesis of the 
DPP4-Selective Inhibitor ABT-341 by a Four-Component Coupling Mediated by 
a Diphenylprolinol Silyl Ether. Angew. Chem. Int. Edit. 2011, 50, 2824–2827. 
[20] Umemiya, S.; Hayashi, Y. Pot Economy in the Synthesis of Prostaglandin A1 and 
E1 Methyl Esters. Angew. Chem. Int. Ed. 2013, 52, 3450. 
[21] Mukaiyama, T.; Ogata, K.; Sato, I.; Hayashi, Y. Asymmetric Organocatalyzed 
Michael Addition of Nitromethane to a 2-Oxoindoline-3-ylidene Acetaldehyde 
and the Three One-Pot Sequential Synthesis of (−)-Horsfiline and (−)-
Coerulescine. Chem. Eur. J. 2014, 20, 13583–13588.  
[22] Hayashi, Y.; Sakamoto, D.; Okamura, D. One-Pot Synthesis of (S)‑Baclofen via 
Aldol Condensation of Acetaldehyde with Diphenylprolinol Silyl Ether Mediated 
Asymmetric Michael Reaction as a Key Step. Org. Lett. 2016, 18, 4. 
[23] Venukadula, P. K.; Chegondi, R.; Maitra, S.; Hanson, P. R. A Concise, 
Phosphate-Mediated Approach to the Total Synthesis of (-)-Tetrahydrolipstatin 
Org. Lett. 2010, 12, 1556–1559. 
[24] Jayasinghe, S.;  Venukadula, P. K.; Hanson, P. R. An Efficient, Modular 
Approach for the Synthesis of (+)-Strictifolione and a Related Natural Product 
Org. Lett. 2014, 16, 122–125. 
[25] Bodugam, M.; Javed, S.; Ganguly, A.; Torres, J.; Hanson, P. R. A Pot-
Economical Approach to the Total Synthesis of Sch-725674. Org. Lett. 2016, 18, 
516–519. 
[26] Javed, S.; Bodugam, M.; Ganguly, A.; Torres, J.; Hanson, P. R. Modular 
Synthesis of Novel Macrocycles Bearing α,β-Unsaturated Chemotypes via a 
Series of One-Pot, Sequential Protocols. Chem. Eur. J. 2016, 22, 6755–6758.  
[27]  For review on the synthesis of Tamiflu, see (a) Farina, V.; Brown, J. D. Tamiflu: 
The supply problem. Angew. Chem. Int. Edit. 2006, 45, 7330–7334. (b) Shibasaki, 
 43 
 
M.; Kanai, M. Synthetic strategies for oseltamivir phosphate. Eur. J. Org. Chem. 
2008, 1839–1850. 
[28] For selected reviews on organocatalysis, see: (a) Dalko, P. I.; Moisan, L. In the 
Golden Age of Organocatalysis. Angew. Chem. Int. Ed. 2004, 43, 5138–5175. (b) 
List, B. The ying  and  yang  of  asymmetric aminocatalysis. Chem. Comm. 2006, 
819–824. (c) Marigo, M.; Jørgensen, K. A. Organocatalytic direct asymmetric α-
heteroatom functionalization ofaldehydes and ketones. Chem. Comm. 2006, 
2001–2011. (d) Gaunt, M. J.; Johansson, C. C. C.; McNally, A.; Vo, N. T. Drug 
Discov. Today 2007, 12, 8–16 (e) Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, 
B. Asymmetric Enamine Catalysis. Chem. Rev. 2007, 107, 5471–5569. (f) 
MacMillan, D.W. C. The advent and development of organocatalysis. Nature 
2008, 455, 304–308.  
[29] (a) Mukaiyama, T.; Ishikawa, H.; Koshino, H.;  Hayashi, Y. One-Pot Synthesis of 
(–)-Oseltamivir and Mechanistic Insights into the Organocatalyzed Michael 
Reaction. Chem. Eur. J. 2013, 17789–17800. (b) Hayashi, Y.; Ogasawara, S. 
Time Economical Total Synthesis of (−)-Oseltamivir. Org. Lett. 2016, 18, 3426–
3429. 
[30] Hayashi, Y.; Okano, T.; Aratake, S.; Hazelard, D. Angew. Chem. Int. Ed. 2007, 
46, 4922–4925. 
[31] Ballini, R.; Petrini, M. Recent synthetic developments in the nitro to carbonyl 
conversion (Nef reaction). Tetrahedron 2004, 60, 1017–1047. 
[32] (a) Kraus, G. A.; Taschner, M. J. Model studies for the synthesis of quassinoids. 
1. Construction of the BCE ring system. J. Org. Chem. 1980, 45, 1175–1176. (b) 
Kraus, G. A.; Roth, B. Synthetic studies toward verrucarol. 2. Synthesis of the AB 
ring system. J. Org. Chem. 1980, 45, 4825–4830. 
[33] For lead references, see: (a) Durham, P. L. Headache 2006, 46 (suppl 1), S3. (b) 




[34] Xu, F.; Zacuto, M.; Yoshikawa, N.; Desmond, R.; Hoerrner, S.; Itoh, T.; Journet, 
M.; Humphrey, G. R.; Cowden, C.; Strotman, N.; Devine, P. Asymmetric 
Synthesis of Telcagepant, a CGRP Receptor Antagonist for the Treatment of 
Migraine. J. Org. Chem. 2010, 75, 7829–7841. 
[35]  (a) List, B.; Doehring, A.; Fonseca, M. T. H.; Jobb, A.; Torresa, R. R. A 
Practical, efficient, and atom economic alternative to the Wittig and Horner–
Wadsworth–Emmons reactions for the synthesis of (E)-α,β-unsaturated esters 
from aldehydes. Tetrahedron 2006, 62, 476–482. (b) Corey, E. J. The Mechanism 
of the Decarboxylation of α,β- and β,γ-Unsaturated Malonic Acid Derivatives and 
the Course of Decarboxylative Condensation Reactions in Pyridine. J. Am. Chem. 
Soc. 1952, 74, 5897–9705. (c) Corey, E. J. The Decarboxylation of α,β-
Unsaturated Malonic Acid Derivatives via β,γ-Unsaturated Intermediates. II. The 
Effect of α-Substituents upon Product Composition and Rate. J. Am. Chem. Soc. 
1953, 75, 1163–1167.  
[36]  Weng, J.; Wang, S.; Huang, L. J.; Luo, Z. Y.; Lu, G. Stereoselective synthesis of 
epoxyisoprostanes: an organocatalytic and "pot-economy'' approach. Chem. 
Commun. 2015, 51, 10170–10173. 
[37]  (a) Marigo, M.; FranzeÅLn, J.; Poulsen, T. B.; Zhuang W.; Jorgensen, K. A. 
Asymmetric Organocatalytic Epoxidation of α,β-Unsaturated Aldehydes with 
Hydrogen Peroxide. J. Am. Chem. Soc. 2005, 127, 6964–6965. (b) SundeÅLn, H.; 
Ibrahem I.; CoÅLrdova. A. Direct organocatalytic asymmetric epoxidation of α,β-
unsaturated aldehydes. Tetrahedron Lett. 2006, 47, 99–103. 
[38] Ahujaa, B. B.; Emmanuvel, L.; Sudalai, A. A Formal Enantioselective Synthesis 
of (–)-Epiquinamide by Proline-Catalyzed One-Pot Sequential α-
Amination/Propargylation of Aldehyde and Asymmetric Dihydroxylation of 
Olefin Synlett 2016, 27, 1699–1702. 
[39] Reddy, M. S.; Kumar, Y. K. A New Synthesis of γ-Butyrolactones via AuCl3- or 
Hg(II)-Catalyzed Intramolecular Hydroalkoxylation of 4-Bromo-3-yn-1-ols Org. 
Lett. 2012, 14, 824–827. 
 45 
 
[40] Huang, P. Q.; Guo, Z. Q.; Ruan, Y. P. A Versatile Approach for the Asymmetric 
Syntheses of (1R,9aR)-Epiquinamide and (1R,9aR)-Homopumiliotoxin 223G. 
Org. Lett. 2006, 8, 1435–1438. 
[41] Liu, C.; Zeng, Z.; Chen, R.; Jiang, X.; Wang, Y.; Zhang, Y. Total Synthesis 
of (+)-Fusarisetin A Driven by a One-Pot Four-Reaction Process. Org. Lett. 2016, 
18, 624–627. 
[42] Chegondi, R.; Hanson, P. R. Synthetic studies to lyngbouilloside: a 
phosphate tether-mediated synthesis of the macrolactone core. 
Tetrahedron Lett. 2015, 56, 3330–3333. 
[43] Maitra, S.; Bodugam, M.; Javed, S.; Hanson, P. R. Efficient Synthesis of the C9–
C25 Subunit of Spirastrellolide B. Org. Lett. 2016, 18, 3094–3097. 
[44] Both (S,S)- and (R,R)-Triene are readily prepared via a two-step coupling of the 
corresponding C2-symmetric 1,3-anti-diene diol and allyl alcohol with POCl3, or 
in one step by employing phosphoramidite chemistry. The C2-symmetric 1,3-anti-
diene diol can be prepared in two steps from Bis(1,5-dichloro-2,4 
pentanedione)copper(II)com-plex (a) Matsui, K.; Motoi, M.; Nojiri, T. The 
Reversible Acylation of β-Diketone with Acyl Chloride in the Presence of 
Aluminum Chloride. Bull. Chem. Soc. Jpn. 1973, 46, 562−565. (b) Rychnovsky, 
S. D.; Griesgraber, G.; Powers, J. P. PREPARATION OF (R,R)-1,2:4,5-
DIEPOXYPENTANE. Organic Syntheses, 2000, 77, 1−11. (c) Rychnovsky, S. 
D.; Griesgraber, G.; Zeller, S.; Skalitzky, D. J. Optically pure 1,3-diols from 
(2R,4R)- and (2S,4S)-1,2:4,5-diepoxypentane. J. Org. Chem. 1991, 56, 
5161−5169. (d) Whitehead, A.; McReynolds, M. D.; Moore, J. D.; Hanson, P. R. 
Multivalent activation in temporary phosphate tethers: a new tether for small 
molecule synthesis. Org. Lett. 2005, 7, 3375−3378; (e) Whitehead, A.; 
McReynolds, M. D.; Moore, J. D.; Hanson, P. R. A concise, phosphate-mediated 
approach to the total synthesis of (-)-tetrahydrolipstatin.  Org. Lett. 2006, 8, 2657. 
(f) Venukadasula, P. K. M.; Chegondi, R.; Maitra, S.; Hanson, P. R. Org. Lett. 
2010, 12, 1556−1559. For preparation of CM partner see: (g) Boland, Rui, W. 
 46 
 
Algal pheromone biosynthesis: stereochemical analysis and mechanistic 
implications in gametes of Ectocarpus siliculosus. J. Org. Chem. 2010, 75, 3958–
3964.] We have routinely prepared the copper salt >100 gram batches and stored 
long-term (>2 years).  
[45]  (a) Kingsbury, J. S.; Harrity, J. P. A.; Bonitatebus, P. J., Jr.; Hoveyda, A. H. A 
Recyclable Ru-Based Metathesis Catalyst. J. Am. Chem. Soc. 1999, 121, 791–799. 
(b) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. Efficient and 
Recyclable Monomeric and Dendritic Ru-Based Metathesis Catalysts. J. Am. 
Chem. Soc. 2000, 122, 8168–8179. (c) Gessler, S.; Randl, S.; Blechert, S. 
Synthesis and metathesis reactions of a phosphine-free dihydroimidazole carbene 
ruthenium complex. Tetrahedron Lett. 2000, 41, 9973–9976. 
[46] Yu, W.; Mei, Y.; Kang, Y.; Hua, Z.; Jin, Z. Improved Procedure for the Oxidative 
Cleavage of Olefins by OsO4−NaIO4 Org. Lett. 2004, 6, 3217–3219. 
[47] Holmquist, C. R.; Roskamp, E. J. A Selective Method For The Direct Conversion 
of Aldehydes Into β-Keto Esters with Ethyl Diazoacetate Catalyzed by Tin(II) 
Chloride. J. Org. Chem. 1989, 54, 3258–3260. 
[48] (a) Boeckman, R. K.; Pruitt, J. R. A new, highly efficient, selective methodology 
for formation of medium-ring and macrocyclic lactones via intramolecular ketene 
trapping: an application to a convergent synthesis of (-)-kromycin. J. Am. Chem. 
Soc. 1989, 111, 8286–8288. (b) Mottet, C.; Hamelin, O.; Garavel, G.; Deprés, J.-
P., Greene, A. E. A Simple and Efficient Preparation of Propargylic β-Keto Esters 
through Transesterification. J. Org. Chem. 1999, 64, 1380–1382. (c) Marshall, J. 
A.; Eidam, P. M. A Formal Synthesis of the Callipeltoside Aglycone. Org. Lett. 
2008, 10, 93–96. (d) Hoye, T. R.; Danielson, M. E.; May, A. E.; Zhao, H. Dual 
Macrolactonization/Pyran–Hemiketal Formation via Acylketenes: Applications to 
the Synthesis of (−)-Callipeltoside A and a Lyngbyaloside B Model System. 
Angew. Chem. Int. Ed. 2008, 47, 9743–9746. (e) Reber, K. P.; Tilley, S. D.; 
Sorensen, E. Bond formations by intermolecular and intramolecular trappings of 
acylketenes and their applications in natural product synthesis. Chem. Soc. Rev. 
 47 
 
2009, 38, 3022–3034. (f) Hoye, T. R.; Danielson, M. E.; May, A. E.; Zhao, H. 
Total Synthesis of (−)-Callipeltoside A. J. Org. Chem. 2010, 75, 7052–7060. g) 
Williams, D. R.; Myers, B. J.; Mi, L.; Binder, R. J. Studies for the Total Synthesis 
of Amphidinolide P.  J. Org. Chem. 2013, 78, 4762–4778. 
[49] Kubizna, P.; Špańik, I.; Kozı̌́sěk, J.; Szolcsańyi, P. Synthesis of 2,6-disubstituted 
piperidine alkaloids from ladybird beetles Calvia 10-guttata and Calvia 14-guttata. 




















Modular Synthesis of Novel Macrocycles Bearing α,β-Unsaturated Chemotypes 















The development of efficient, pot- and step-economical protocols for the 
synthesis of medium- and large-sized bioactive heterocycles 1  is important in the 
screening campaigns for facilitating drug discovery.2 In particular, naturally occurring 
macrocyclic lactones, lactams, and their synthetic analogs represent an important class of 
bioactive molecules in compound collections.1,3 Additionally, macrocycles are privileged 
structures for biological studies as they can display unique features, such as 
conformational pre-organization, flexibility, selectivity, and potentially higher affinity 
with protein targets.4 Hence, macrocycles are promising molecules for the modulation of 
challenging processes,5  such as protein-protein interactions6  and epigenetic events.7 
Macrocycles, both naturally occurring and synthetic analogs, display a broad spectrum of 
biological activities in a variety of different areas ranging from anti-fungal activity,8 
anthelmintic activity,9 hepatitis C virus (HCV), NS3/4A serine protease,10 antibiotics,11 
CDK2/cyclin A inhibitors,12 Hsp90 inhibitors,13 protein kinase C (PKC) inhibitors,14 in 
drug discovery15 to insecticidal agents in agriculture.16 Furthermore, the significance of 
macrocycles has been demonstrated in drug development with more than a hundred 
naturally occurring and synthetic macrocycle-containing compounds currently being 
explored in therapy. 17  
Of particular interest, naturally occurring macrocycles bearing α,β-unsaturated 
entities have shown a wide range of important medicinal activities, including antifungal, 
anticancer, and antibacterial (Figure 2.1).18 Notably, a number have been found to 
covalently react with proteins to carry out their biological role.19,20 Examples include 
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protein kinase inhibitor hypothemycin19a and antibacterial agent atrop-abyssomicin C,20 
which function by covalently binding to their targets through Michael addition of a 
cysteine residue. 
 












































































































































Similarly, syringolin A targets the proteasome via irreversible reaction21 of a catalytic 
threonine at the α,β-unsaturated amide.19c As a result of these contributions and others, 
scaffolds bearing electrophilic functionalities are highly attractive biological probes for 
applications in imaging,22 activity-based protein profiling,23 and therapeutics.24,2d-e 
2.2. Previous strategies for the syntheses of medium to large-size heterocycles 
As evident from their biological activities (Figure 2.1), macrocycles are key 
structural elements in the synthesis of bioactive natural products and natural product-
based libraries for probe development and drug discovery.25,5a However, macrocycles are 
severely underexplored due to their structural complexity and synthetic intractability. 
Furthermore, it is assumed that natural product macrocycles and their synthetic analogs 
will tend to violate the recommended ranges in Lipinski’s rule-of-five and other 
guidelines for balancing aqueous solubility and lipid-membrane permeability to achieve 
oral absorption.26 However, this is not the case for many bioactive natural macrocyclic 
agents (erythromycin, rapamycin, vancomycin, cyclosporin) and their synthetic analogs, 
which serve as drugs and drug candidates in the early phase clinical development.27 
These challenges associated with the molecular structure and synthesis limit the 
pharmaceutical application of macrocycles in probe development and drug discovery. 
Inspite of these challenges, and motivated by the intriguing biological activity and 
inspired by synthetic complexity of naturally occurring macrocycles,2b,17a substantial 
efforts have been devoted toward highly efficient and robust synthetic methods for the 
preparation of macrocycles. Over the last decade, significant efforts have been 
undertaken toward the synthesis of complex naturally-occurring macrocycles and their 
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synthetic derivatives. A number of different synthetic protocols have been developed for 
the synthesis of a diverse range of macrocycles.1 The focus of this section will be on the 
recent synthetic methodologies reported in literature for the synthesis of macrocyclic 
compounds, which are the integral parts of bioactive natural products and drug-like 
molecules. 
2.2.1. Synthesis of medium- and large-sized rings via Build/Couple/Pair (B/C/P) 
strategy  
 In 2010, the Marcaurelle group reported an aldol-based build/couple/pair (B/C/P) 
strategy for the syntheses of stereochemically and skeletally diverse collection of 
medium- to large-sized rings (Scheme 2.1).28 In the build phase, four stereoisomers of 
Boc-protected γ-amino acid 2.1.1 were generated through asymmetric syn- and anti-aldol 
reactions. Additionally, PMB-protected D- and L-alaninol 2.1.2 were synthesized, which 
served as coupling partners. In the couple phase, a coupling reaction of aldol-derived 
amino acid 2.1.1 and chiral amine 2.1.2 afforded eight stereoisomers of the corresponding 
amide, which were subsequently reduced to amines 2.1.3. In the pair phase, the linear 
amines 2.1.3 were cyclized via three different ring forming strategies; nucleophilic 
aromatic substitution (SNAr), Huisgen [3+2] cycloaddition and/or ring-closing metathesis 
to furnished structurally diverse collection of 8- to 14-membered scaffolds 2.1.4–2.1.8. 
The compounds generated through this B/C/P strategy were screened, which led to the 
discovery of potent macrocyclic histone deacetylase inhibitors.  
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2.2.2. Synthesis of macrolactones and macrolactams via oxidative ring expansion 
strategy 
In 2012, Tan and co-workers reported a modular and concise approach for the 
diversity-oriented synthesis of functionalized macrolactone and macrolactam scaffolds 
via oxidative cleavage of the bridging double bond in polycyclic enol ethers and 
enamines (Scheme 2.2).29 The requisite polycyclic enol ethers and enamine scaffolds, 
bearing different functional handles, were assembled in four to five synthetic 
transformations. β-keto esters 2.2.2a-f were generated via α-C acylation of cyclic ketone 
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subsequently treated with two equivalents of LDA and TMSCl sequentially to provide the 
dienes 2.2.3a-f. Hetero-Diels-Alder reaction of diene 2.2.3a-f with aldehyde and N-nosyl 
imine furnished dihydropyrones 2.2.4a-f and dihydropyridones 2.2.5a-f in good yield 
(90–94%), respectively.31 Diastereoselective reduction of the ketone functionality in 
2.2.4a-f and 2.2.5a-f using NaBH4 and CeCl3, followed by TBS-protection afforded the 
corresponding ring expansion precursors 2.2.8a-f and 2.2.9a-f in good to excellent 
overall yields. 
Scheme 2.2. Diversity-oriented syntheses of macrolactones and macrolactams via 
oxidative ring expansion approach. 
 
 
After screening a variety of different reaction conditions for oxidative ring 
expansion, polycyclic enol ethers 2.2.8a-f and enamine 2.2.9a-f were successfully 
transformed to macrolactone and macrolactam scaffolds in moderate to good yields 
utilizing catalytic RuCl3 and stoichiometric amounts of additives (oxone). The resulting 
macrocycles were subjected to a detailed cheminformatic analysis, which showed that 
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these structurally diverse macrolactones and macrolactams overlap with the chemical 
space of bioactive natural products, high-profile synthetic drugs, and drugs-like libraries 
that are currently targeted by the pharmaceutical industry. 
2.2.3. A diversity-oriented synthesis of functionalized macrocyclic scaffolds via 
multidimensional coupling strategy 
In 2013, the Spring group reported an advanced diversity-oriented strategy, which 
involved multidimensional coupling reactions for the syntheses of functionalized 
macrocyclic scaffolds from simple and easily prepared starting materials (Scheme 2.3).32 
This strategy involved exploiting the pluripotent reactivity of aza-ylides derived from 
readily prepared azides. Seven azido building blocks were readily generated in the build 
phase from common precursors 2.3.1. The azides 2.3.2 and 2.3.3 were converted in situ 
to aza-ylides, which were subsequently treated with a variety of electrophiles in the 
multidimensional coupling phase through an aza-Wittig reaction to generate various 
structural motifs 2.3.4 and 2.3.5. The aza-Wittig reaction installed the terminal azide or 
alkyne functionality, which served as a macrocyclization handle in the subsequent pair 
phase.  
The macrocyclization was accomplished either via enyne metathesis33 or copper-
and ruthenium-catalyzed 34  azide alkyne cycloaddition to afford structurally diverse 
macrocyclic compounds 2.3.6–2.3.10. The resulting compounds were subsequently 
subjected to fluorous-tag cleavage to provide the final macrocyclic scaffolds. This 
efficient and divergent macrocyclization strategy enabled the synthesis of 73 compounds 
based on 59 discrete scaffolds in only four to five steps. The polyfluorocarbon-tag was 
utilized to facilitate the purification procedures. The principal moment-of-inertia35 plot 
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indicated that the diverse functionalized macrocyclic scaffolds, prepared through this 
advanced diversity-oriented strategy, cover a broad range of molecular shapes.32 
Scheme 2.3. Diversity-oriented synthesis of a macrocyclic scaffolds via a 
multidimensional coupling strategy. 
 
 
2.2.4. Organo- and metal-catalyzed synthesis of drug-like macrocyclic scaffolds 
In 2014, Spring and co-workers developed an orthogonal organo- and metal-
catalyzed strategy towards the diversity-oriented synthesis of natural product-like 
macrolactones by exploiting the pluripotency of aldehyde (Scheme 2.4).36 Aldehyde 2.4.1 
and its coupling partner 2.4.2 were readily prepared in a few steps from commercially 
available starting materials. Aldehyde 2.4.1 was treated with the coupling partner 2.4.2 
utilizing NHC-catalyst (2.4.6 and 2.4.7) to generate intermediate 2.4.3 in good yield. 

























































R = COORF, 2.3.6
R = COOMe, 2.3.7
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using a build/couple/couple (B/C/C) sequence. Finally, the macrocyclization of linear 
precursors was achieved via RCM reaction using G-II catalyst in moderate to good yields. 
Scheme 2.4. Synthesis of drug-like macrolactone utilizing B/C/C/P strategy. 
 
2.2.5. Synthesis of diverse medium to large-macrocycles via Successive Ring 
Expansion (SuRE) strategy  
In 2015, Unsworth and co-workers reported the synthesis of structurally diverse, 
functionalized medium to large-macrocycles utilizing a Successive Ring Expansion 
(SuRE) approach (Scheme 2.5). 37  This method was established via a one-pot 
acylation/ring-expansion sequence, in which the linear fragments were inserted 
sequentially into a cyclic β-ketoester moiety 2.5.1. The products 2.5.1 underwent ring 
expansion to generate medium to large macrocycles 2.5.2a–b. This coupling/ring 
expansion sequence can be repeated multiple times to generate functionalized 
macrocyclic compounds of any size 2.5.3a–b. The benefits of the SuRE strategy include 
















1. 2.4.6 (10 mol%), NaOAc
CH2Cl2, 40 ºC, 25%
2. G-II (10 mol%), 
CH2Cl2, reflux, 76%
2. G-II (10 mol%), CH2Cl2
reflux, 35%
1. PhNO, 2.4.7 (10 mol%)
















2.4.6 Ar = C6F5 X = BF4









variety of different functional groups to macrocycles, iii) there is no need to perform a 
discrete end-to-end macrocyclization step, which needs high dilution. 
Scheme 2.5. Synthesis of medium to large macrocycles via successive ring expansion 
strategy. 
 
2.3. Results and Discussions  
Motivated by the biological activities and electrophilic nature of α,β-unsaturated 
macrolactone- and macrolactam-containing bioactive natural products and medicinal 
drugs (Figure 2.1), we are interested in the syntheses of both cyclic and acyclic  
α,β-unsaturated chemotypes (Figure 2.2). In particular, the synthesis of electrophilic 
motifs, with exocyclic α,β-unsaturated ketones or amide functionality attached to a ring.  
Representative examples, include: (i) azinomycin containing an exocyclic  
α,β-unsaturated ketones or amide functionality attached to a ring (2.2a, potent anti-tumor), 
(ii) parthenolide (2.2b) containing an exocyclic enone  and possessing anti-inflammatory 
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cysteine protease inhibitors), (iv) Sch-725674 (2.2d) an α,β-unsaturated macrolactone 
possessing antifungal activity,38 and (v) macbecin (2.2d), a macrolactam with a dienyl 
moiety incorporated in the macrocyclic ring possessing potent antitumor activity (Figure 
2.2).39 Furthermore, we anticipated that these electrophilic motifs once synthesized could 
be attenuated electronically, sterically, stereochemically, and lipophilically, as well as by 
potentially masking their α,β-unsaturated functionality. 
 







































































































2.3.1. Rational design 
At the outset of our studies, we investigated the preparation of 14-membered 
macrolactone 2.3a via a sequence of four consecutive one-pot processes to significantly 
reduce compound isolations and chromatographic purifications to achieve concise and 
rapid synthesis (Figure 2.3). The strategy highlights the utilization of a phosphate tether-
mediated one-pot sequential RCM/CM/chemoselective hydrogenation [“H2”] protocol40 
applied to the phosphate triene (R,R)-2.3g41 and cross-metathesis (CM) partner 2.3h,42 
followed by a one-pot sequential Pd-catalyzed allylic transposition and tether removal 
pathway. The method continues with subsequent simple protecting group manipulations 
that are also streamlined in a one-pot process. The synthesis of 2.3a was accomplished in 
short order via a final one-pot protocol that consists of a ring-closing metathesis (RCM) 
and MOM deprotection sequence. Overall, the synthesis of macrolactone 2.3a entails the 
use of a series of four consecutive, one-pot sequential operations starting from phosphate  
(R,R)-2.3g.  
To assess the library amenability of the method, we envisioned diversifying the 
macrocyclic α,β-unsaturated unit via installation of electronically attenuated electrophilic 
warheads. This was accomplished at the alcohol functionalization stage, following the 
MOM-protection and TBS-deprotection, by introducing sulfonylation or phosphorylation 
reactions in addition to acrylation (Figure 2.3), which provided the macrosultone 2.3b 
and macrophostone 2.3c analogs. Diversification at the electrophilic warhead was further 
applied via a one-pot sequential Mitsunobu reaction, azide reduction and amine 
functionalization protocol to construct macrolactam surrogates (Path-B, Figure 2.3), 
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including sulfur and phosphorous-based α,β-unsaturated chemotypes (2.3d–f). 
 
 
Figure 2.3. Syntheses of α,β-unsaturated macrocycles via a sequence of four to six one-
pot sequential processes. 
2.3.2. Synthesis of 14-membered macrolactone 2.3a and macrosultone 2.3b 
Initial attempts were focused on the synthesis of 14-membered macrolactone 2.3a 
and macrosultone 2.3b starting from (R,R)-triene-2.3g and CM partner 2.3h via a series 
of four consecutive one-pot sequential operations. The key reactions involved in the 
generation of macrolactone and macrosultone are (i) a phosphate tether-mediated one-pot 
sequential RCM/CM/chemoselective hydrogenation [“H2”] protocol,40 (ii) one-pot 






































































































































































removal,43 (iii) one-pot MOM-protection/TBS-deprotection/acrylation or sulfonylation 
and (v) a final one-pot RCM/MOM-deprotection protocol. Overall, the synthesis of the 
14-membered macrocycles (macrolactone and macrosultone) were accomplished in a 
sequence of four consecutive pots, consisting of 11 reactions, and starting form readily-
prepared triene (R,R)-2.3g and CM partner 2.3h with only four workup and purification 
procedures. 
Efforts towards the synthesis of macrolactone 2.3a commenced with our 
previously developed phosphate tether-mediated one-pot sequential 
RCM/CM/chemoselective hydrogenation [“H2”] protocol to couple phosphate triene 
(R,R)-2.3g and CM partner 2.3h,42 providing bicyclic phosphate 2.3i (Scheme 2.6). (R,R)-
triene 2.3g was first subjected to RCM reaction in the presence of the Hoveyda-Grubbs II 
(HG-II) catalyst44 in refluxing CH2Cl2. After completion of RCM reaction, the solvent 
was evaporated under reduced pressure and CM partner 2.3h in dichloroethane (DCE) 
was added to the crude reaction mixture, followed by addition of the HG-II catalyst 
under argon. After completion of the CM reaction, subsequent chemoselective diimide 
reduction of CM adduct 2.6.1 with o-nitrobenzenesulfonyl hydrazine (o-NBSH)45 and 
Et3N (2g/mL of o-NBSH) in CH2Cl2 at room temperature, furnished 
bicyclo[5.3.1]phosphate 2.3i. This first one-pot operation afforded phosphate triester 2.3i 
in 40% overall yield over the course of three reactions, representing an average yield of 
74% for each reaction in the same flask (74% av/rxn).  
Exploiting the orthogonal leaving and protecting group ability of bicyclic 
phosphate 2.3i, we next applied a one-pot sequential Pd-catalyzed, reductive allylic 
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transposition/methylation/phosphate tether removal protocol.43 In this regard, the bicyclic 
phosphate 2.3i was subjected to Pd-catalyzed, reductive allylic transposition [Pd(OAc)2, 
PPh3 HCOOH, Cs2CO3], and subsequent methylation utilizing dimethyl sulphate 
((MeO)2SO2) to generate the phosphate triester 2.6.3. Next, in the same pot, the crude 
phosphate triester, without further purification and solvent change, was subjected to 
reductive phosphate tether removal utilizing LiAlH4 to afford 1,3-anti-diol 2.3j. This one-
pot sequential operation enabled the stereoselective synthesis of the 1,3-anti-diol 
fragment 2.3j in 56% yield (83% av/rxn) over three reactions in a single pot.  
Scheme 2.6. Synthesis of TBS-protected diol 2.3j via consecutive two one-pot sequential 
protocols. 
 
The method continued with simple protecting group manipulations and acylation 
with acryloyl chloride to access the acrylate fragment 2.3l. In this regard, we developed a 
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one-pot, sequential acetate-protection, followed by a TBS-deprotection and acrylation 
sequence, to access the acrylate fragment 2.7.3 (Scheme 2.7). Next, the TBS-protected 
diol 2.3j was subjected to acetate-protection using Ac2O, DMAP and pyridine in CH2Cl2 
at room temperature. After completion of reaction, the solvent was removed under 
reduced pressure and the residue was dissolved in THF followed by addition of TBAF. 
The reaction mixture was refluxed for 1 h. After completion of reaction, the solvent was 
evaporated and CH2Cl2 was added, followed by Et3N under inert atmosphere. 
Scheme 2.7. Synthesis of macrolactone 2.3a utilizing acetate protecting group. 
  
The reaction mixture was lowered to 0 ºC and acryloyl chloride was added dropwise, and 
it was stirred for 1 h. The reaction mixture was quenched with ice-cold water, extracted 
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 65 
SiO2 chromatography, which furnished the acrylate fragment 2.7.3 in 71% yield from the 
three-reaction sequence in a single pot. The diene fragment 2.7.3 was subsequently 
cyclized via RCM utilizing the G-II catalyst, affording acetate-protected macrolactone 
2.7.4 in 67% yield. Next, we attempted various reaction conditions to remove the acetate-
protecting group, but, unfortunately we were unable to generate the macrolactone 2.3a. 
We observed a Michael addition to the α,β-unsaturated functionality of macrolactone 
2.8.3, which was confirmed by 1H NMR spectroscopy.  
In order to solve this issue, we replaced the acetate with a MOM-protecting group 
(Scheme 2.8). Thus, TBS-protected alcohol 2.3j was subjected to a one-pot sequential 
MOM-protection/TBS-deprotection/acrylation sequence. In this regard, TBS-protected 
alcohol 2.3j was subjected to MOM-protection utilizing MOMCl and DIPEA in CH2Cl2 
at room temperature. After reaction completion, the solvent was evaporated and, without 
further purification, THF was added followed by TBAF under argon. The reaction 
mixture was refluxed for 1 h until complete consumption of the starting material had 
occurred, then the solvent was removed and the crude product was dissolved in CH2Cl2. 
Addition of Et3N and acryloyl chloride at 0 ºC generated the acrylate fragment 2.3l. The 
reaction mixture was quenched with ice-cold water, extracted with CH2Cl2 and purified 
with silica gel chromatography. This one-pot, three-reaction protocol afforded the 
acrylate fragment 2.3l in 75% overall yield (91% av/rxn).  
To our delight, the synthesis of 14-membered macrocycle 2.3a was accomplished 
in short order via a final one-pot protocol consisting of a ring-closing metathesis (RCM) 
and MOM-deprotection sequence. After completion of reaction, the solvent was 
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evaporated, and the crude product was purified through flash column chromatography, 
which afforded the macrolactone 2.3a in 67% overall yield (82% av/rxn). Overall, the 14-
membered α,β-unsaturated macrolactone 2.3a was synthesized from triene (R,R)-2.3g and 
CM partner 2.3h in 11.2% total yield using eleven reactions in four pots, thus 
significantly reducing purification events. 
Scheme 2.8. Synthesis of 14-membered macrolactone 2.3a.  
 
Encouraged by these results, we were next interested in exploring the applicability 
of our method for the generation of different sulfur and phosphorus-based derivatives of 
the 14-membered macrolactone. In particular, acyclic vinyl sulfonates and their analogs 
have a rich biological profile that has seen a resurgence of interest in the recent years due 
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Chagas disease, malaria, and leishmaniasis, as well as kinases involved in cancer.47 To 
exploit the adaptability of our modular approach, we investigated the replacement of the 
acrylation reaction with a vinyl sulfonylation starting from TBS-protected diol 3.2j 
(Scheme 2.9). We were pleased to find that the four-pot sequential protocol already 
developed for the synthesis of macrolactone 3.2a only required swapping acryloyl 
chloride with 2-chloroethanesulfonyl chloride to access macrosultone analog 3.2b. 
In similar fashion, the TBS-protected diol 2.3j was subjected to a one-pot 
sequential MOM-protection/TBS-deprotection to access MOM-protected alcohol 2.8.2 
(Scheme 2.9). 
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The crude product 2.8.2 was subjected to a sulfonlyation reaction using 2-
chloroethanesulfonyl chloride, Et3N and DMAP in CH2Cl2 (0 ºC to RT) to accomplish 
the synthesis of vinyl sulfonate 2.3m in a one-pot operation consisting of three reactions 
with 72% overall yield (89.5% av/rxn). Vinyl sulfonate 2.3m was subsequently subjected 
to one-pot sequential RCM/MOM-deprotection operation to generate macrosultone 2.3b 
in 70% yield over a sequence of two reactions in one-pot (84% av/rxn). Overall, both the 
macrolactone 2.3a and macrosultone 2.3b scaffolds were efficiently synthesized over a 
sequence of four consecutive one-pot sequential protocols with excellent overall yields. 
The workup and purification procedures were reduced to four steps over eleven reactions, 
highlighting the green nature of this method. 
2.3.3. Synthesis of 14-membered macrolactam 2.3d and macrosultam 2.3e analogs 
Next, we evaluated our approach for the syntheses of macrolactam 2.3d and 
macrosultam 2.3e derivatives in order to provide additional warhead diversity. On the 
basis of the efficiency observed during the acrylation and sulfonylation reactions in 
previous protocols, we anticipated the use of similar transformations to install the 
corresponding amine-based, α,β-unsaturated warheads in the 14-membered macrocycle. 
To this end, we accommodated a one-pot procedure involving a Mitsunobu reaction on 
the C8 carbinol (Scheme 2.3, path B), followed by azide reduction with LiAlH4 and 
subsequent amine functionalization. To develop this route, we investigated the use of 
alkaline aqueous solutions for in situ quenching of LiAlH4 and successive amine 
functionalization. In this event, we found that saturated NaHCO3 allows for deactivation 
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of the reducing agent and simultaneously, provides efficient basic conditions for the 
addition of acryloyl chloride.  
Following a one-pot, two-reaction procedure, TBS-protected diol 2.3j was 
converted to MOM-protected alcohol 2.8.2 in 81% yield (Scheme 2.10). The MOM- 
protected alcohol 2.8.2 was subsequently subjected to another one-pot, three-reaction 
sequence consisting of Mitsunobu reaction/reduction/acrylation to afford the desired 
acrylamide fragment 2.3o.  
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In this regard, a Mitsonubu reaction (DPPA, DIAD and PPh3 in THF at 0 ºC) was 
performed to convert the MOM-protected alcohol 2.8.2 to the corresponding azide 
fragment 2.10.1. After completion of the Mitsonubu reaction, LiAlH4 was added to the 
crude product in the same pot without any solvent change, which afforded the amine 
fragment 2.10.2. Excess LiAlH4 was quenched in situ by addition of aqueous saturated 
NaHCO3, which also served as base for the subsequent reaction.  
Next, we added acryloyl chloride to the crude reaction mixture and it was stirred 
for 1 h at 0 ºC, which furnished the acrylamide 2.3o in 73% yield over three reactions in 
one-pot (90% av/rxn) without any solvent adjustment. The acrylamide 2.3o was then 
subjected to a final one-pot sequential RCM/MOM deprotection, which afforded 
macrolactam 2.3d in 60% yield over the two reactions in one-pot. Overall, the 
macrolactam analog was successfully assembled in a series of five one-pot sequential-
protocols using a total of only five workup and purification procedures. 
Analogously, the macrosultam analog 2.3e was obtained via a sequence of three 
consecutive one-pot operations starting from TBS-protected diol 2.3j (Scheme 2.11). In 
similar fashion, TBS-protected alcohol 2.3j was transformed to MOM-protected alcohol 
3.8.2 via a one-pot MOM-protection/TBS-deprotection sequence. The MOM-protected 
alcohol was converted to the corresponding vinyl sulfonamide 2.3p via one-pot 
sequential Mitsonubu/reduction/sulfonylation sequence. Applying saturated K2CO3 and 
2-chloroethanesulfonyl chloride during the third reaction of the one-pot event, enabled 
the generation of sulfonamide 2.3p in 81% overall yield (93% av/rxn) over the course of 
three reactions. Next, the corresponding macrosultam 2.3e was obtained via a one-pot 
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RCM/MOM-deprotection sequence with a 64% yield over two reactions in one-pot (80% 
av/rxn).  
Scheme 2.11. Synthesis of macrosultam 2.3e via sequence of five consecutive one-pot 
operations.  
 
Taken collectively, both macrolactam 2.3d and macrosultam 2.3e analogs were 
efficiently synthesized via a sequence of five consecutive one-pot sequential operations 
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2.3.4. Synthesis of 14-membered macrophostone 2.3c and macrophostam 2.3f 
analogs 
Next, we were interested in the synthesis of related phosphorus macrocycles 2.3c 
and 2.3f, given the rich biological history of phosphorus-containing molecules.48 The 
RCM precursors 2.3n and 2.3q were synthesized in similar fashion, with the difference of 
carrying out the warhead installation in a separate pot due to reagent incompatibilities 
(Figure 2.3). Accordingly, following a one-pot, two-reaction protocol consisting of 
MOM-protection followed by TBS-deprotection of 2.3j afforded MOM-protected alcohol 
2.8.2 (Scheme 2.12). The crude alcohol was then subjected to a phosphorylation reaction, 
which afforded an inseparable diastereomeric mixture (dr ~ 1:1) of 2.3n. 
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Thus, after three reactions in two pots, the P-chiral vinyl phosphonates 2.3n-RP and 2.3n-
SP were obtained in 60% overall yield (84.5% av/rxn). The diastereomeric mixture was 
then subjected to RCM reaction utilizing the G-II catalyst, which furnished the MOM-
protected macrophostone 2.3c in 77 % yield.   
Likewise, the P-chiral vinyl phosphonamidates 2.3q-RP and 2.3q-SP were 
furnished in 57% over three reactions in two pots (83% av/rxn). In this regards, TBS-
protected alcohol 2.3j was subjected to a one-pot sequential MOM-protection/TBS-
deprotection sequence to afford the MOM-protected alcohol 2.8.2 in 89% yield over two 
reactions in one-pot (Scheme 2.13). 
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A subsequent one-pot Mitsonubu/reduction sequence afforded the amine 2.10.3. After the 
workup, the crude amine was subjected to a phosphorylation reaction to afford the 
inseparable diastereomeric mixture (dr ~ 1:1) of RCM precursor 2.3q-RP/SP in 57% yield 
over three reaction in two-pots. In the final step, the diastereomeric mixtures underwent 
efficient RCM reaction to deliver α,β-unsaturated, P-stereogenic phostams 2.3f- RP/SP in 
71% yields. Overall, macrocycles 2.3c and 2.3f were accessed from (R,R)- 2.3g and CM 
partner 2.3h after conducting ten and twelve reactions, respectively, with a number of 
efficient processes that reduced the number of reaction pots to five and six. 
2.4. Conclusion 
In summary, we have disclosed a series of efficient one-pot sequential protocols 
that enable the asymmetric synthesis of natural product-like macrocycles bearing an  
α,β-unsaturated entity (2.3a-f).49 The macrocycles were accessed in four- to six-pot 
processes from (R,R)-2.3g and CM partner 2.3h with total yields ranging from 7.3% to 
11.2%. The overall pot-economical approach is operationally simple, efficient, and 
library amenable. A notable merit of the method is the application of multiple 
consecutive pot-economic operations that significantly avoid purification procedures 
between successive reactions. Based on our previous applications of the RCM/CM/[“H2”] 
protocol, we expect that a CM partner can be tactically chosen to assemble macrocycles 
with additional diversity, including various ring sizes, substituents and stereochemistries. 
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Further expansion of this approach for the synthesis of a variety of novel medium- and 
large-sized macrocycles will be reported in due course. 
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Pot-Economical Approach for the Asymmetric Total Synthesis of  







The development of novel methods that enable the expedient syntheses of 
complex bioactive targets and corresponding analogs is important in modern day organic 
synthesis. In this regards, the synthesis of advanced intermediates, medicinal compounds, 
natural products and their synthetic analogs with minimum number of chemical 
operations is of prime importance. In particular, one-pot sequential protocols for the 
synthesis of bioactive natural product and corresponding analogs play a crucial role in the 
early phase of probes development and drug discovery. Accordingly, one-pot sequential 
protocols are gaining popularity1 as a powerful tool to achieve the syntheses of complex 
bioactive medicinal agents. 2 , 3  Among several featured publications, Hayashi and 
coworkers have employed consecutive, one-pot sequential protocols for the streamlined 
synthesis of representative examples of these targets.4 In this regard, they were able to 
complete the multi-reaction syntheses of (–)-oseltamivir,2a,b prostaglandin A1 and E1 
methyl esters,2e (–)-horsfiline and (–) coerulescine3a in step- and pot-economical manner. 
A later synthesis of (–)-oseltamivir5 was accomplished in a one-pot operation. In similar 
fashion, the syntheses of ABT-3412d and (S)-baclofen6 were accomplished via a one-pot 
protocol.  
As part of our ongoing efforts to develop efficient methods for the synthesis of 
complex target molecules,3b-d we have recently reported a modular syntheses of novel 
macrocycles possessing α,β-unsaturated chemotypes employing a series of one-pot 
sequential protocols (Figure 1).7 This efficient and library amenable method utilizes four 
to six consecutive one-pot sequential operations. We highlighted a phosphate tether-
mediated asymmetric approach for the synthesis of a series of novel carbon-, sulfur- and 
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phosphorus-based macrocycles 3.1c–e (Figure 3.1). Encouraged by the aforementioned 
literature precedence2,3,4,5 and motivated by the efficiency of our previously developed 
one-pot sequential protocols, Chapter 3 highlights our recent disclosure of an 
enantioselective total synthesis of antifungal natural product Sch-725674 (3.1f) and its 
analogs 3.1g–k (Figure 3.1).3d 
 
Figure 3.1. Sch-725674 (3.1f) and corresponding analogs 3.1g–k. 
3.1.1. Sch-725674 and related natural products 
Sch-725674 (3.1f), an antifungal macrolide, was isolated from a culture of 
aspergillus sp and structurally elucidated in 2005 by Yang and co-workers.8 This natural 
product exhibits activity against saccharomyces cerevisiae and candida albicans with 
MIC values of 8 and 32 µg/mL, respectively. Key structural features of 3.1f include a 14-
membered macrolactone ring, an E-configured α,β-unsaturated ester, a lipophilic n-pentyl 
side chain and a 1,3-anti-diol moiety embedded within a four-carbon (C4–C7) subunit 
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the absence of commonly found methyl groups on the backbone of macrolide antibiotics 
erythromycin (3.2a) and narbomycin (3.2b). The closest structural relatives of Sch-
725674 are the self-germination inhibitor gloeosporone9 (3.2c) and the recently isolated 
gliomasolides A to E (3.2d–h),10 which show cytotoxic activity against the growth of 
HeLa cell lines (Figure 3.2), thus making 3.1f a potentially attractive biological and 
synthetic target. 
 
Figure 3.2. Natural product macrolactones Sch-725674, gloeosporone, 3.2c and 
gliomasolides A-E, 3.2d–3.2h. 
3.2. Overview of previous total synthesis of Sch-725674 (3.1f)  
Due to anti-fungal activity and novel structural features, Sch-725674 has attracted 
significant attention from several synthetic groups. The asymmetric total synthesis of 
Sch-725674 has been reported by Curran, 11 Prasad,12,13 Kaliappan14 and recently by 
Reddy and coworkers.15 For the purpose of this chapter, only key features of the synthetic 
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3.2.1. Synthesis of a 16-stereoisomers library of Sch-725674 using a fluorous 
tagging strategy 
 
 In 2012, the Curran group reported an elegant synthesis of a library of all 16 
possible stereoisomers of Sch-725674 (3.1f) utilizing a fluorous tagging approach 
developed in their group (Scheme 3.1).11 This strategy involved the syntheses of two-
mixtures of four fluorous-tagged quasi-isomers16 M-3.1.1–3.1.4-trans and M-3.1.5–M-
3.1.8-cis and two enantiopure fragments of (R)-3.1.9 and (S)-3.1.10.  
Scheme 3.1. Synthesis of complete stereoisomer library of Sch-725674 (3.1f) using 
fluorous tagging strategy. 
 
 
Starting with M-3.1.1–M-3.1.4-trans series, the authors hydrolyzed the methyl ester of 
M-3.1.1–M-3.1.4-trans compounds using TMSOK and the acids obtained were divided 
into two flasks. Each half portion of M-3.1.1–M-3.1.4-trans were coupled with either 
(R)-3.1.9 or (S)-3.1.10 under Yamaguchi reaction conditions, which afforded the RCM 
precursors (M-3.1.11–M-3.1.18-trans) in good yield (74%–84%). Ring-closing 



















with O4/O5 cis or trans

















1. 2, 4, 6-trichloro
benzoyl chloride
 Et3N, DMAP






















































hydrogenation with poisoned Pd catalyst, furnished the final tagged quasi-isomeric 
mixtures of M-3.1.19–M-3.1.22-trans in good to excellent yields. 
In similar fashion, the M-3.1.5–M-3.1.8-cis series of isomers were converted to 
the final tagged quasi-isomeric mixtures M-3.1.23–M-3.1.26-cis. After separation, tag-
cleavage and purification of the final compounds with chiral HPLC afforded the 
penultimate precursors of the 16 true stereoisomers of Sch-725674. The complete 
stereochemical configuration (4R,5S,7R,13R) of Sch-725674 was assigned by Curran and 
coworkers, and was based on the comparison of spectral data of the synthesized 16 
stereoisomers with the published spectra8 of 3.1f.  
3.2.2. An asymmetric synthesis of macrolactone core of Sch-725674 
In 2014, Prasad et al reported an enantioselective synthesis of the macrolactone 
core of Sch-725674 from commercially available furfural using RCM as a key reaction 
(Scheme 3.2).12 The synthesis of Weinreb amide 3.2.1 was accomplished according to 
literature procedures. 17  Grignard addition to Weinreb amide 3.2.1 followed by 
stereoselective reduction,18 utilizing Me4N(OAc)3BH to provide the 1,3-diol fragment 
3.2.2 in 97% yield. TBS-protection of both hydroxy groups in 3.2.2 using 
TBSCl/imidazole, followed by oxidation of the furan with NBS/NaHCO3 proceeded 
smoothly to furnish keto-aldehyde 3.2.3 in 76% yield. Aldehyde 3.2.3 was further 
oxidized to the corresponding carboxylic acid in 93% yield. Stereoselective reduction of 
the ketone function in 3.2.3 under Luche reduction conditions19 afforded the alcohol in 
quantitative yield, which was subsequently protected using TESOTf, 2,6-lutidine to 
afford the TES-protected alcohol 3.2.4 in 97% yield.  
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Next, the authors coupled acid 3.2.4 with homoallylic alcohol 3.2.520 under 
Yamaguchi reaction conditions, followed by selective TES-deprotection using EtOCOCl 
in MeOH, to furnish alcohol fragment 3.2.6 in 54% yield. Mitsunobu inversion of  
alcohol 3.2.6 generated the p-nitrobenozate in 83% yield, which was subsequently 
subjected to deprotection under basic conditions (K2CO3, MeOH), followed by TBS-
protection, to afford RCM precursor 3.2.7 in good yield. 
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Ring-closing metathesis of the diene 3.2.7 using G-II catalyst afforded the macrolactone 
core 3.2.8 in 97% yield. After screening different reaction conditions for the reduction of  
C–C double bond at C10–C11 position of 3.2.8, the authors were unable to attain the 
desired reduced product. However, the authors reported that the required selective 
hydrogenation of the C–C double could be accomplished by employing the reduction 
conditions reported by Curran’s and coworker (H2, Pd/SrCO3)11, Which would complete 
the synthesis of the macrolactone core of Sch-725674. 
3.2.3. An enantioselective total synthesis of Sch-725674 
In 2014, Prasad and coworker reported an enantiospecific total synthesis of Sch-
725674 (3.1f) beginning with commercially available L-(+)-tartaric acid (Scheme 3.3).13 
The three key features of the synthesis were utilization of Ley’s dithiaketalization of an 
alkynone, Boord olefination and RCM. The forward synthesis of Sch-725674 began with 
Grignard addition of 3.3.2 to the bis-Weinreb amide 3.3.1, which furnished an alkynyl 
ketone. Subsequent dithianylation of the ketone, under Ley's conditions, furnished 1,3-
dithianyl ketone 3.3.3 in quantitative yield. Cross metathesis of olefin 3.3.3 with chiral 
homoallylic alcohol 3.3.421 using the G-II catalyst (3 mol%) afforded the extended 
alkene 3.3.5 in 67% yield.  
Next, the authors carried out a stereoselective reduction of the ketone moiety in 
3.3.5 using excess of NaBH4, which not only furnished the secondary alcohol but also 
removed the bis-Weinreb amide to generate the triol moiety in quantitative yield. 
Dithaine-deprotection of the ketone functionality in 3.3.5 using MeI and CaCO3 
furnished the β-hydroxy ketone fragment 3.3.6 in 90% yield. Stereoselective reduction of 
ketone in 3.3.6 using Me4N(OAc)3BH (Evan’s reagent)22 afforded the 1,3-anti-diol 
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fragment in good yield. Subsequent hydrogenation of the C–C double bond in the 1,3-
anti-diol subunit using H2/Pd-C furnished the tetrol fragment 3.3.7 in 94% yield. 
Selective tosylation of the primary alcohol in 3.3.7, followed by iodination of the 
resulting tosylate, afforded the iodide fragment 3.3.8, which was subsequently subjected 
to acrylation followed by Boord olefination (Zn, EtOH) to furnish the RCM precursor 
3.3.10. Ring-closing metathesis of diene 3.3.10 bearing three free hydroxyl groups 
utilizing the G-II catalyst furnished Sch-725674 (3.1f) in 36% yield. In summary, the 
asymmetric total synthesis of Sch-725674 was accomplished in a route with a longest 
linear step (LLS) sequence of 12 steps, and with 2.6% overall yield starting from the bis-
Weinreb amide of L-(+)-tartaric acid (3.3.1). 
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3.2.4. An asymmetric total synthesis of Sch-725674 
In 2015, Kaliappan and coworkers reported an enantioselective total synthesis of 
Sch-725674 in a route featuring an LLS of 13 steps (Scheme 3.4).14 The three key 
reactions involved in the synthesis of Sch-725674 (3.1f) were a step-wise dithiane 
alkylation, a cross metathesis and Yamaguchi macrolactonization. The forward synthesis 
of 3.1f commenced with the synthesis of iodide 3.4.2 from commercially available (S)-2-
(chloromethyl)oxirane.  
Scheme 3.4. Enantioselective total synthesis of Sch-725674, 3.1f.  
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provide the intermediate 3.4.3 in 86% yield, followed by reaction with the second 
electrophile 3.4.4 to generate dialkylated product 3.4.5 with 72% yield. MOM and TBS-
deprotection using PPTS and MeOH furnished the triol fragment 3.4.6 in 60% yield. The 
resulting alkene fragment 3.4.6 was subsequently subjected to CM with methyl acrylate 
as a CM partner using the G-II catalyst (15 mol%) to afford E-methyl ester 3.4.7 in 74% 
yield. Acetonide protection of 1,2-diol in 3.4.7 using 2,2-DMP, followed by hydrolysis of 
the methyl ester, afforded the acid 3.4.8. Yamguchi macrolactonization23 of acid 3.4.8, 
followed by dithiane deprotection, using Stork’s reagent,24 furnished the macrolactone 
core of Sch-725674, 3.4.10, in 59% yield. Stereoselective reduction of the carbonyl 
function in 3.4.10 using NaBH4, followed by acetonide deprotection using CSA, 
furnished Sch-725674 in 71 % yield through the last step. Overall, the asymmetric 
synthesis of Sch-725674 (3.1f) was accomplished in 13 steps from a known alcohol.28  
3.2.5. Formal total synthesis of Sch-725674 
More recently, Reddy and coworkers reported the formal total synthesis of Sch-
725674 (Scheme 3.5).15 The forward synthesis of 3.1f began with CM of known 
acetonide-protected alkene 3.5.125 and pre-synthesized alcohol 3.5.2,26 which afforded 
the ester fragment 3.5.3 with good yield (82%) and excellent E-selectivity. After 
screening different reaction conditions, the desired ketone was obtained using Wacker 
oxidation27 of C–C double bond in 3.5.3 using O2 (200 Psi) and PdCl2. Subsequent 
hydrolysis of the ester using bis(tributyltin)oxide in refluxing toluene furnished the seco-
acid 3.5.4 in 69% yield. Yamaguchi macrolactonization of seco-acid 3.5.4 using 2,4,6-
trichlorobenzoyl chloride and DMAP in refluxing toluene yielded the macrolactone 3.5.5 
in 52% yield. Stereoselective reduction of the ketone moiety in 3.5.5 using NaBH4 
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followed by acetonide deprotection using 6N HCl completed the formal total synthesis of 
Sch-725674 by an efficient series of steps. 
Scheme 3.5. The formal total synthesis of Sch-725674, 3.1f.  
 
3.3 Results and discussion 
3.3.1 Proposed retrosynthetic analysis of Sch-725674 
Retrosynthetic analysis revealed that Sch-725674 (3.1f) could be assembled via 
RCM of diene 3.3a (Figure 3.3). Derivation of the RCM precursor 3.3a was planned 
using two consecutive one-pot sequential protocols from epoxide 3.3b, namely a 
Finkelstein substitution/Boord olefination/acetonide deprotection procedure and a one-
pot two-reaction sequence involving tosylation and acrylation reaction. Epoxide 3.3b was 
synthesized from allylic alcohol 3.3c via Sharpless asymmetric epoxidation (SAE). The 
allylic alcohol in turn was accessed via reductive tether removal, followed by acetonide 
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protection of bicyclic phosphate 3.3d. The bicyclic phosphate 3.3d in turn, was obtained 
from triene phosphate (S,S)-3.3f following a one-pot RCM/CM/chemoselective 
hydrogenation sequence utilizing 3.3e28 as the cross metathesis (CM) partner. This one-
pot three-reaction sequence enabled the installation of the requisite C13 n-pentyl side 
chain and the C5–C7 1,3-anti-diol subunit. A salient feature of this approach is the 
modular installation of the C9–C13 fragment via CM, as well as introduction of the 
acrylate at a later stage, opening opportunities for future analog generation. 
 
Figure 3.3. Retrosynthetic analysis of Sch-725674, 3.1f. 
3.3.2. Forward synthesis of Sch-725674 
The forward synthesis of Sch-725674 (3.1f) commenced with the previously 
developed one-pot sequential RCM/CM/[“H2”] protocol. 29  (S,S)-Triene 3.3f 30  was 
subjected to RCM using the Hoveyda-Grubbs second-generation catalyst (HG-II)31 (2 
mol%) in refluxing CH2Cl2 (Scheme 3.6). After completion of the RCM reaction (30 





























































(DCE)32 and introduced to the same pot under argon, followed by addition of the HG-II 
catalyst (10 mol%). After the CM event had proceeded for 5 h at 70 ºC, chemoselective 
diimide reduction of the external olefin in bicyclic phosphate 3.6.2 was performed by 
addition of o-nitrobenzenesulfonylhydrazine (o-NBSH)33 and Et3N (2 mL/g of o-NBSH) 
to the reaction mixture. This one-pot, three-reaction sequence provided bicyclic 
phosphate 3.3d in 59% overall yield, equivalent to an average yield of 84% per reaction 
(84% av/rxn). Next, reductive conditions (LiAlH4, THF, 0 ºC), were used to remove the 
phosphate tether in 3.3d (Scheme 3.6). The corresponding tetrol was obtained in high 
purity following the Fieser workup,34 and, without chromatography purification, the 
crude 1,3-anti-diol was subjected to a selective acetonide protection. The crude tetrol was 
treated with 2,2-dimethoxypropane (2,2-DMP) and catalytic amounts of camphorsulfonic 
acid (CSA) as outlined in Scheme 3.6, providing 1,3-acetonide 3.3c in 71% yield over 
two reactions in two pots. 
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The acetonide-protected allylic alcohol was next subjected to Sharpless 
asymmetric epoxidtion (SAE)35 by treatment with  (-)-diethyl tartrate (DET), Ti(Oi-Pr)4, 
cumene hydroperoxide, 36  which afforded the corresponding diastereomeric epoxide 
products in 72% yield (80% brsm) with 3.3b as the desired major diastereomer (88% 
ds)37 (Scheme 3.7). Following the successful assembly of epoxide 3.3b in scalable 
quantities, a second one-pot protocol consisting of tosylation and acrylation sequence was 
applied. To this end, the primary alcohol in 3.3b was chemoselectively transformed 
overnight to tosylate (TsCl, Et3N, DMAP) in the presence of the C13 carbinol. Next, 
acryloyl chloride was simply added to the same pot at 0 ºC to afford the acrylate fragment 
3.7.2 in 86% yield for these two reactions in one-pot (93% avg/rxn).   
Scheme 3.7. Synthesis of acrylate fragment 3.7.2. 
  
 
A subsequent one-pot protocol was established by subjecting 3.7.2 to a 
Finkelstein substitution, Boord olefination (Zn, EtOH), and acetonide deprotection 
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commenced by exposing the tosyl group in 3.7.2 to Finkelstein conditions (NaI, acetone, 
reflux) followed by a solvent change from acetone to ethanol and addition of activated 
zinc powder under reflux to promote Boord elimination over a 2 h period. Final addition 
of HCl at room temperature released the 1,3-anti-diol to deliver triol 3.8.2 in 79% yield 
over three reactions in a single pot operation (93% av/rxn).38  
With 3.8.2 in hand, the synthesis of Sch-725674 (3.1f) was accomplished via a 
final RCM as reported by Prasad and coworkers, the structural characterization of Sch-
725674 was in good accord with data reported by Prasad and coworkers.13 Overall, the 
total synthesis of 3.1f was accomplished in seven pots from the readily prepared triene 
(S,S)-3.3f and the olefin 3.3e. Chromatography isolations were also reduced to six 
procedures, which saved time and minimized chemical waste generation.  
Scheme 3.8. End game; synthesis of Sch-725674. 
 
While we were unable to match the reported 36% yield for the RCM reaction,13 
we found that simple protection of the alcohols significantly increased the efficiency of 
this final macrocyclization event via RCM reaction (Scheme 3.9). In this regard, we 
developed a two-reaction, one-pot sequential method that consisted of RCM and 
methoxymethyl (MOM) deprotection to further streamline the synthesis toward 3.1f. To 
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3.9.1 was obtained in 97% yield after treating with MOMCl under basic conditions. Next, 
the one-pot protocol began by treating metathesis precursor 3.9.1 with the GII39 catalyst 
(10 mol%) in refluxing CH2Cl2. After completion of the metathesis event (12 h), the 
solvent volume was reduced and MOM-deprotection proceeded smoothly by adding 
trifluoroacetic acid to the same pot, delivering Sch-725674 (3.1f) in 84% yield over two-
reactions in one-pot (92% av/rxn). This alternative approach considerably improved the 
yield of the RCM event, providing Sch-725674 in 14.6% overall yield from triene (S,S)-
3.3f and CM partner 3.3e following eight pots and seven chromatography purifications. 




Taken collectively, we disclosed a pot-economical synthetic route to the 
antifungal natural product Sch-725674. Overall, a seven-pot route was developed from 
readily prepared phosphate triene (S,S)-3.3f and olefin fragment 3.3e and included seven 
isolations and six chromatography purifications. Key to the strategy is the application of a 
phosphate tether-mediated one-pot sequential RCM/CM/hydrogenation process, a one-
pot tosylation/acrylation sequence, and a one-pot sequential Finkelstein reaction/Boord 
olefination/acetonide deprotection protocol. An alternative approach was introduced at 
the final stage of the synthesis involving a one-pot sequential RCM/MOM-deprotection 
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collectively, the use of sequential reactions in the same pot provided a streamlined 
synthesis of Sch-725674 in minimal production time by allowing multiple bond 
transformations in a single flask without the need for purification of several 
intermediates, thus also reducing waste generation. 
3.4. A pot-economical approach for the total syntheses of Sch-725674 analogs  
We anticipated that the aforementioned pot-economical and library amenable 
approach3d could further be exploited for the synthesis of simplified analogs of Sch-
725674 (3.1f) (Figure 3.4).  
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The key reactions involved in the synthesis of Sch-analogs (3.1g–3.1k) are one-pot 
sequential RCM/CM/“H2”, one-pot sequential protecting group manipulation, 
Mitsunobu/reduction/acrylation and a final one-pot sequential RCM/deprotection. 
Starting from readily prepared (S,S)-triene-3.3f and CM partner 3.4b, we were able to 
accomplish the synthesis of five structurally diverse analogs (3.1g–3.1k) of Sch-725674 
(3.1f) in five–seven pots with a total of ten–thirteen reactions requiring only five–seven 
workup and purification procedures, respectively. All five Sch-analogs have been 
submitted for antifungal and antibacterial screening to our biological collaborators.	  
3.4.1. Syntheses of macrolactone 3.1g and macrolactam 3.1h analogs of Sch-725674 
The synthesis of macrolactone analog 3.1g began with our previously optimized 
phosphate tether-mediated one-pot sequential RCM/CM/“H2”29 protocol (Scheme 3.10). 
(S,S)-triene 3.3f was cyclized via RCM reaction using HG-II catalyst, after completion of 
RCM reaction, the solvent was evaporated and CM partner 3.4b was introduced in DCE 
followed by HG-II catalyst (10 mol%) and the reaction mixture was heated at 70 ºC for 5 
h. After completion of CM event, the reaction mixture was brought to room temperature 
and the crude product was subjected to a chemoselective hydrogenation reaction using o-
NBSH and Et3N (2 mL/g of o-NBSH).33 This one-pot three-reaction sequence afforded 
the bicyclic phosphate 3.10.3 in 62% yield with 85.5% av/rxn. Regio- and 
diasteroselective allylic cuprate displacement reaction of bicyclic phosphate 3.10.3 
utilizing CuCN, LiCl and Me2Zn afforded the monocyclic phosphate 3.10.4. The crude 
acid 3.10.4 obtained was subsequently subjected to phosphate tether removal using Red-
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Al®, which afforded the requisite polyol 3.10.5 bearing a stereotetrad in 79% yield over 
two reactions in two pots with a single chromatographic purification. 
Scheme 3.10. Synthesis of TBS protected diol 3.10.5. 
 
The TBS-protected diol 3.10.5 was next subjected to a one-pot sequential MOM-
protection/TBS-deprotection/acrylation sequence (Scheme 3.11).7 To this end, the 
alcohol 3.10.5 was first subjected to MOM-protection using MOMCl, DIPEA and 
CH2Cl2. After completion of reaction, the TBS-group was removed using TBAF in 
refluxing THF for 1 h, which produced the alcohol fragment 3.11.2. The crude alcohol 
3.11.2 was acrylated using Et3N and acryloyl chloride at 0 ºC, which furnished the 
acrylate fragment 3.11.3 in 72% yield over three reactions in one-pot (90% av/rxn). 
Finally, a one RCM/MOM-deprotection sequence afforded the macrolactone 3.1g in 85% 
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Scheme 3.11. Synthesis of macrolactone analog 3.1g. 
 
Accordingly, we were able to accomplish the synthesis of macrolactam analog 
3.1h using three consecutive one-pot sequential operations, starting from TBS-protected 
alcohol 3.10.5 (Scheme 3.12). Accordingly, a one-pot sequential MOM-protection/TBS-
deprotection afforded the MOM-protected alcohol 3.12.1 in excellent yield (89% over 
two reactions in one-pot 94.5% av/rxn). Next, we carried out a one-pot sequential 
transformation consisting of a Mitsunobu/reduction/acrylation sequence to furnish the 
acrylamide 3.12.4 in excellent yield. To this end, the MOM-protected alcohol 3.12.1 was 
subjected to Mitsunobu reaction using DPPA, DIAD, in THF. After completion of 
Mitsunobu reaction, the crude azide 3.12.2 was reduced using LiAlH4 at 0 ºC in THF to 
furnish the amine product 3.12.3 without any solvent change. Acrylation of the crude 
amine afforded the acylamide fragment 3.12.4 in 74% yield over three reactions in one-
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(Scheme 3.11), the diene 3.12.4 was subjected to a final one-pot RCM/MOM-
deprotection sequence to accomplish the synthesis of macrolactam analog 3.1h in good 
yield over two reactions in one-pot.  
Scheme 3.12. Synthesis of macrolactam analog 3.1h of Sch-725674. 
 
Overall both analogs 3.1g and 3.1h of Sch-725674 (3.1f) were efficiently 
synthesized in a pot- and step-economical manner from readily prepared starting 
materials (3.3f and 3.4b) over five and six pots consisting of a total of ten and twelve 
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3.4.2. Syntheses of amine substituted macrolactone 3.1i and 3.1j  
For the syntheses of both macrolactone 3.1i and 3.1j, the common precursor 
3.10.5 was subjected to a consecutive three one-pot sequential processes, which furnished 
the desired products (3.1i and 3.1j) in efficient and pot-economical manner (Scheme 
3.13). Toward this goal, the TBS-protected diol 3.10.5 was subjected to a one-pot 
sequential Mitsunobu/reduction/Boc-protection sequence to furnish the Boc-protected 
amine 3.13.2 in 80% yield over three reactions in one-pot (93% av/rxn). A second one-
pot two reactions sequence consisting of TBS- deprotection/acrylation enabled the 
synthesis of acrylate fragment 3.13.3 in excellent yield over two reactions.  
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Next, we carried out a third consecutive one-pot sequential RCM/Boc 
deprotection sequence, which afforded the macrolactone analog 3.1i in 69% yield over 
two reactions. The corresponding macrolactone analog 3.1j was obtained by simply 
quenching the HCl salt of amine substituted macrolactone 3.1i with NaHCO3 to afford 
the Michael addition product 3.1j in 67% yield for the three reactions in one-pot. Both 
the amine substituted macrolactone analogs 3.1i and 3.1j were efficiently synthesized 
starting from readily prepared (S,S)-triene, 3.3f and CM partner 3.4b  in a sequence of six 
pots consisting of a total of twelve and thirteen reactions, respectively. 
3.4.3. Synthesis of amine substituted macrolactam 3.1k  
In similar fashion, the amine substituted macrolactam analog 3.1k was 
synthesized in three pots consisting a total of six reactions starting from Boc-protected 
amine 3.13.2 (Scheme 3.14). Toward this goal, the TBS-deprotection of 3.13.2 afforded 
the alcohol 3.14.1 in excellent yield.  
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Subsequently, a one-pot Mitsonubu/reduction/acrylation sequence produced the 
acrylamide 3.14.4 in 75% yield over three reactions in one pot. Finally, the acrylamide 
3.14.4 was converted to the corresponding macrolactam 3.1k via a one-pot RCM/Boc 
deprotection in 70% yield for two reactions in a single pot. Overall, we were able to 
accomplish the asymmetric synthesis of amine substituted macrolactam analog 3.1k of 
Sch-725674 from readily prepared (S,S)-triene 3.3f and CM partner 3.4b in 7 pots 
consisting a total of thirteen reactions. 
3.5. Conclusion  
In summary, we were able to accomplish the asymmetric synthesis of structurally 
diverse analogs of Sch-725674 in a rapid, efficient, pot-economical and library amenable 
manner. In this regard, five different Sch-analogs 3.1g–3.1k were synthesized via a 
sequence of 5-to-7 consecutive one-pot sequential operations consisting of a total of 10–
13 reactions with only 5-to-7 workup/purification procedures. All final compounds have 
been submitted for biological evaluations (antifungal and antibacterial activities) to our 
collaborators. 
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Bioactive natural products and corresponding analogs with unique structural 
features have long been a center of attention for organic chemists. In particular, marine 
macrolide glycosides1 with cytotoxic, antibacterial,2 antifungal and antiviral3 activities 
have inspired many successful total syntheses. (–)-Lyngbouilloside (4.1) 4  and (–)-
lyngbyaloside B (4.1d)5 are closely related cytotoxic 14-membered macrolides, which 
were isolated in 2002 from two different marine cyanobacteria of the genus lyngbya 
bouillonii (Oscillatoriaceae) (Figure 4.1). Initial biological screening demonstrated that 
4.1a and 4.1d exhibit modest cytotoxic activity against neuroblastoma and KB cells with 
IC50 values of 17 µM and 4.3 µM, respectively.6 Motivated by the biological activity and 
unique structural features of both (–)-lyngbouilloside (4.1a) and (–)-lyngbyaloside B 
(4.1d), a number of partial and total syntheses of 4.1a and 4.1d have been reported in the 
literature.7  
In 2013, Fuwa and coworkers reported the total synthesis of (–)-13-desmethyl-
lyngbyaloside B (4.1f) as part of their ongoing program towards the total synthesis of 
lyngbyaloside B (4.1d) (Figure 4.1).7d Later, in 2015, they accomplished the total 
synthesis of (–)-lyngbyaloside B (4.1d).7e Based on spectroscopic analysis, the authors 
reported that the previously assigned stereochemical configuration of 4.1d was incorrect. 
The authors, therefore, reassigned the stereochemical configuration of (–)-lyngbyaloside 
B (4.1d) and resynthesized (–)-lyngbyaloside B (4.1e) with the corrected stereochemical 
configuration (Figure 4.1). After completion of the total synthesis of 4.1e, Fuwa and 
coworkers evaluated the anti-proliferative activity of 4.1d, 4.1e, 4.1f and (–)-
lyngbyaloside B aglycon against human cancer cells lines and found good inhibition 
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potencies against the proliferation of HL-60 cells.7e These biological results revealed 
some important implications for understanding the structural activity relationship of  
(–)-lyngbyaloside B and its unnatural analogs including; (i) the presence of 3,4-di-o-
methyl-L-rhamnopyranoside moiety is essential for anti-proliferative activity against the 
tested cell lines, (ii) analysis of stereochemical configuration at the C10/C11 position in 
4.1d and 4.1e had no effect on the anti-proliferative activity, and (iii) (–)-13-desmethyl-
lyngbyaloside B (4.1f) displayed more potent anti-proliferative activity against all tested 
cell lines compared to 4.1d and 4.1e.  
 
Figure 4.1. (–)-lyngbouilloside (4.1a),  and (–)-lyngbyaloside B (4.1e) and their 
corresponding unnatural analogs. 
This revelation is of prime importance since the omission of the methyl 
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compounds with enhanced anti-proliferative activity against HL-60 cells, but also 
significantly simplifies the synthesis (32 steps for 4.1d; 22 steps for 4.1f, Figure 4.1). 
Motivated by these intriguing results and aligned with our ongoing efforts toward the 
total synthesis of (–)-lyngbouilloside (4.1a), we were interested in the asymmetric 
synthesis and biological evaluation of (–)-13-desmethyl-lyngbouilloside (4.1c) and 
corresponding analogs (Figure 4.1). This chapter will describe a brief history of the 
previously reported total syntheses of (–)-lyngbouilloside (4.1a), (–)-lyngbyaloside B 
(4.1d) and the ongoing efforts towards the asymmetric total synthesis of (–)-13-
desmethyl-lyngbouilloside (4.1c). 
4.2. Overview of previous efforts toward the syntheses of (–)-lyngbouilloside 
(4.1a)  
 
In 2002, Gerwick and coworkers isolated and structurally characterized a novel 
cytotoxic macrolide, (–)-lyngbouilloside (4.1a), from cyanobacteria lyngbya bouillonii.  
(–)-Lyngbouilloside display modest cytotoxic activity against neuroblastoma cells with 
an IC50 value of 17 µM.4 Based on spectroscopic analysis and chemical derivatization, the 
structure of 4.1a was identified as a glycosylated 14-membered macrolide (Figure 4.1) 
containing a six-membered cyclic hemiketal, an (E,E)-configured octadienyl side chain, 
and an L-rhamnose-derived pyranoside ring at the C5 position of the macrolactone ring. 
Thus far, there is no literature report of the total synthesis of (–)-lyngbouilloside (4.1a). 
However, there are a number of reports of the partial syntheses of 4.1a. 
4.2.1. Stereoselective synthesis of the C1–C13 fragment of (–)-lyngbouilloside 
In 2008, Cossy and coworkers reported the first stereoselective synthesis of the 
fully functionalized carbon backbone 4.2a of (–)-lyngbouilloside using a pivotal cross-
metathesis (CM) reaction between fragments 4.2b and 4.2c (Figure 4.2).7a The authors 
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envisioned a retrosynthetic approach for the C9–C13 fragment 4.2b that could be 
synthesized from commercially available (S)-citramalic acid (4.2d) whereas the C1–C8 
fragment 4.2c could be accessed from commercially available 4-pentenal (4.2e). 
 
Figure 4.2. Retrosynthetic analysis of the C1–C13 fragment of (–)-lyngbouilloside (4.1a). 
The forward synthesis of the subunit 4.2b commenced with esterification of  
(S)-citramalic acid (4.2d) followed by reduction of the resulting dimethyl citramalate, to 
access the corresponding 1,2-diol (Scheme 4.1). Subsequent selective protection as an 
acetonide using acetone and PTSA provided the known acetal fragment 4.1.1 in 76%, 
overall yield. The acetal fragment was oxidized to the aldehyde using PCC, which was 
converted to the corresponding homoallylic alcohol with high diastereoselectivity (dr > 
95:5) using a face-selective crotyltitanium complex (S,S)-Ti8 (72% over all yield). The 
resulting alcohol was protected as PMB ether, affording the CM partner 4.2b in 93% 
yield.  
The synthesis of fragment 4.2c began with an aldol reaction of 4.1.2 with 
commercially available 4-pentenal to furnish the alcohol 4.1.3. Allylic oxidation was 
performed using SeO2 and t-BuOOH to access the required enone fragment 4.2c. With 
both desired fragments (4.2b and 4.2c) in hand, a cross-metathesis reaction was 
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olefin in the enone fragment using H2 on Pd/C to afford the fully functionalized backbone 
of (–)-lyngbouilloside (4.1a). Finally, reduction of the ketone moiety in fragment 4.1.4 
using Me4N(OAc)3BH (TABH) furnished the C1–C13 fragment in excellent yield. 
Overall, the synthesis of fully functionalized C1–C13 fragment 4.2a of  
(–)-lyngbouilloside was achieved in nine steps with 38% overall yield starting form 
commercially available (S)-citramalic acid (4.2d). 
Scheme 4.1. Synthesis of fragments 4.2b and 4.2c and completion of fully functionalized 
C1–C13 fragment 4.2c of (–)-lyngbouilloside (4.1a). 
 
 
4.2.2. Enantioselective synthesis of the lyngbouilloside macrolactone core 
In 2009, Ley and coworkers reported an enantioselective synthesis of the 
macrolactone core 4.3b of (–)-lyngbouilloside (4.1a) (Figure 4.3).7b The key reactions 
involved in the synthesis of 4.3b were enolate-lactone coupling and a late-stage 
RCM/hydrogenation sequence that furnished the macrolactone core of 4.1a in a 
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NMR chemical shift calculations, the authors proposed that the stereochemical 
assignment at the C11 position of (–)-lyngbouilloside (4.1a) might be incorrect. 
 
Figure 4.3. Retrosynthetic analysis of macrolactone core 4.3b of (–)-lyngbouilloside 
(4.1a). 
 The required lactone 4.3d and ester 4.3c fragments for the construction of 
macrolactone 4.3b were synthesized from the corresponding known ynone 4.2.110 and 
epoxide 4.2.211 in seven and eight steps, respectively (Scheme 4.2). The lactone 4.3d was 
treated with two equivalents of the lithium enolate of 4.3c to afford the corresponding 
lactol in quantitative yield, which was subsequently converted to the acetal fragment 
4.2.3 in 98% yield. After extensive model reaction studies, the diene fragment 4.2.3 was 
successfully cyclized to the macrolactone fragment 4.3b utilizing the HG-II catalyst. The 
macrolactone was next subjected to TBS-deprotection using TBAF, followed by 
hydrogenation of the resulting C=C double bond using H2, Pd/C, and demethylation 
using PPTS, to provide the fully functionalized macrolactone core 4.2.5 of  




















































Scheme 4.2. Convergent synthesis of macrolactone core 4.2.4 of lyngbouilloside. 
 
4.2.3. Asymmetric total synthesis of (–)-lyngbouilloside aglycon 
In 2012, Cossy and coworkers reported the first enantioselective total synthesis of 
(–)-lyngbouilloside aglycon 4.4a according to the originally assigned structure (Figure 
4.4). The authors utilized a pivotal acylketene macrolactonization of a tertiary methyl 
carbinol (C13 in 4.4a)7c to circumvent fundamental issues associated with 
macrolactonization of sterically encumbered alcohols. Based on spectroscopic analysis, 
the authors proposed a revised structure of (–)-lyngbouilloside (4.1b) with a 
stereochemical reassignment of the C11 stereogenic center. The authors proposed that 
lyngbouilloside aglycon 4.4a could be assembled via macrolactonization of the 1,3-anti-
diol fragment 4.4b, which in turn can be synthesized from β-hydroxyenone 4.4c (Figure 
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4.4d and 4.4e via a CM reaction. Both 4.4d and 4.4e could be readily prepared from 
commercially available 3-methylbut-3-enol (4.4f) and 4-pentenal (4.4g), respectively. 
 
Figure 4.4. Retrosynthetic analysis of lyngbouilloside aglycon 4.4a. 
The forward synthesis of lyngbouilloside aglycon commenced with the synthesis 
of the CM partner 4.4d (Scheme 4.3), which was completed in nine steps starting from 
commercially available 3-methylbut-3-enol (4.4f). Cross metathesis reaction between diol 
fragment 4.4d and previously reported enantiopure dioxinone fragment 4.4e7a using the 
HG-II catalyst, afforded the enone fragment 4.4c in 78% yield with excellent E-
selectivity (E/Z > 95:5). Conjugate reduction of the enone fragment 4.4c, using Stryker’s 
reagent,12 afforded the β-hydroxy ketone, which was subsequently subjected to the Evans 
TABH-mediated 1,3-anti reduction.13  This two-step sequence afforded 1,3-anti diol 
fragment 4.4b in 71% overall yield with excellent diastereoselectivity (dr >95:5). Next, 











































































the three secondary alcohols were selectively reprotected utilizing TESCl and imidazole, 
which provided the macrocyclization precursor in 60% yield over two steps.  
Scheme 4.3. Total synthesis of (–)-lyngbouilloside agylcon 
 
The 14-membered macrolactone core was efficiently assembled via thermolysis 
of the corresponding dioxinone under rigorous anhydrous conditions, whereby the 
resulting acylketene intermediate was trapped with free quaternary alcohol to provide the 
macrolactone core 4.3.1. TES-deprotection with THF•Py resulted in the simultaneous 
formation of the pyran ring, followed by TIPS-group removal using AgF•py, which 
furnished the terminal alkyne. A Sonogashira coupling reaction of the terminal alkyne in 
4.3.1 enabled the installation of the side chain, followed by a one-pot 
hydrosilylation/protodesilylation completed the synthesis of (–)-lyngbouilloside aglycon 
4.4a in 18% over the last four steps. In summary, Cossy and coworkers completed the 
asymmetric total synthesis of lyngbouilloside aglycon 4.4a in 20 steps with 2.1% overall 
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4.2.4. Phosphate tether-mediated synthesis of macrolactone core of (–)-
lyngbouilloside 
In 2015, the Hanson group reported a concise synthesis of the macrolactone core 
4.5a, based on the originally assigned structure of (–)-lyngbouilloside (4.1a) (Figure 
4.5).7g The key reactions involved in the synthesis of macrolactone core 4.5a were 
phosphate tether-mediated one-pot sequential RCM/CM/chemoselective hydrogenation,15 
Roskamp homologation, 16  and Boeckman acylketene cyclization. 17  Retrosynthetic 
analysis revealed that the macrolactone core 4.5a could be generated from β-ketoester 
4.5b via a Boeckman acylketene cyclization (Figure 4.5). The β-ketoester 4.5b in turn 
could be accessed via oxidative cleavage of the terminal olefin in 4.5c, followed by a 
two-carbon Roskamp homologation of the resulting aldehyde. 
 




























































The alkene fragment 4.5c could be obtained via a phosphate tether-mediated one-pot, 
sequential RCM/CM/chemoselective hydrogenation of (R,R)-triene 4.5e 18  and CM 
partner 4.5d. The key fragment 4.5d could be generated in nine steps from commercially 
available geraniol (4.5f) involving Brown anti-crotylation and Sharpless asymmetric 
epoxidation as key reactions. 
The forward synthesis of macrolactone core 4.5a commenced with the synthesis 
of the C8–C16 fragment 4.5d (Scheme 4.4). The commercially available geraniol (4.5f) 
was subjected to Sharpless asymmetric epoxidation19 followed by regioselective opening 
of the resulting epoxide using Red-Al, afforded the 1,3-diol fragment in 85% yield.20 The 
resulting 1,3-diol was subsequently protected as PMP-acetal 4.4.1 with 1:1 
diastereoselectivity. Next, the authors subjected the olefin 4.4.1 to ozonolysis, and the 
resulting aldehyde was reduced to the corresponding primary alcohol 4.4.2 via an in situ 
reductive workup. TBS-protection of the primary alcohol in 4.4.2 followed by 
regioselective opening of the PMP-acetal ring using DIBAL furnished the alcohol 
fragment 4.4.3 in excellent yield.  
Scheme 4.4. Synthesis of C8–C16 fragment from geraniol (4.5f). 
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Primary alcohol 4.4.3 was subjected to Parikh-Doering oxidation 21  followed by 
asymmetric Brown anti-crotylation,22 which afforded the required homoallylic alcohol 
4.4.4 in 72% yield over two steps. The authors performed TBS-protection of the 
secondary alcohol in 4.4.4 to complete the synthesis of the requisite C8–C16 CM partner 
4.4d in excellent yield.  
With the CM partner 4.4d in hand, the Hanson and coworkers performed a 
phosphate tether-mediated one-pot sequential RCM/CM/chemoselective hydrogenation to 
couple (R,R)-triene-4.5e with CM partner 4.4d (Scheme 4.5). This one-pot three-reaction 
protocol afforded the bicyclic phosphate 4.5.1 in 65% overall yield (87% av/rxn). 
Scheme 4.5. Synthesis of lyngbouilloside macrolactone 4.5a. 
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Regioselective opening of bicyclic phosphate 4.5.1 via Pd-catalyzed reductive allylic 
transposition, followed by methylation using TMSCHN2 in MeOH, afforded the 
monocyclic phosphate ester in excellent overall yield (82%). The phosphate tether was 
removed using LiAlH4 to furnish 1,3-anti-diol fragment 4.5.2 as a single diastereomer in 
good yield. The free alcohols in 1,3-anti-diol fragment 4.5.2 were protected with TESOTf 
(2,6-lutidine, CH2Cl2) to generate TES-protected alcohol 4.5c in quantitative yield. The 
olefin 4.5c was subjected to oxidative cleavage employing a modified Johnson-Lemieux 
protocol developed by Jin and coworkers23 to afford the corresponding aldehyde 4.5.3. 
The crude aldehyde, without further purification, was subjected to Roskamp 
homologation16 to provide β-keto ester 4.5.4 in 76% yield over two steps with only one 
purification procedure. Next, PMB-ether was deprotected using DDQ to generate alcohol 
4.5b in 98% yield. Boeckman acylketene cyclization17 of the resulting alcohol in 
refluxing toluene (0.0007 M) afforded the macrolactone core 4.5a of (–)-lyngbouilloside 
(4.1a) in good yield (90%). 
4.3. Isolation, biological activity and total synthesis of (–)-lyngbyaloside B (4.1d) 
reported by the Fuwa group 
In 2002, the Moore group isolated a structurally similar 14-membered macrolide 
(–)-lyngbyaloside B (4.1d) from cyanobacterium Lyngbya sp. (Figure 1).5 Initial 
biological screening demonstrated that (–)-lyngbyaloside B exhibited moderate cytotoxic 
activity against KB cells with IC50 values of 4.3 µM. The structure and relative 
stereochemical configuration of 4.1d were proposed based on extensive 2D-NMR studies 
and ROESY correlations. However, the absolute stereochemistry of (–)-lyngbyaloside B 
(4.1d) remained unknown due to the scarce availability of the authentic natural source.  
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4.3.1. Total synthesis of (–)-13-desmethyl-lyngbyaloside B  
In 2013, Fuwa and coworkers reported the synthesis of (–)-13-desmethyl-
lyngbyaloside B (4.1f), an unnatural analog of (–)-lyngbyaloside B (4.1d) (Figure 4.6).7d 
Upon retrosynthetic analysis of (–)-13-desmethyl-lyngbyaloside B (4.1f), the authors 
envisioned that 4.1f could be assembled from the corresponding macrolactone 4.6a via 
glycosylation 24  and a Stille-type reaction, 25  which install the L-rhamnose-derived 
pyranoside ring 4.6b at the C5 position of the macrolactone core and the bromodiene side 
chain 4.6c, respectively. The macrolactone core 4.6a could be constructed through a 
convergent manner from alcohol 4.6d and carboxylic acid 4.6e using Yamaguchi reaction 
conditions followed by RCM reaction.  
 
Figure 4.6. Retrosynthetic analysis of (–)-13-desmethyl-lyngbyaloside B (4.1f). 
The required alcohol fragment 4.6d and carboxylic acid 4.6e were synthesized in 
seven and nine steps, respectively, from a known homoallylic alcohol26 and a TES-
protected alcohol (Scheme 4.6).27 The diene fragment 4.6.1 was assembled in quantitative 
yield from the corresponding carboxylic acid 4.6e and alcohol fragments 4.6d via 
esterification reaction.28 Ring-closing metathesis of the diene 4.6.1 using the HG-II 












































resulting C–C double bond, and selective deprotection of TBDPS with TBAF, furnished 
the alcohol 4.6.3 in 86% yield over 2 steps. 
Scheme 4.6. Total synthesis of (–)-13-desmethyl-lyngbyaloside B (4.1f). 
 
Oxidation of the primary alcohol in 4.6.3 followed by Takai olefination29 of the 
resulting aldehyde and MPM deprotection furnished the (E)-vinyl iodide 4.6.4 in good 
yield. The resulting (E)-vinyl iodide was subsequently coupled with vinyl stannane 4.6c30 
via Stille type reaction to afford the vinyl silane 4.6.5 in 74% yield. Bromodesilylation31 
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glycosylation reaction to introduce the L-rhamopyranose ring stereoselectively at C5 
position of the macrolactone core by treating the aglycon 4.6.6 with trichloroacetimidate 
4.6b. Finally, global deprotection led to the completion of 4.1f. Taken collectively, 
starting form the known homoallylic alcohol26 the synthesis of (–)-13-desmethyl-
lyngbyaloside B (4.1f) was completed in 7% overall yield in a route having an LLS of 20 
steps. 
4.3.2. Total synthesis and biological evaluation of (–)-lyngbyaloside B and 
its analogs 
In 2015, Fuwa and coworkers reported the first total synthesis, stereochemical 
reassignment, and biological evaluation of (–)-lyngbyaloside B (4.1d).7e 
Retrosynthetically, the authors planned a late-stage introduction of glycoside ring 4.7b 
and bromodiene side chain via glycosylation24 and Stille-type reaction,25 respectively 
(Figure 4.7). The macrolactone core 4.7a was envisaged via macrocyclization of 
acylketene generated from the corresponding dioxinone fragment 4.7c. 
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The dioxinone fragment was planned in a convergent manner from the olefin fragment 
4.7d, aldehyde 4.7e and a known silyl dienol ether 4.7f using a Abiko–Masamune anti-
aldol reaction,32 followed by a vinylogous Mukaiyama aldol reaction. 33  
The forward synthesis of (–)-lyngbyaloside B (4.1d) began with the synthesis of 
olefin fragment 4.7d and aldehyde fragment 4.7e (Scheme 4.7). Both 4.7d and 4.7e were 
synthesized from the corresponding known aldehyde34 and ester35 fragments in six and 
eight steps, respectively. The key building blocks 4.7d and 4.7e were subsequently 
subjected to Abiko-Masamune anti-aldol reaction32 to afford the alcohol 4.7.1 in 87% 
yield (d.r. = 10:1). Silylation of the alcohol 4.7.1 using TBSCl, followed by reductive 
removal of the ester, provided the primary alcohol in 79% yield. The resulting alcohol 
was subsequently subjected to tosylation, followed by reduction with LiEt3BH, furnished 
olefin 4.7.2 in good yield. Oxidative cleavage of the terminal olefin in 4.7.2 afforded 
aldehyde 4.7.3 in 92% over two reactions.  
A vinylogous Mukaiyama Aldol reaction33 of aldehyde 4.7.3 provided the 
dioxinone fragment 4.7.4 in 87% yield. TES-protection of the alcohol in 4.7.4, followed 
by MPM-deprotection, afforded the quaternary alcohol 4.7c in 93% yield. The alcohol 
was subsequently cyclized to the corresponding macrolactone in refluxing toluene, 
followed by exposure to acidic conditions (PPTS, MeOH), to provide the methyl acetal 
4.7.5 in 88% yield. Selective TBS-deprotection, followed by oxidation of the resulting 
primary alcohol using TEMPO and PhI(OAc)2, provided the aldehyde fragment in 96% 
yield. Takai iodoolefination of the aldehyde afforded the vinyl iodide 4.7a in 54% yield 
as an inseparable mixture of E/Z isomers (7:1). Next, the authors coupled the vinyl iodide 
4.7a with vinyl stannane 4.6c through a Stille-type reaction to afford vinyl silane 4.7.6 in 
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73% yield. Bromodesilylation of vinyl silane, followed by stereoselective glycosylation 
with trichloroacetimidate 4.7b, afforded 4.7.8 in 71% yield. Finally, global deprotection 
using NaOMe and HF provided the natural product (–)-lyngbyaloside B (4.1d) in good 
yield.36 
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Based on spectroscopic analysis, Fuwa and coworkers reported that the previously 
assigned stereochemical configuration of (–)-lyngbyaloside B (4.1d) was incorrect 
(Figure 4.8).7e Utilizing 13C NMR, 1H NMR and ROESY correlations the authors 
reassigned the stereochemcial configuration at C10/C11 of (–)-lyngbyaloside B (4.1e). 
The authors synthesized (–)-lyngbyaloside B (4.1e) from the corresponding ent-4.8a and 
4.8b in similar fashion as described for 4.1d. 37 The specific rotation value obtained for 
4.1e ([a]D25 –16.9 (c 0.20, CHCl3)) was in close agreement with the authentic natural 
product ([α]D25 –20 (c 0.10, CHCl3)). After resynthesizing (–)-lyngbyaloside B (4.1e) the 
authors tested the natural product (–)-lyngbyaloside B (4.1e) and its unnatural analogs 
(4.1d, 4.8b and 4.5a) against human cancer cells lines and found good inhibition 
potencies against the proliferation of HL-60 cells. 
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4. 4. Results and Discussion 
4.4.1. Proposed retrosynthetic analysis of (–)-13-desmethyl-lynbouilloside (4.1c) 
Inspired by these efforts, as well as intriguing biological activity, our proposed 
retrosynthetic analysis revealed that (–)-13-desmethyl-lynbouilloside 4.1c could be 
accomplished via glycosylation and Julia olefination of macrolactone 4.9a, which in turn 
can be accessed from the β-ketoester 4.9b via Boeckman acylketene cyclization (Figure 
4.9).17 Oxidative cleavage of the terminal olefin in 4.9c, followed by Roskamp two-
carbon homologation,16 would enable the synthesis of β-ketoester 4.9b. Olefin 4.9c was 
planned from the corresponding bicyclic phosphate 4.9d via a one-pot, sequential, three-
reaction protocol consisting of Pd-catalyzed reductive allylic transposition/ 
methylation/reductive tether removal of phosphate tether.  
 
 


















































































The synthesis of the bicyclic phosphate 4.9d was envisaged from (R,R)-triene 4.9e and 
CM partner 4.9f via phosphate tether-mediated one-pot sequential 
RCM/CM/chemoselective hydrogenation “H2” protocol.15 The advanced fragment 4.9f 
could be accomplished from (S,S)-triene 4.9g, via an iterative one-pot sequential 
RCM/CM/“H2” protocol, followed by a one-pot sequential TIPS/MOM protection. 
4.4.2. Forward synthesis of (–)-13-desmethyl-lynbouilloside (4.1c) 
Toward the aforementioned goal, the forward synthesis of (–)-13-desmethyl-
lynbouilloside commenced with the synthesis of CM partner 4.9f (Scheme 4.8). Utilizing 
our previously developed phosphate tether-mediated one-pot sequential 
RCM/CM/chemoselective hydrogenation “H2” protocol, we were able to synthesize 
bicyclic phosphate 4.8.3 in 53% over three reactions (81% av/rxn) in a single pot. In this 
regard, (S,S)-triene 4.9g was first subjected to RCM reaction utilizing the HG–II catalyst 
(3 mol%). After completion of RCM, the solvent was evaporated and CM partner 4.8.1 
was introduced as solution in DCE followed by the HG–II (6 mol%) catalyst under 
argon. The reaction mixture was heated to 70 ºC for 6 h, and next another portion of the 
HG–II catalyst (4 mol%) and CM partner was added, and the reaction mixture stirred for 
an additional 4 h at 70 ºC.  
After complete consumption of starting material, the crude CM product 4.8.2 was 
subjected to chemoselective hydrogenation of the external olefin in 4.8.2 using o-NBSH 
and Et3N (2ml/1g of o-NBSH) to afford the bicyclic phosphate 4.8.3 in 53% yield over 
three reactions in one pot (81% av/rxn). Regio- and diastereoselective allylic cuprate 
additions to the bicyclic phosphate 4.8.3 using CuCN, LiCl and Me2Zn provided the acid, 
which was subsequently subjected to phosphate tether removal by RedAl to afford the 
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required triol 4.8.4 bearing a stereotriad in 80% yield over two reactions in two pots, 
followed by a single purification procedure. Taking advantage of the steric factor, we 
were able to selectively protect the alcohol at the C6 position in 4.8.4 using TIPSOTf and 
2,6-lutidine. The crude product was subsequently protected as the MOM-ether using 
MOMCl and DIPEA in the same pot, with no solvent change to provide the CM partner 
4.9f in 95 % yield over two reactions in one-pot with 97.5% av/rxn. 
Scheme 4.8. Synthesis of CM partner 4.9f (four pots, seven reactions). 
 
With the CM partner 4.9f in hand, we carried out an iterative phosphate tether-
mediated one-pot sequential RCM/CM/“H2” protocol to assemble the bicyclic phosphate 
4.9d (Scheme 4.9). Toward this goal, (R,R)-triene 4.9e was cyclized via RCM reaction 
using the HG–II catalyst (3 mol%). After completion of RCM, the solvent was 
evaporated and the crude bicyclic phosphate was treated with CM partner 4.9f in DCE 
under argon. The reaction mixture was refluxed for 24 hours, and the HG-II catalyst and 
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triene 4.9f = 1.2 equiv., 0.2 equiv., 0.2 equiv.) after 10, 8 and 6 hours, respectively. After 
completion of the CM reaction, crude product 4.9.1 was subjected to chemoselective 
hydrogenation “H2” reaction using o-NBSH and Et3N (2mL of Et3N/1g of o-NBSH) at 
room temperature.  
Scheme 4.9. Synthesis of key fragment 4.9.4 (six reactions in two pots). 
 
It should be noted, that for the chemoselective hydrogenation of the external olefin in the 
crude CM product 4.9.1, five equivalents of o-NBSH and Et3N (2mL of Et3N/1g of o-
NBSH) were added sequentially every 8 hours and the reaction mixture was stirred for 72 
hours at room temperature. The bicyclic phosphate 4.9d was obtained in 47% yield over 
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The bicyclic phosphate 4.9d was subjected to a one-pot sequential Pd-catalyzed 
reductive allylic transposition/methylation/reductive tether removal protocol37 furnishing 
1,3-anti-diol fragment 4.9.4 in 51% yield over a three reaction-sequence in one-pot (81% 
av/rxn). This one-pot processes began with Pd-catalyzed reductive allylic transposition 
[Pd(OAc)2, PPh3 HCOOH, Cs2CO3] to afford the terminal olefin 4.9.2, which was 
subsequently methylated in the same pot with no solvent change using dimethyl sulfate 
(Me2SO4). After methylation, the phosphate tether was removed under reductive 
conditions, using LiAlH4, to afford the key fragment 4.9.4 in 51% yield over three 
reactions in one-pot (81% av/rxn). 
With 1,3-anti diol 4.9.4 in hand, PMB-protection of the 1,3-anti-diol in 4.9.4 
using PMBBr (NaH, THF) afforded the PMB-protected alcohol 4.9c in 71% yield 
(Scheme 4.10). Oxidative cleavage of the terminal olefin in 4.9c using a modified 
Johnson-Lemieux protocol developed by Jin and coworkers23 (OsO4, NaIO4, 2,6-lutidine) 
provided the corresponding aldehyde 4.10.1. Without further purification, the crude 
aldehyde 4.10.1 was subjected to a two-carbon Roskamp homologation16 using ethyl 
diazoacetate and SnCl4•5H2O to afford the β-keto ester 4.10.2 in 69% overall yield, over 
two reactions in two pots and one purification procedure. Next, we deprotected the TIPS-
group using TBAF to afford the Boeckman cyclization precursor 4.9b in 87% yield. 
Thermolysis of the β-keto ester 4.9b in toluene (0.0007 M) using a Dean-Stark condenser 
afforded the macrolactone 4.9a in 81% yield. So far, we are at this stage of the synthesis 
of (–)-13-desmethyl-lyngbouilloside (4.1c), further studies towards the completion of the 
molecule are in progress.  
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Scheme 4.10. Synthesis of macrolactone core of (–)-13-desmethyl-lynbouilloside. 
 
4.5. Conclusion 
In summary, we have accomplished the asymmetric synthesis of the macrolactone 
core 4.9a of (–)-13-desmethyl-lyngbouilloside (4.1c) from readily prepared (R,R)-4.9e- 
and (S,S)-4.9g phosphate trienes. This efficient route highlights phosphate tether 
mediated process, which establish asymmetry and one-pot sequential protocol, which 
enabled the synthesis of the macrolactone core 4.9a in 11 longest linear pot sequence 
with a total of 18 reactions. This pot economical approach included four one-pot 
sequential operations, which minimized workup and chromatographic purification 





















































































completion of the molecule 4.1c are underway and will be reported in due course. 
Overall, this approach will enable the expedient syntheses of (–)-13-desmethyl-
lyngbouilloside (4.1c) and structurally diverse analogs of (–)-lyngbouilloside (4.1a).  
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General Experimental Section 
 All reactions were carried out in oven- or flame-dried glassware under argon 
atmosphere using standard gas-tight syringes, cannulae, and septa. Stirring was achieved 
with oven-dried magnetic stir bars. Et2O, THF and CH2Cl2 were purified by passage 
through a purification system (Solv-Tek) employing activated Al2O3  (Pangborn, A. B.; 
Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Safe and Convenient 
Procedure for Solvent Purification Organometallics 1996, 15, 1518–1520). Et3N was 
purified by passage over basic alumina and stored over KOH. Butyllithium was 
purchased from Aldrich and titrated prior to use. All olefin metathesis catalysts were 
acquired from Materia and used without further purification. Flash column 
chromatography was performed with Sorbent Technologies (30930M-25, Silica Gel 60A, 
40-63 µm) and thin layer chromatography was performed on silica gel 60F254 plates 
(EM-5717, Merck). 1H, 13C, and 31P NMR spectra were recorded on either a Bruker 
DRX-400 or Bruker DRX-500 MHz spectrometers operating at 400 MHz or 500 MHz for 
1H NMR, 101 MHz or 126 MHz for 13C NMR, and 162 MHz for 31P NMR using CDCl3 
or Methanol-d4 as solvents. The 1H NMR data are reported as the chemical shift in parts 
per million, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; p, pentet; m, 
multiplet), coupling constant in hertz, and number of protons. High-resolution mass 
spectrometry (HRMS) was recorded on a LCT Premier Spectrometer (Micromass UK 
Limited) operating on ESI (MeOH). Observed rotations at 589 nm were measured using 




5.1: Modular Synthesis of Novel Macrocycles Bearing α,β-Unsaturated 
Chemotypes via a Series of One-Pot, Sequential Protocols (Chapter-2). 




To a stirring solution of (R,R)-triene 2.3g (100 mg, 0.43 mmol)1 in a freshly 
distilled, freeze-degas-thawed CH2Cl2 (28 mL, 0.015 M) was added Hoveyda-Grubbs 2nd 
Gen. catalyst (HG-II) (5.4 mg, 2 mol %). The reaction mixture was refluxed (40 ºC) for 
30 min. After completion of RCM reaction (monitored via TLC), the solvent was 
evaporated and cross metathesis partner 2.3h (215 mg, 0.65 mmol)2 in a freshly distilled 
(FDT) 1,2-dichloroethane (DCE) (6.3 mL, 0.07 M) was added followed by the addition 
of HG-II catalyst (8 mg, 3 mol %). After being stirred for 4 h at 70 ºC, a second portion 
of HG-II (5.4 mg 2 mol %) and cross-metathesis partner 2.3h (143 mg 0.43 mmol) were 
added. The reaction mixture was stirred for further 4 h at 70 ºC (until TLC showed the 
consumption of starting materials). The reaction mixture was cooled to room temperature 
and o-nitrobenzenesulfonyl hydrazine (o-NBSH) (900 mg, 4.3 mmol) and Et3N (1.8 mL, 
at 2 mL/g) were added and stirred for 12 h (Note: the reaction flask was wrapped with 
                                                
[1].  For the preparation of (R,R)-4, see: a) A. Whitehead, M. D. McReynolds, J. D. Moore, P. R. Hanson, 
P. R. Org. Lett. 2005, 7, 3375−3378;  b) A. Whitehead, M. D. McReynolds, J. D. Moore, P. R. Hanson, 
P. R. Org. Lett. 2006, 8, 2657;  c) P. K. M. Venukadasula, R. Chegondi, S. Maitra, P. R. Hanson, Org. 
Lett. 2010, 12, 1556−1559. 
[2]. Rui, W. Boland, J. Org. Chem. 2010, 75, 3958–3964. 
o-NBSH, Et3N, rt, 18 h
40%, 3 rxns in one-pot







HG-II (2 mol %) 
CH2Cl2 (0.015 M)
 reflux, 30 min, then
HG-II (5 mol %), DCE 












aluminum foil to avoid decomposition of o-NBSH due to light). After 12 h, another 5 
equiv. of o-NBSH (450 mg, 2.15 mmol) and Et3N (1.8 mL, at 2 mL/g) were added. The 
reaction mixture was stirred for another 6 h until crude NMR showed the starting material 
was consumed completely. The reaction mixture was diluted with EtOAc and sat. 
NaHCO3 was added. The organic layer was extracted with EtOAc (3x200 mL) and the 
combined organic layers were washed with brine, dried (Na2SO4) and concentrated under 
reduced pressure. The crude compound was purified by flash column chromatography 
(hexane/EtOAc 1:3) to afford bicyclic phosphate 2.3i [90 mg, 40% yield over 3 reactions, 
74% average yield per reaction (av/rxn)] as a colorless viscous liquid. TLC (hexane/ethyl 
acetate 1/3): Rf: 0.48. 
FTIR (neat): 2929, 2854, 2358, 1471, 1303, 1253, 1103, 1072, 972, 835, 773 cm-1. 
Optical Rotation: [α]D23 = –79.6 (c 1.0, CHCl3).  
1H NMR (500 MHz, CDCl3): δ 7.37–7.27 (m, 5H), 6.03 (dddd, J = 12.0, 8.9, 5.4, 2.2 Hz, 
1H), 5.59 (ddd, J = 11.8, 4.0, 2.5 Hz, 1H), 5.23–5.13 (m, 1H), 5.00 (ddt, J = 14.8, 5.7, 2.8 
Hz, 1H), 4.60–4.54 (m, 1H), 4.53 (d, J = 1.2 Hz, 2H), 4.37 (ddd, JHP = 27.7, JHH = 14.7, 
6.7 Hz, 1H), 3.84–3.77 (m, 1H), 3.39 (dd, J = 9.7, 5.6 Hz, 1H), 3.35 (dd, J = 22.5, 9.7, 
5.5 Hz, 1H), 2.16 (ddd, J = 18.2, 11.8, 6.5 Hz, 1H), 1.79–1.67 (m, 2H), 1.59–1.47 (m, 
2H), 1.47–1.34 (m, 2H), 1.34–1.23 (m, 5H), 0.88 (s, 9H), 0.051 (s, 3H), 0.045 (s, 3H).  
13C NMR (126 MHz, CDCl3): δ 138.7, 130.1, 128.5 (2), 128.1, 127.8 (2), 127.7, 77.4, 
75.0, 73.5, 71.6, 63.2, 63.1, 35.9, 35.8, 35.0 (d, JCP = 5.9 Hz), 34.8, 29.6, 26.1 [(3), 
SiMe3], 25.3, 24.8, -4.1, -4.5. 
31P NMR (162 MHz, CDCl3): δ -3.75. 
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To a stirring solution of bicyclic phosphate 2.3i (245 mg, 0.48 mmol) in  
THF (1.6 mL, 0.3 M) under argon was added Cs2CO3 (780 mg, 2.4 mmol) and HCO2H 
(48 µL, 1.2 mmol). Next, a solution of 5 mol % Pd(OAc)2 (7.7 mg, 0.024 mmol) and 
PPh3 (12 mg, 0.048 mmol) in THF (1.6 mL) under argon was immediately transferred via 
cannulae to the reaction mixture. The reaction mixture was stirred at 60 ºC for 1 h 
(monitored by TLC). After 1 h, all starting materials were consumed and the color of 
reaction mixture turned black. After the reaction was complete, dimethylsulfate (Me2SO4) 
was added and the reaction mixture was refluxed for 3 h (TLC showed that phosphate 
acid was methylated completely). The reaction mixture was cooled to 0 ºC, then LiAlH4  
(53 mg, 1.44 mmol) was added portion-wise. Next, the reaction mixture was stirred at 0 
ºC for 1 h. After the completion of reduction, it was quenched following the Fieser 
workup3 via slow sequential addition of H2O (1 mL/g of LiAlH4), followed by 10% 
                                                
[3]. L. F. Fieser, M. Fieser in Reagents for Organic Synthesis, Vol. 1, Wiley: New York, 1967, pp. 











OTBSMe2SO4, reflux, 3 h, then
LiAlH4, 0 ºC, 1 h
 56%, 3 rxns in one-pot
 (83% av/rxn) OBn
Pd(OAc)2 (5 mol %) HCO2H 




NaOH (1 mL/g of LiAlH4) and finally H2O (3 mL/g of LiAlH4) and the ice bath was 
removed and the reaction mixture was stirred for 2 h. The reaction mixture was filtered, 
extracted with EtOAc (3x50 mL) and dried (Na2SO4). The resulting solution was filtered 
again, concentrated and purified using a short silica gel flash column chromatography 
(hexane/EtOAc 3:1), which afforded the TBS-protected diol 2.3j (120 mg, 56% yield 
over 3 reactions in one-pot, 83% av/rxn) as a colorless liquid. TLC (hexane/ethyl acetate 
3/1): Rf: 0.22. 
FTIR (neat): 3402, 2929, 2854, 1720, 1641, 1460, 1452, 1359, 1253, 1110, 1047, 912, 
835 cm-1. 
Optical Rotation: [α]D23 = –1.5 (c 0.8, CHCl3).  
1H NMR (500 MHz, CDCl3): δ 7.38–7.27 (m, 5H), 5.90–5.73 (m, 1H), 5.23–5.08 (m, 
2H), 4.53 (s, 2H), 4.03–3.97 (m, 1H), 3.97–3.90 (m, 1H), 3.84–3.78 (m, 1H), 3.40 (dd, J 
= 10.0, 5.5 Hz, 1H), 3.36 (dd, J = 9.6, 5.4 Hz, 1H), 2.36–2.22 (m, 3H), 1.66–1.60 (m, 
2H), 1.59–1.50 (m, 2H), 1.49–1.37 (m, 3H), 1.36–1.25 (m, 4H), 0.89 (s, 9H), 0.056 (s, 
3H), 0.049 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ 138.7, 134.9, 128.5 (2), 127.8 (2), 127.7, 118.5, 75.0, 
73.5, 71.7, 69.5, 68.4, 42.3, 42.1, 37.7, 34.9, 30.0, 26.1 [(3), SiMe3], 26.0, 25.4, 18.4, -
4.1, -4.5. 






 To a stirring solution of TBS-protected diol 2.3j (72 mg, 0.16 mmol) in CH2Cl2 
(1.6 mL, 0.1 M) was added N,N-diisopropylethylamine (DIPEA) (195 µL, 1.12 mmol) 
and 4-dimethylaminopyridine (DMAP) (2 mg, 0.016 mmol). The reaction mixture was 
cooled to 0 ºC and chloromethyl methyl ether (MOMCl) (60 µL, 0.8 mmol) was added 
drop wise and the reaction mixture was stirred at room temperature for 4 h (monitored via 
TLC). After completion of reaction, the solvent was evaporated. To a solution of crude 
reaction mixture in THF (1.6 mL, 0.1 M) was added TBAF (290 µL, 0.48 mmol) drop 
wise and the reaction mixture was refluxed for 1 h (reaction was monitored via TLC). 
After complete consumption of the starting material, it was quenched with aqueous 
ammonium chloride (NH4Cl), extracted with EtOAc (3x20 mL), dried (Na2SO4), filtered 
and concentrated under reduced pressure. The crude compound was purified by silica gel 
chromatography (hexane/EtOAc 10:1) to furnish the MOM-protected alcohol 2.8.2 (51 
mg, 81% yield over two steps, 90% av/rxn) as a colorless viscous liquid. TLC 
(hexane/ethyl acetate 4/1): Rf: 0.41. 
TIR (neat): 3479, 2927, 2854, 1454, 1215, 1147, 1099, 1041, 916, 771 cm-1. 





 MOMCl, DIPEA, DMAP







TBAF, THF, reflux, 1 h




1H NMR (400 MHz, CDCl3): δ 7.40–7.29 (m, 5H), 5.89–5.76 (m, 1H), 5.15–5.04 (m, 
2H), 4.73–4.63 (m, 4H), 4.57 (s, 2H), 3.86–3.75 (m, 2H), 3.70 (p, J = 5.6 Hz, 1H), 3.51 
(dd, J = 9.4, 3.0 Hz, 1H), 3.40 (s, 3H), 3.39 (s, 3H), 3.33 (t, J = 8.7 Hz, 1H), 2.34 (t, J = 
8.5 Hz, 2H), 1.64–1.39 (m, 7H), 1.39–1.21 (m, 5H). 
13C NMR (126 MHz, CDCl3): δ 138.2, 134.6, 128.7 (2), 128.01, 127.95 (2), 117.7, 96.3, 
96.2, 75.4, 74.9, 74.8, 73.6, 70.6, 55.9, 55.9, 40.4, 40.1, 35.4, 33.2, 30.1, 25.7, 25.1.  
HRMS: calculated for C24H40NaO6 (M+Na)+ 447.2723; found 447.2735 (TOF MS ES+). 
2S,8S,10S)-1-(Benzyloxy)-8,10-bis(methoxymethoxy)tridec-12-en-2-yl acrylate (2.3l): 
 
 To a stirring solution of TBS-protected diol 2.3j (15 mg, 0.033 mmol) in CH2Cl2 
was added DIPEA (25 µL, 0.2 mmol) and DMAP (0.42 mg, 0.003 mmol). The reaction 
mixture was stirred for 15 min, cooled to 0 ºC and added MOMCl (10.1 µL, 0.13 mmol) 
drop wise. The reaction mixture was stirred at room temperature for 4 h (monitored by 
TLC). After completion of reaction, the solvent was evaporated and to the crude reaction 
mixture was added THF (0.3 mL, 0.1 M) followed by drop wise addition of TBAF (50 
µL, 0.16 mmol) at room temperature. The reaction mixture was refluxed for 1 h 
(monitored via TLC). After completion of reaction, the solvent was evaporated and 





 MOMCl, DIPEA, DMAP
CH2Cl2, 0 ºC-rt, 4 h, then






DMAP, CH2Cl2, 0º C-rt, 1 h





(0.4 mg, 0.0033 mmol). The reaction mixture was cooled to 0 ºC, added acryloyl chloride 
(5.3 µL, 0.066 mmol) drop wise and stirred at room temperature for 1 h (monitored via 
TLC). After completion, it was quenched with ice water, extracted with CH2Cl2 (3x10 
mL), dried (MgSO4) and concentrated. The compound was purified using silica gel 
chromatography (hexane/EtOAc 15:1), which afforded the 2.3l (12 mg, 75% yield over 3 
reactions, 91% av/rxn) as a viscous liquid. TLC (hexane/ethyl acetate 3/1): Rf: 0.51.  
FTIR (neat): 2931, 1724, 1406, 1269, 1195, 1099, 1043, 916, 810 cm-1. 
Optical Rotation: [α]D23 = +6.5 (c 0.55, CHCl3).  
1H NMR (400 MHz, CDCl3): δ 7.37–7.28 (m, 5H), 6.42 (dd, J = 17.4, 1.5 Hz, 1H), 6.15 
(dd, J = 17.3, 10.4 Hz, 1H), 5.88–5.77 (m, 2H), 5.17–5.05 (m, 3H), 4.73–4.63 (m, 4H), 
4.59 (d, J = 12.1, 1H), 4.51 (d, J = 12.1, 1H), 3.82–3.75 (m, 1H), 3.73–3.64 (m, 1H), 3.55 
(d, J = 4.8 Hz, 2H), 3.39 (s, 3H), 3.38 (s, 3H), 2.34 (t, J = 4.9 Hz, 2H), 1.70–1.63 (m, 
1H), 1.63–1.57 (m, 1H), 1.57–1.41 (m, 3H), 1.40–1.23 (m, 7H).  
13C NMR (101 MHz, CDCl3): δ 166.1, 138.3, 134.6, 130.9, 128.9, 128.6, 127.9 (2), 
127.8 (2), 117.6, 96.4, 96.2, 75.4, 74.9, 73.3, 73.2, 71.3, 55.9, 55.9, 40.4, 40.1, 35.4, 31.1, 
29.9, 25.5, 25.0. 





ethenesulfonate (2.3m):  
 
 To a stirring solution of TBS-protected diol 2.3j (36 mg, 0.08 mmol) in CH2Cl2 
was added DIPEA (97 µL, 0.56 mmol) and DMAP (1.01 mg, 0.008 mmol). The reaction 
mixture was stirred for 15 min, cooled to 0 ºC and added MOMCl (30 µL, 0.40 mmol) 
drop wise. The reaction mixture was stirred at room temperature for 4 h (monitored via 
TLC). After completion of reaction, the solvent was evaporated. To the reaction mixture 
was added THF (0.3 mL, 0.1 M), followed by drop wise addition of TBAF (69 µL, 0.24 
mmol). The reaction was refluxed for 1 h (monitored via TLC). After completion of 
reaction, the solvent was evaporated and CH2Cl2 (0.3 mL, 0.1 M), followed by Et3N (27 
µL 0.198 mmol) and DMAP (0.4 mg, 0.0033 mmol) were added. The reaction mixture 
was cooled to 0 ºC, added 2-chloroethane sulfonyl chloride (25 µL, 0.24 mmol) drop 
wise and stirred for 1 h (monitored via TLC). After completion, it was quenched with ice 
water, extracted with CH2Cl2 (3x10 mL), dried (MgSO4), concentrated and purified using 
silica gel chromatography (hexane/EtOAc 12:1) to afford 2.3m (30 mg, 72% yield over 3 
reactions, 89.5% av/rxn) as a viscous liquid. TLC (hexane/ethyl acetate 3/1): Rf: 0.26.  
FTIR (neat): 3431, 2931, 1637, 1454, 1363, 1172, 1099, 1041, 916, 790 cm-1; 





 MOMCl, DIPEA, DMAP
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Et3N, DMAP, CH2Cl2, 0º C-rt, 1 h







1H NMR (400 MHz, CDCl3): δ 7.40–7.28 (m, 5H), 6.58 (dd, J = 16.6, 9.9 Hz, 1H), 6.34 
(d, J = 16.7 Hz, 1H), 5.94 (d, J = 9.9 Hz, 1H), 5.88–5.76 (m, 1H), 5.14–5.05 (m, 2H), 
4.74–4.63 (m, 5H), 4.57 (d, J = 11.8 Hz, 1H), 4.52 (d, J = 11.8 Hz, 1H), 3.83–3.75 (m, 
1H), 3.74–3.65 (m, 1H), 3.64–3.54 (m, 2H), 3.40 (s, 3H), 3.38 (s, 3H), 2.34 (t, J = 6.4 Hz, 
2H), 1.77–1.65 (m, 2H), 1.64–1.47 (m, 4H), 1.45–1.24 (m, 6H). 
13C NMR (101 MHz, CDCl3): δ 137.8, 134.6, 134.1, 128.7, 128.6, 128.1, 127.9, 117.6, 
96.3, 96.3, 82.8, 75.4, 74.9, 73.6, 71.4, 55.9, 55.9, 40.4, 40.1, 35.4, 31.9, 29.8, 25.1, 24.9.  
HRMS: calculated for C26H42NaO8S (M+Na)+ 537.2498; found 537.2493 (TOF MS 
ES+). 
 (R/SP,2S,8S,10S)-1-(Benzyloxy)-8,10-bis(methoxymethoxy)tridec-12-en-2-yl ethyl 
vinylphosphonate (2.3n, RP and SP):  
 
 Pot 1: To a stirred solution of TBS-protected diol 2.3j (50 mg, 0.11 mmol) in 
CH2Cl2 (1.1 mL, 0.1 M) were added DIPEA (135 µL, 0.77 mmol) and DMAP (1.5 mg, 
0.011 mmol). The reaction mixture was cooled to 0 ºC, and MOMCl (41.7 µL, 0.55 
mmol) was added drop wise and the reaction mixture was stirred at room temperature for 
4 h (monitored via TLC). After completion of reaction, the solvent was evaporated. To 




 1. MOMCl, DIPEA, DMAP
CH2Cl2, 0 ºC-rt, 4 h, then
TBAF, THF, reflux, 1 h






n-BuLi, THF, -40 ºC, 1 h, (dr ~1:1)








wise addition of TBAF (95 µL, 0.33 mmol) under argon. The reaction mixture was 
refluxed for 1 h (monitored via TLC). After completion, it was quenched with NH4Cl and 
extracted with EtOAc (3x20 mL), dried (Na2SO4), filtered and concentrated under 
reduced pressure.  The crude material was taken to the next pot without further 
purification. 
 Pot 2: To a solution of crude MOM-protected alcohol in THF (0.5 mL, 0.1 M) 
under argon was added n-BuLi (57 µL, 0.14 mmol, 2.5 M in hexanes) drop wise at -40 ºC 
and the reaction mixture was stirred for 30 min. Next, a solution of ethyl 
vinylphosphonochloridate (51 mg, 0.33 mmol) in THF (0.5 mL) was added slowly to the 
reaction mixture and stirred for 1 h at -40 ºC (the reaction was monitored by TLC). After 
completion, the reaction mixture was quenched with aqueous NH4Cl, extracted with 
EtOAc (3x10 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. 
The crude product was purified via flash chromatography (hexane/EtOAc 1:1), which 
afforded an inseparable ~1:1 diastereomeric mixture of 2.3n (36 mg, 60% yield over 3 
reactions, 84.5% av/rxn) as a colorless viscous liquid. TLC (100% ethyl acetate): Rf: 
0.60.  
FTIR (neat): 2925, 1726, 1556, 1454, 1384, 1247, 1099, 1041, 916 cm-1. 
1H NMR of two diastereomers (500 MHz, CDCl3): δ 7.37–7.28 (m, 5H), 6.34–6.21 (m, 
1H), 6.16–5.95 (m, 2H), 5.83 (ddt, J = 17.3, 10.3, 7.1 Hz, 1H), 5.13–5.06 (m, 2H), 4.73–
4.63 (m, 4H), 4.62–4.49 (m, 3H), 4.15–4.01 (m, 2H), 3.82–3.76 (m, 0.5H of single 
diastereomer), 3.73–3.66 (m, 1.5H of two diastereomers), 3.63–3.51 (m, 2H), 3.41–3.37 
	 166	
(m, 6H), 2.34 (t, J = 5.7 Hz, 2H); 1.73–1.57 (m, 5H), 1.56–1.44 (m, 2H), 1.42–1.24 (m, 
8H).  
HRMS: calculated for C28H47NaO8P (M+Na)+ 565.2906; found 565.2911 (TOF MS 
ES+). 
General procedure A; One-pot, sequential RCM/MOM-deprotection.  
 To a degased solution of diene (0.05 mmol) in CH2Cl2 (33 mL, 0.001 M) was 
added the G-II catalyst (10 mol %) and the reaction mixture was refluxed for 5–8 h 
(monitored via TLC). After completion of the reaction, the solvent was evaporated. To 
the crude RCM product was added 2 mL mixture of MeOH and HCl (3.0 M) in a ratio of 
1:1.5, respectively. The reaction mixture was stirred at room temperature for 36–48 h 
(monitored via TLC).  After completion, the reaction mixture was quenched with aqueous 
NaHCO3 (pH ~8), extracted with CH2Cl2 (3x10 mL), dried (Na2SO4), filtered, 
concentrated under reduced pressure, and purified using flash chromatography to furnish 






Following general procedure A, the compound 2.3a was synthesized and purified via 
 silica gel column chromatography (hexane/EtOAc 3:2), 15 mg of 2.3l (0.031 mmol) 
generated 7.6 mg of 2.3a [67% over 2 rxns in one-pot (82% av/rxn)] as a colorless 
viscous liquid. TLC (hexane/ethyl acetate 3/7): Rf: 0.23. 
FTIR (neat): 3446, 2923, 2854, 1718, 1652, 1558, 1458, 1259, 1095, 991 cm-1. 
Optical Rotation: [α]D23 = –2.5 (c 0.2, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.38–7.27 [m, 5H, C6H5CH2O–], 6.98 [ddd, J = 15.9, 8.9, 
6.2 Hz, 1H, –CH2CH=CHCO–], 5.93 [d, J = 15.5 Hz, 1H, –CH2CH=CHCO–], 5.19 [p, J 
= 5.9 Hz, 1H, –CH2OCH2CH(O)CH2], 4.59 [d, J = 12.1 Hz, 1H, PhCHaHbOCH2–], 4.55 
[d, J = 12.1 Hz, 1H, PhCHaHbOCH2–], 4.27–4.20 [m, 1H, –
CH=CHCH2CH(OH)CH2CH(OH)CH2–], 4.01–3.94 [m, 1H, –CH=CHCH2CH(OH)-
CH2CH(OH)CH2–], 3.62 [dd, J = 10.3, 5.9 Hz, 1H, PhCH2OCHaHbCH(O)CH2–], 3.56 
[dd, J = 10.3, 4.9 Hz, 1H, PhCH2OCHaHbCH(O)CH2–], 3.37–3.33 [m, 1H, –
CH2CH(OH)CH2–, 2.61–2.54 [m, 1H, –CHaHbCH=CHCO–], 2.50–2.42 [m, 1H, –
CHaHbCH=CHCO–], 1.86 (ddd, J = 15.0, 5.8, 4.0 Hz, 1H, –
CH2CH(OH)CHaHbCH(OH)CH2–], 1.75–1.60 [m, 3H, aliphatic], 1.55–1.45 [m, 2H, 








G-II ( 10 mol %)
CH2Cl2 (0.001 M)
 reflux, 5 h, then
HCl (3 M), MeOH, rt, 48 h






13C NMR (126 MHz, CDCl3): δ 166.1, 146.0, 138.2, 128.6(2), 127.89(2), 127.86, 124.7, 
73.4, 73.3, 71.3, 69.7, 68.5, 40.3, 39.3, 35.6, 29.5, 28.5, 24.6, 24.2. 
HRMS: calculated for C21H30NaO5 (M+Na)+ 385.1991; found 385.2008 (TOF MS ES+). 
 (6S,8S,14S,E)-14-((Benzyloxy)methyl)-6,8-dihydroxy-1-oxa-2-thiacyclotetradec-3-
ene 2,2-dioxide (2.3b): 
 
Following general procedure A, the compound 2.3m was synthesized and purified 
via silica gel column chromatography (hexane/EtOAc 1:1), 34 mg of 2.3b (0.031 mmol) 
generated 18.5 mg of 2.3b [70% over 2 rxns in one-pot (84% av/rxn)] as a semi solid. 
TLC (100% ethyl acetate 1/1): Rf: 0.51. 
FTIR (neat): 3421, 2925, 2858, 1355, 1640, 1622, 1166, 1089, 1062, 910, 855 cm-1. 
Optical Rotation: [α]D23 = –10.2 (c 0.45, CHCl3).  
1H NMR (500 MHz, CDCl3): δ 7.39–7.28 [m, 5H, C6H5CH2O–], 6.92 [dt, J = 15.2, 7.6 
Hz, 1H, –CH2CH=CHSO3–], 6.38 [dt, J = 15.3, 1.4 Hz, 1H, –CH2CH=CHSO3–], 4.67–
4.54 [m, 3H, PhCH2OCH2CH(O)CH2–], 4.25–4.17 [m, 1H, –
CH=CHCH2CH(OH)CH2CH(OH)CH2–], 4.06 [dd, J = 14.6, 7.8 Hz, 1H, –
CH=CHCH2CH(OH)CH2CH(OH)CH2–], 3.72 [dd, J = 10.7, 4.5 Hz, 1H, 
PhCH2OCHaHbCH(O)CH2–], 3.68 [dd, J = 10.7, 4.8 Hz, 1H, PhCH2OCHaHbCH(O)CH2–














G-II ( 10 mol %)
CH2Cl2 (0.001 M)
 reflux, 6 h, then
HCl (3 M), MeOH, rt, 40 h





2.19 [d, J = 3.0 Hz, 1H, –CH2CH(OH)CH2–], 1.81–1.74 [m, 3H, aliphatic], 1.68 [dd, J = 
5.4, 2.8 Hz, 1H, aliphatic], 1.66–1.61 [m, 2H, aliphatic], 1.55–1.47 [m, 1H, aliphatic], 
1.43–1.31 [m, 4H, aliphatic], 1.28–1.22 [m, 1H, aliphatic]. 
 13C NMR (126 MHz, CDCl3): δ 143.6, 138.0, 128.6 (2), 127.99 (2), 127.94, 127.76, 
81.7, 73.8, 71.4, 68.6, 68.5, 38.6, 38.6, 36.1, 30.3, 26.7, 24.2, 24.0. 
HRMS: calculated for C20H30NaO6S (M+Na)+ 421.1661; found 421.1665 (TOF MS 
ES+). 
General procedure B: Ring-closing metathesis reaction (RCM): 
 To a degased solution of diene (0.05 mmol) in CH2Cl2 (33 mL, 0.001 M) was 
added G-II catalyst (10 mol%) and the reaction mixture was refluxed for 4-6 h 
(monitored via TLC). After completion of the reaction, solvent was evaporated. The 




(RP and SP 6S,8S,14S,E)-14-((Benzyloxy)methyl)-6,8-bis(methoxymethoxy)-1-oxa-2-
thiacyclotetradec-3-ene 2,2-dioxide (2.3c, RP and SP): 
 
Following general procedure B, the diastereomers were synthesized and purified 
via silica gel flash column chromatography [diastereomer 1 (hexane/EtOAc 2:3), 
diastereomer 2 (hexane/EtOAc 1:2)], 20 mg of 2.3n (0.036 mmol) generated 14.6 mg of 
2.3c (77% for two diastereomers) as a colorless viscous liquid.  
Diastereomer 1 (RP and SP), TLC (100% ethyl acetate): Rf: 0.33:  
FTIR (neat): 2925, 2854, 2378, 2341, 1456, 1245, 1147, 1097, 968, 771 cm-1. 
Optical Rotation: [α]D23 = +27.2 (c 0.12, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.37–7.28 [m, 5H, C6H5CH2O–], 6.88 [dddd, J = 22.2, 
17.1, 9.6, 5.2 Hz, 1H, –CH2CH=CHPO(OEt)O–], 5.82–5.72 [m, 1H, –
CH2CH=CHPO(OEt)O–], 4.75–4.51 [m, 6H, –OCH2OCH3, –OCH2OCH3, PhCH2OCH2–
], 4.16–4.00 [m, 3H, –PO(OCH2CH3)O–, PhCH2OCH2CH(O)CH2–], 3.96–3.90 [m, 1H, –
CH=CHCH2CH(OMOM)CH2CH(OMOM)CH2–], 3.76–3.69 [m, 1H, –
CH=CHCH2CH(OMOM)CH2CH-(OMOM)CH2–], 3.64–3.59 [m, 2H, 
PhCH2OCH2CH(O)CH2–], 3.41 [s, 3H, –OCH2OCH3], 3.38 [s, 3H, –OCH2OCH3], 2.77–
2.70 [m, 1H, –CHaHbCH=CHPO(OEt)O–], 2.36–2.28 [m, 1H, –
G-II (10 mol %)
CH2Cl2 (0.001 M)














P = MOM 77% dr ~1:1
2.3n
2.3c (RP and SP)
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CHaHbCH=CHPO(OEt)O–], 1.72–1.63 [m, 3H, aliphatic], 1.62–1.55 [m, 3H, aliphatic], 
1.55–1.46 [m, 1H, aliphatic], 1.45–1.19 [m, 8H, aliphatic].  
P31NMR (162 MHz, CDCl3): δ 17.42. 
13C NMR (126 MHz, CDCl3): δ 149.0 (d, JCP = 5.9 Hz), 138.3, 128.5, 127.9, 122.7, 
121.1, 96.1, 95.7, 75.7 (d, JCP = 5.9 Hz), 73.8, 73.4, 73.0, 72.6 (d, JCP = 3.0 Hz), 61.4 (d, 
JCP = 5.9 Hz), 56.0, 55.8, 40.3, 32.4, 31.6 (d, JCP = 4.8 Hz), 29.9, 27.6, 23.7, 22.8, 16.5 
(d, JCP = 7.1 Hz).  
HRMS: calculated for C26H44O8P (M+H)+ 515.2774; found 515.2792 (TOF MS ES+). 
Diastereomer 2 (RP and SP), TLC (100% ethyl acetate): Rf: 0.26:  
FTIR (neat): 2927, 2358, 1631, 1556, 1454, 1247, 1099, 1031, 916, 738 cm-1. 
Optical Rotation: [α]D23 = –0.75 (c 0.4, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.38–7.28 [m, 5H, C6H5CH2O–], 6.72 [dddd, J = 21.3, 
17.1, 8.0, 6.7 Hz 1H, –CH2CH=CHPO(OEt)O–], 5.82 [ddt, J = 21.5, 17.1, 1.3, 1H, 
CH2CH=CHPO(OEt)O–], 4.71 [d, J = 6.7 Hz, 1H, –OCHaHbOCH3], 4.69 [d, J = 6.7 Hz, 
1H, –OCHaHbOCH3], 4.65 [s, 2H, –OCH2OCH3], 4.57 [s, 2H, PhCH2OCH2–], 4.34–4.26 
[m, 1H, PhCH2OCH2CH(O)CH2–], 4.16–4.04 [m, 2H, –PO(OCH2CH3)O–], 3.97–3.90 
[m, 1H, –CH=CHCH2CH(OMOM)CH2CH(OMOM)CH2–], 3.83–3.76 [m, 1H, –
CH=CHCH2CH(OMOM)-CH2CH(OMOM)CH2–], 3.65 [dd, J = 10.3, 5.9 Hz, 1H, 
PhCH2OCHaHbCH(O)CH2–], 3.57 [dd, J = 10.2, 4.9 Hz, 1H, PhCH2OCHaHbCH(O)CH2–
], 3.39 [s, 3H, –OCH2OCH3], 3.38 [s, 3H, –OCH2OCH3], 2.62–2.51 [m, 2H, –
CH2CH=CHPO(OEt)O–], 1.80–1.71 [m, 1H, –CH2CH(OMOM)CHaHbCH-
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(OMOM)CH2–], 1.71–1.61 [m, 4H, aliphatic], 1.55–1.46 [m, 1H, aliphatic], 1.46–1.21 
[m, 9H, aliphatic]. 
31P NMR (162 MHz, CDCl3): δ 14.79. 
13C NMR (126 MHz, CDCl3): δ 148.9 (d, JCP = 4.0 Hz), 138.2, 128.6, 128.0, 121.5, 120.1, 
96.0, 95.6, 76.8 (d, JCP = 7.6 Hz), 73.7, 73.0, 73.1, 72.3 (d, JCP = 3.2 Hz), 62.2 (d, JCP = 5.9 
Hz), 55.9, 55.8, 40.1, 38.7, 32.6, 31.2, 26.9, 23.6, 22.8, 16.5 (d, JCP = 6.4 Hz). 
HRMS: calculated for C26H43NaO8P (M+Na)+ 537.2593; found 537.2597 (TOF MS 
ES+). 
N-((2R,8S,10S)-1-(Benzyloxy)-8,10-bis(methoxymethoxy)tridec-12-en-2-yl)- 
acrylamide (2.3o):  
 
To a stirred solution of MOM-protected alcohol 2.8.2 (50 mg, 0.11 mmol) and 
PPh3 (61.7 mg, 0.22 mmol) in dry THF (1.5 mL) was added DIAD (47.6 mg, 0.22 mmol). 
The reaction mixture was stirred for 5 min, DPPA (71.3 mg, 0.27 mmol) was added and 
the reaction mixture was stirred for 2 h at 0 ºC (reaction was monitored by TLC). After 
completion of the reaction, LiAlH4 (53.7 mg, 1.41 mmol) was added in portions at  
0 ºC and the reaction mixture was stirred for 1 h at room temperature (monitored via 
TLC, the azide was reduced to the corresponding amine). The reaction mixture was 
quenched with aq. saturated NaHCO3 solution (0.75 mL), stirred for 15 min at 0 ºC and 







THF, 0 ºC, 2 h, then




Osat. NaHCO3 (aq), 0 ºC
acryloyl chloride, 1 h
73%, 3 rxns in one-pot
(90% av/rxn)2.8.2 2.3o
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temperature and the reaction mixture stirred for 1 h. After completion of the reaction, the 
reaction mixture was quenched with NH4Cl, extracted with EtOAc (3x20 mL), dried 
(Na2SO4) and concentrated under reduced pressure. The compound was purified using 
silica gel chromatography (hexane/EtOAc 3:1), which furnished acrylamide 2.3o (41 mg, 
73% over 3 reactions, 90% av/rxn) as colorless viscous liquid. TLC (hexane/ethyl acetate 
1/1): Rf: 0.32. 
FTIR (neat): 3421, 2929, 2858, 1656, 1625, 1542, 1454, 1406, 1215, 1145, 1099, 916, 
736 cm-1. 
Optical Rotation: [α]D23 = +40 (c 0.65, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.39–7.28 (m, 5H), 6.28 (dd, J = 17.0, 1.5 Hz, 1H), 6.07 
(dd, J = 16.9, 10.3 Hz, 1H), 5.87–5.73 (m, 2H), 5.64 (dd, J = 10.2, 1.5 Hz, 1H), 5.14–
5.05 (m, 2H), 4.73–4.63 (m, 4H), 4.54 (d, J = 11.9 Hz, 1H), 4.49 (d, J = 11.9 Hz, 1H), 
4.19–4.12 (m, 1H), 3.82–3.76 (m, 1H), 3.72–3.65 (m, 1H), 3.56–3.49 (m, 2H), 3.39 (s, 
3H), 3.38 (s, 3H), 2.34 (ddt, J = 7.0, 5.7, 1.4 Hz, 2H), 1.67–1.44 (m, 7H), 1.38–1.24 (m, 
5H). 
13C NMR (126 MHz, CDCl3): δ 165.1, 138.2, 134.6, 131.2, 128.7, 128.02 (2), 127.90 (2), 
126.6, 117.7, 96.3, 96.2, 75.4, 74.8, 73.5, 71.6, 55.9, 55.9, 49.2, 40.3, 40.1, 35.4, 32.1, 
29.9, 26.3, 25.0. 








To a stirring solution of MOM-protected alcohol 2.8.2 (25 mg, 0.055 mmol) and 
PPh3 (30.7 mg, 0.11 mmol) in dry THF (1 mL) was added DIAD (23.8 mg, 0.11 mmol) at 
0 ºC. The reaction mixture was stirred for 5 min, DPPA (35.6 mg, 0.13 mmol) was added 
and stirred for 2 h at 0 ºC (monitored by TLC). After completion of the reaction, LiAlH4 
(26.8 mg, 0.70 mmol) was added in portions at 0 ºC and the reaction mixture was stirred 
for 1 h at room temperature (monitored via TLC, the azide was reduced to the 
corresponding amine). The reaction mixture was quenched with aq. saturated K2CO3 
solution (0.75 mL), stirred for 15 min at 0 ºC and diluted with THF (1.0 mL). 2-
Chloroethanesulfonyl chloride (17 mg, 0.16 mmol) was added at the same temperature 
and the reaction mixture was stirred for 2 h. After completion of the reaction, it was 
quenched with NH4Cl, extracted with EtOAc (3x15 mL), dried (Na2SO4), and 
concentrated under reduced pressure. The crude compound was subjected to silica gel 
chromatography (hexane/EtOAc 3:1) to afford acrylamide 2.3p (25 mg, 81% over 3 
reactions, 93% av/rxn) as a colorless gummy liquid. TLC (hexane/ethyl acetate 3/7): Rf: 
0.37. 
FTIR (neat): 2931, 2858, 1456, 1330, 1211, 1149, 1099, 1039, 916, 734 cm-1.   







THF, 0 ºC, 2 h, then







sat. K2CO3 (aq), 0 ºC
2-chloroethanesulfonyl chloride
rt, 2 h




1H NMR (500 MHz, CDCl3): δ 7.40–7.29 (m, 5H), 6.45 (dd, J = 16.6, 9.9 Hz, 1H), 6.20 
(d, J = 16.6 Hz, 1H), 5.88–5.77 (m, 2H), 5.13–5.05 (m, 2H), 4.74–4.64 (m, 4H), 4.53–
4.48 (m, 3H), 3.82–3.76 (m, 1H), 3.72–3.66 (m, 1H), 3.51 (dd, J = 9.4, 4.0 Hz, 1H), 3.43 
(dd, J = 9.4, 4.1 Hz, 1H), 3.40 (s, 3H), 3.39 (s, 3H), 2.34 (ddt, J = 7.1, 5.8, 1.3 Hz, 2H), 
1.66–1.45 (m, 7H), 1.41–1.24 (m, 5H). 
13C NMR (126 MHz, CDCl3): δ 137.9, 137.3, 134.5, 128.72 (2), 128.2, 128.02 (2), 125.7, 
117.7, 96.3, 96.2, 75.4, 74.8, 73.5, 71.8, 55.9, 55.9, 54.1, 40.3, 40.1, 35.4, 32.9, 29.8, 
26.0, 25.0. 
HRMS: calculated for C26H43NNaO7S (M+Na)+ 536.2658; found 536.2665 (TOF MS 
ES+). 
EthylN-((R/SP,2R,8S,10S)-1-(benzyloxy)-8,10-bis(methoxymethoxy)tridec-12-en-2-
yl)-P-vinylphosphonamidate (2.3q, RP and SP): 
 
The solution of MOM-protected alcohol 2.8.2 (50 mg, 0.11 mmol) and PPh3 (61.7 
mg, 0.22 mmol) in dry THF (1.5 mL) was treated with DIAD (47.6 mg, 0.22 mmol) at 0 
ºC and stirred for 5 min. DPPA (71.3 mg, 0.27 mmol) was added at the same temperature 
and stirred for 2 h. After completion of the reaction, LiAlH4 (53.7 mg, 1.41 mmol) was 
added in portions at 0 ºC and stirred for 1 h at room temperature (reaction was monitored 






1) DPPA, DIAD, PPh3
THF, 0 ºC, 2 h, then










CH2Cl2, 0 ºC–rt, 1 h
57%, 3 rxns in two pots
(83% av/rxn)
2.8.2
2.3q (PR and PS)
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quenched with aq. saturated NaHCO3 solution (2.0 mL) and stirred for 15 min at 0 ºC and 
extracted with EtOAc (3x20 mL). The combined organic layers were washed with a 
solution of 2.0 N HCl (2x10 mL). The combined aqueous layers were basified with 
saturated aq. K2CO3 solution (pH ~12). Then, the crude amine was extracted with EtOAc 
(3x20 mL) and the combined organic layers were washed with brine (15 mL), dried 
(Na2SO4) and concentrated.  
The crude amine was utilized for the next reaction without further purification. To 
a solution of crude amine in CH2Cl2 (1.0 mL) were added Et3N (66.0 µL, 0.47 mmol) and 
DMAP (1.3 mg, 0.011 mmol), stirred for 5 min. A solution of ethyl 
vinylphosphonochlordate (50.0 mg, 0.33 mmol) in CH2Cl2 (0.8 mL) was added drop wise 
at 0 ºC and stirred for 1 h at room temperature. When the TLC showed that all the amine 
was consumed, it was quenched with aq. NaHCO3 solution and extracted with CH2Cl2 
(3x10 mL), dried (Na2SO4) concentrated under reduced pressure and purified using silica 
gel flash chromatography (hexane/EtOAc 2:3) to afford two inseparable (~1:1) 
diastereomers of 2.3q (36 mg, 57% yield over 3 reactions, 83% av/rxn) as a colorless 
viscous liquid. TLC (100% ethyl acetate): Rf: 0.38. 
FTIR (neat): 2929, 2856, 1456, 1211, 1147, 1097, 1039, 958, 916, 784, 736 cm-1. 
1H NMR of two diastereomers (400 MHz, CDCl3): δ 7.39–7.29 (m, 5H), 6.25–5.99 (m, 
3H), 5.95–5.76 (m, 1H), 5.15–5.05 (m, 2H), 4.74–4.62 (m, 4H), 4.51 (s, 2H), 4.09–3.95 
(m, 2H), 3.79 (p, J = 5.5 Hz, 0.7H of single diastereomer), 3.74–3.64 (m, 1.3H of two 
diastereomers), 3.44 (dt, J = 12.2, 4.1 Hz, 2H), 3.40 (s, 3H), 3.39 (s, 3H), 3.33–3.19 (m, 
1H), 2.70 (td, J = 9.9, 5.7 Hz, 1H), 2.34 (t, J = 6.4 Hz, 1H), 1.68–1.43 (m, 7H), 1.41–1.20 
(m, 8H). 
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Following general procedure A, the compound was synthesized and purified via 
silica gel flash chromatography (hexane/EtOAc 1:4), 25 mg of 2.3o (0.055 mmol) 
generated 12 mg of 2.3d [60% over 2 rxns (77.5% av/rxn)], as a colorless viscous oil. 
TLC (ethyl acetate /methanol 20/1): Rf: 0.22. 
FTIR (neat): 3373, 3286, 2923, 2854, 1681, 1627, 1541, 1099, 1004, 813 cm-1. 
Optical Rotation: [α]D23 = +7.7 (c 0.35, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.39–7.28 [m, 5H, C6H5CH2O–], 6.18 [ddd, J = 16.5, 8.8, 
7.4 Hz, 1H, –CH2CH=CHCONH–], 5.93 [d, J = 15.1 Hz, 1H, –CH2CH=CHCONH–], 
5.83 [d, J = 9.2 Hz, 1H, –CH2CH=CHCONH–], 4.55 [d, J = 11.9 Hz, 1H, 
PhCHaHbOCH2–], 4.51 [d, J = 11.9 Hz, 1H, PhCHaHbOCH2–], 4.20–4.09 [m, 2H, 
PhCH2OCH2CH(NH)CH2–, –CH=CHCH2CH(OH)CH2CH(OH)CH2– ], 4.05–3.97 [m, 
1H, –CH=CHCH2CH(OH)CH2CH(OH)CH2–], 3.56 [dd, J = 9.5, 4.2 Hz, 1H, 
PhCH2OCHaHbCH(NH)CH2–], 3.51 [dd, J = 9.5, 4.2 Hz, 1H, 
PhCH2OCHaHbCH(NH)CH2–], 3.11–3.03 [m, 1H, –CHaHbCH=CHCONH–], 2.74–2.67 
G-II (10 mol %), 
CH2Cl2 (0.001 M)
 reflux, 8 h, then















[m, 1H, –CHaHbCH=CHCONH–], 1.80 [ddd, J = 14.3, 7.8, 5.4 Hz, 1H, –
CH2CH(OH)CHaHbCH(OH)CH2–], 1.74–1.58 [m, 4H, aliphatic], 1.55–1.47 [m, 2H, 
aliphatic], 1.46–1.30 [m, 5H, aliphatic]. 
13C NMR (126 MHz, CDCl3): δ 166.9, 138.4, 138.2, 128.68(2), 128.0, 127.93(2), 126.1, 
73.5, 73.1, 69.6, 67.7, 49.5, 42.3, 35.4, 34.6, 31.1, 26.9, 24.4, 23.0. 
HRMS: calculated for C21H31NNaO4 (M+Na)+ 384.2151; found 384.2146 (TOF MS 
ES+). 
(3R,9S,11S,E)-3-((Benzyloxy)methyl)-9,11-dihydroxy-1-thia-2-azacyclotetradec-13-
ene 1,1-dioxide (2.3e): 
 
Following general procedure A, the compound was synthesized and purified via 
silica gel column chromatography (hexane/EtOAc 1:3), 20 mg of 2.3p (0.038 mmol) 
generated 9.9 mg of 2.3e [64% over 2 rxns (80% av/rxn)], as a yellowish semi-solid. TLC 
(hexane/ethyl acetate 1/3): Rf: 0.39. 
FTIR (neat): 3363, 3286, 2927, 2858, 1436, 1323, 1143, 1120, 1072, 981 cm-1. 
Optical Rotation: [α]D23 = +22.8 (c 0.25, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.39–7.28 [m, 5H, C6H5CH2O–], 6.66 [ddd, J = 15.4, 
10.5, 4.8 Hz, 1H, –CH2CH=CHSO2NH–], 6.25 [dd, J = 15.0, 1.8 Hz, 1H, –
P = MOM
 G-II (10 mol %) 
CH2Cl2 (0.001 M)
 reflux, 7 h, then


















CH2CH=CHSO2NH–], 4.64–4.55 [m, 2H, PhCHaHbOCH2–, PhCH2OCH2CH(NH)CH2–], 
4.50 [d, J = 11.7, 1H, PhCHaHbOCH2–], 4.19–4.11 [m, 1H, –
CH=CHCH2CH(OH)CH2CH(OH)CH2–], 4.11–4.03 [m, 1H, –
CH=CHCH2CH(OH)CH2CH(OH)CH2–], 3.62 [dd, J = 9.3, 4.5 Hz, 1H, 
PhCH2OCHaHbCH(NH)CH2–], 3.53 [dd, J = 9.3, 3.3 Hz, 1H, PhCH2OHaHbCH-
(NH)CH2–], 3.44 [bs, 1H, –CH2CH(OH)CH2–], 3.25–3.17 [m, 1H, –CH2CH(OH)CH2–], 
2.72–2.65 [m, 1H, –CHaHbCH=CHSO2NH–], 2.55 [dt, J = 13.9, 10.7 Hz, 1H, –
CHaHbCH=CHSO2NH–], 2.31 [bs, 1H, –CH2CH=CHSO2NH–], 1.79–1.66 [m, 3H, 
aliphatic], 1.65–1.58 [m, 3H, aliphatic], 1.58–1.49 [m, 1H, aliphatic], 1.46–1.36 [m, 1H, 
aliphatic], 1.35–1.18 [m, 4H, aliphatic]. 
13C NMR (126 MHz, CDCl3): δ 141.6, 138.1, 131.2, 128.67(2), 128.0, 127.93(2), 73.7, 
72.5, 69.3, 68.7, 52.5, 38.9, 37.9, 36.3, 29.9, 26.3, 24.7, 24.5. 
HRMS: calculated for C20H32NO5S (M+H)+ 398.2001; found 398.2004 (TOF MS ES+). 
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(RP and SP 6S,8S,14S,E)-14-((Benzyloxy)methyl)-2-ethoxy-6,8-bis(methoxymethoxy)-
1-aza-2-phosphacyclotetradec-3-ene 2-oxide (2.3f, RP and SP): 
 
 
Following general procedure B, the diastereomers were synthesized and purified 
via silica gel flash column chromatography [diastereomer 1 (hexane/EtOAc 1:2), 
diastereomer 2 (hexane/EtOAc 1:3)], 20 mg of 2.3q (0.036 mmol) generated 13.4 mg of 
2.3f (71% for two diastereomers) as a colorless viscous liquid. 
Diastereomer 1 (RP and SP), TLC (100% ethyl acetate): Rf: 0.45:  
FTIR (neat): 2929, 1643, 1556, 1454, 1211, 1147, 1099, 1035, 827 cm-1. 
Optical Rotation: [α]D23 =
 +4.0 (c 0.22, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.37–7.28 [m, 5H, C6H5CH2O–], 6.65 [dddd, J = 22.4, 
16.9, 9.0, 5.6 Hz, 1H, –CH2CH=CHPO(OEt)NH–], 5.77 [dd, J = 20.6, 17.0 Hz, 1H, –
CH2CH=CHPO(OEt)NH–], 4.70 [d, J = 6.95, 1H, –OCHaHbOCH3], 4.68 [d, J = 6.95, 1H, 
–OCHaHbOCH3], 4.65 [d, J = 6.95, 1H, –OCHaHbOCH3], 4.63 [d, J = 6.95, 1H, –
OCHaHbOCH3], 4.56 [d, J = 12.0 Hz, 1H, PhCHaHbOCH2–], 4.51 [d, J = 12.0 Hz, 1H, 
PhCHaHbOCH2–], 4.03–3.94 [m, 2H, –PO(OCH2CH3)NH–], 3.88 [tt,  J= 7.7, 3.5Hz, 1H, , 
–CH=CHCH2CH(OMOM)CH2CH(OMOM)CH2–], 3.80–3.74 [m, 1H, –
CH=CHCH2CH(OMOM)CH2CH-(OMOM)CH2–], 3.58–3.51 [m, 2H, 



















2.3f (PR  and PS)
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PhCH2OCH2CH(NH)CH2–], 3.42–3.30 [m, 7H, –OCH2OCH3, –OCH2OCH3, 
PhCH2OCH2CH(NH)CH2–], 2.75 [t, J = 9.5 Hz, 1H, –CH2CH=CHPO(OEt)NH–], 2.68–
2.61 [m, 1H, –CHaHbCH=CHPO(OEt)NH–], 2.47–2.39 [m, 1H, –
CHaHbCH=CHPO(OEt)NH–], 1.78–1.52 [m, 5H, aliphatic], 1.51–1.38 [m, 2H, aliphatic], 
1.38–1.30 [m, 3H, aliphatic], 1.30-1.19 [m, 5H, aliphatic]. 
31P NMR (162 MHz, CDCl3): δ 20.19. 
13C NMR (126 MHz, CDCl3): δ 147.1 (d, JCP = 4.5 Hz), 138.5, 128.57(2), 127.84(2), 
125.2, 123.8, 96.0, 95.6, 73.9 (d, JCP = 3.2 Hz), 73.4, 73.4, 73.1, 60.3, 60.2, 55.8, 50.4, 
40.4, 38.7, 32.8 (d, JCP = 5.1 Hz), 32.6, 27.3, 25.1, 23.5, 16.7 (d, JCP = 6.8 Hz).  
HRMS: calculated for C26H44NNaO7P (M+Na)+ 536.2753; found 536.2767 (TOF MS 
ES+). 
Diastereomer 2 (RP and SP), TLC (100% ethyl acetate): Rf: 0.35:  
FTIR (neat): 2925, 2854, 1558, 1456, 1209, 1147, 1099, 1037, 950, 916 cm-1. 
Optical Rotation: [α]D23 =
 +18.0 (c 0.2, CHCl3). 
1H NMR (400 MHz, CDCl3): δ 7.39–7.28 [m, 5H, C6H5CH2O–], 6.82–6.66 [m, 1H, –
CH2CH=CHPO(OEt)NH–], 5.83 [dd, J = 21.4, 17.2 Hz, 1H, , –CH2CH=CHPO(OEt)NH–
], 4.74–4.59 [m, 4H, –OCH2OCH3, –OCH2OCH3], 4.53 [s, 2H, PhCH2OCH2–], 4.07–3.82 
[m, 3H, –PO(OCH2CH3)NH–, –CH=CHCH2CH-(OMOM)CH2CH-(OMOM)CH2–], 
3.76–3.67 [m, 1H, CH=CHCH2CH(OMOM)CH2CH(OMOM)CH2–], 3.48 [dd, J = 9.2, 
3.5 Hz, 1H, PhCH2OCH2CH(NH)CH2–], 3.42–3.34 [m, 8H, –OCH2OCH3, –OCH2OCH3, 
PhCH2OCH2CH(NH)CH2–], 2.87 [dd, J = 10.6, 6.5 Hz, 1H, –
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CHaHbCH=CHPO(OEt)NH–], 2.72–2.62 [m, 1H, –CH2CH=CHPO(OEt)NH–], 2.41–2.32 
[m, 1H, –CHaHbCHCHPO(OEt)NH–]; 1.72–1.52 [m, 5H, aliphatic], 1.52–1.39 [m, 2H, 
aliphatic], 1.39–1.17 [m, 8H, aliphatic]. 
31PNMR (162 MHz, CDCl3): δ 20.22. 
13C NMR (126 MHz, CDCl3): δ 147.3 (d, JCP = 4.1 Hz), 138.3, 128.62(2), 127.92(2), 
123.7, 122.3, 96.2, 95.8, 74.3, 73.6, 72.9, 72.8 (d, JCP = 2.5 Hz), 59.9, 56.0 (d, JCP = 5.5 
Hz), 55.8, 50.6, 40.1, 39.4, 32.8 (d, JCP = 6.0 Hz), 32.4, 27.7, 24.7, 22.9, 16.6 (d, JCP = 
7.1 Hz). 























































































































































































































































































































































































































5.2a: A Pot-Economical Approach to the Total synthesis of Sch-725674 (Chapter 3) 
One-pot RCM, CM, chemoselective hydrogenation sequential protocol to (6S,8R)-8-((R)-
6-hydroxyundecyl)-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-4-ene-1-oxide (3.3d): 
 
To a stirred solution of (S,S)-triene 3.3f4 (2.0 g, 8.69 mmol) in a freshly distilled, 
freeze-degas-thawed CH2Cl2 (1.08 L, 0.008 M) was added Hoveyda-Grubbs 2nd Gen. 
catalyst (HG-II) (108 mg, 0.17 mmol, 2 mmol%) and the reaction was heated to reflux 
for 30 min. After completion of RCM, CH2Cl2 was completely removed under reduced 
pressure. Next, freshly distilled, freeze-degas-thawed 1,2-dichloroethane (DCE) (174 mL, 
0.05 M) was added to the crude RCM product. The cross partner 3.3e5 (1.77 g, 10.4 
mmol) and HG-II (216 mg, 0.34 mmol, 4 mmol%) were introduced under argon 
atmosphere. The reaction was refluxed for an additional 5 h until completion of the CM 
reaction (monitored by TLC). The reflux was stopped, and o-nitrobenzenesulfonyl 
hydrazine (o-NBSH) (18.86 g, 86.9 mmol) and Et3N (37.7 mL, at 2 mL/g of o-NBSH) 
were added at room temperature and the reaction was stirred for about 12 h. Next, excess 
o-NBSH (9.43 g, 43.45 mmol) and Et3N (18.8 mL, at 2 mL/g of o-NBSH) were added. 
The reaction was stirred for an additional 8 h at the same temperature until the crude 
                                                
[4]. For the preparation of (S,S)-8, see: (a) Whitehead, A.; McReynolds, M. D.; Moore, J. D.; Hanson, P. R. 
Org. Lett. 2005, 7, 3375−3378. (b) Thomas, C. D.; McParland, J. M.; Hanson, P. R. Eur. J. Org. Chem. 
2009, 5487−5500. (c) Venukadasula, P. K. M.; Chegondi, R.; Maitra, S.; Hanson, P. R. Org. Lett. 2010, 12, 
1556−1559. 






i. HG-II  (2 mol%), CH2Cl2
    reflux, 30 min
ii. HG-II (4 mol%), DCE
reflux, 5 h
3
iii. o-NBSH, Et3N, DCE, rt, 20 h














NMR showed the absence of starting material (CM product). A saturated solution of 
NaHCO3 (50 mL) was added to the reaction mixture and diluted with excess EtOAc (400 
mL). The organic layer was separated and aqueous phase was extracted with EtOAc 
(2x100 mL). The combined organic layers were washed with brine (80 mL), dried 
(Na2SO4), concentrated under reduced pressure, and subjected to flash chromatography 
(25% EtOAc/CH2Cl2) to provide phosphate 3.3d as a brownish semi solid (1.77 g, 59% 
over 3 rxns in one-pot, 84% avg/rxn).  
Optical Rotation: [α]D23 +58.0 (c 0.25, CHCl3); 
FTIR (neat): 3405, 2929, 2856, 1463, 1292, 1101, 1070, 975, 877 cm-1;   
1H NMR (400 MHz, Chloroform-d): δ 6.07–5.99 [m, 1H, -CH=CHCH2OP(O)-], 5.59 [dt, 
J = 11.9, 3.5 Hz, 1H, -CH=CHCH2OP(O)-], 5.18 [d, J = 24.0 Hz, 1H, -
CH2CHP(O)CH=CH-], 5.00 [ddd, J = 15.0, 6.1, 3.1 Hz, 1H, -CH2CH2CHOP(O)CH2], 
4.61–5.51 [m, 1H, -CH=CHCHaHbOP(O)-], 4.36 [ddd, J = 27.6, 14.9, 6.7 Hz, 1H, 1H, -
CH=CHCHaHbOP(O)-], 3.62–3.53 [m, 1H, -CH2CH(OH)CH2], 2.17 [ddd, J = 18.1, 11.9, 
6.0 Hz, 1H, -CHOP(O)CHaHbCHOP(O)-], 1.82–1.65 [m, 2H, -
CHaHbCHOP(O)CHaHbCHOP(O)-], 1.64–1.19 [m, 17H, aliphatic protons and -
CHaHbCHOP(O)CHaHbCHOP(O)-], 0.89 [t, J = 6.8 Hz, 3H, CH3];  
13C NMR (126 MHz, Chloroform-d): δ 129.9, 127.9, 76.7, 71.9, 62.94, 62.89, 37.5, 37.2, 
35.6, 34.8, 31.9, 29.2, 25.4, 25.3, 24.5, 22.6, 14.0;  
31P NMR (162 MHz, Chloroform-d): δ -3.72; 






To a stirring solution of phosphate 3.3d (1.5 g, 4.33 mmol) in anhydrous THF (45 
mL) was added LiAlH4 (0.494 g, 13.0 mmol) in portions at 0 oC under argon atmosphere. 
The reaction was stirred at the same temperature for 1 h. After reaction completion 
(monitored by TLC), it was quenched with the slow sequential addition of H2O (1.5 mL), 
followed by 10% NaOH (1.5 mL) and H2O (4.5 mL) [Fieser workup].6 The mixture was 
warmed to room temperature and stirred for another 30 min and added 10% HCl (pH ~ 
4). The aqueous layer was extracted with EtOAc (3 x 100 mL). The combined organic 
layers were washed with brine (40 mL), dried over Na2SO4 and concentrated under 
reduced pressure to give the crude tetrol (1.35 g) as a white solid. Without 
chromatographic purification, the crude tetrol was directly subjected to the next step. 
To a stirring solution of the above crude tetrol (1.35 g) in a 1:1 mixture of CH2Cl2 
and acetone (25 mL) was added 2,2-dimethoxy propane (6 mL) and followed by a 
catalytic amount of CSA (50 mg, 0.216 mmol) at 0 oC. The reaction mixture was stirred 
at room temperature for 2 h. Next, it was treated with aqueous saturated NaHCO3 
solution (15 mL) and diluted with CH2Cl2 (120 mL). The organic layer was separated and 
the aqueous layer was back extracted with CH2Cl2 (2 x 50 mL). The combined organic 
                                                
[6]. (a) Fieser, L. F.; Fieser, M. Reagents for Organic Synthesis, Vol. 1; Wiley: New York, 1967; pp 
581−595. (b) Mićović, V. M.; Mihailović, M. L.The reduction of acid amides 














71% over 2 rxns 
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layers were washed with brine (40 mL), dried (Na2SO4), filtered and concentrated in 
vacuo. The crude material was purified using silica gel column chromatography (25% 
EtOAc/Hexanes) to afford 1,3-acetonide 3.3c (1.05 g, 71% over 2 rxns in 2 pots) as a 
colorless liquid.  
Optical Rotation: [α]D23 –41.6 (c 0.25, CHCl3);  
FTIR (neat): 3415, 3384, 2929, 2856, 1629, 1458, 1379, 1222, 1033, 1010 cm-1; 
1H NMR (400 MHz, Chloroform-d): δ 5.76 (dt, J = 12.4, 6.5 Hz, 1H), 5.58 (dd, J = 11.3, 
7.1 Hz, 1H), 4.65 (dd, J = 15.3, 7.3 Hz, 1H), 4.26 (dd, J = 13.3, 6.7 Hz, 1H), 4.15 (dd, J = 
13.3, 6.6 Hz, 1H), 3.87–3.77 (m, 1H), 3.62–3.53 (m, 1H), 1.98 (bs, 1H), 1.79–1.60 (m, 
2H), 1.59–1.49 (m, 1H), 1.49–1.20 (m, 23H), 0.89 (t, J = 6.4 Hz, 3H);  
13C NMR (126 MHz, Chloroform-d): δ 132.6, 131.1, 100.4, 71.9, 66.4, 63.5, 58.9, 38.7, 
37.4, 37.3, 35.8, 31.9, 29.5, 25.5, 25.3 (2C), 25.3, 24.6, 22.6, 14.0;  







To a stirred suspension of (–)-diethyl tartrate (72 mg, 0.35 mmol) and 4Å MS in 
anhydrous CH2Cl2 (3.0 mL) at -20 oC was added titanium isopropoxide (85 µL, 0.292 
mmol) under argon atmosphere. The suspension was stirred for 20 min at the same 
temperature. Next, cumene hydroperoxide (115 µL, 0.605 mmol, 80%) was added slowly 
to the reaction mixture and allowed to stir for 20 min. A solution of allyl alcohol 3.3c 
(100 mg, 0.292 mmol) in CH2Cl2 (1.5 mL) was added dropwise and allowed to stir at -20 
oC for 7 days until TLC indicated most of the starting material was consumed (stirring 
during day, freezer at night). The reaction mixture was quenched with NaOH in aq. 
saturated Na2SO4 solution (100 mg in 1.5 mL) and stirred for 2 h at the room 
temperature. The quenched mixture was filtered through celite and EtOAc (3x10 mL) 
was used to wash the filter cake. The filtrate (EtOAc soln) was washed with brine (10 
mL), dried (Na2SO4) and concentrated under reduced pressure. The crude material was 
subjected to column chromatography (28-30% EtOAc/Hexanes) to afford a major 
diastereomer 3.3b (67 mg, 64%, 88% ds) and minor diastereomer 3.3b2 (9.0 mg, 8.6%) 
as colorless liquids, along with recovered starting material 3.3c (10.0 mg).  
Optical Rotation: [α]D23 –8.4 (c 0.25, CHCl3);  















Cumene hydroperoxide, 4 Å MS












1H NMR (400 MHz, Chloroform-d): δ 3.91–3.82 (m, 2H), 3.77 (dd, J = 14.6, 7.4 Hz, 
1H), 3.69 (dd, J = 12.2, 6.3 Hz, 1H), 3.63–3.54 (m, 1H), 3.35 (s, 1H), 3.25 (dd, J = 10.7, 
5.8 Hz, 1H), 3.04 (dd, J = 7.3, 4.3 Hz, 1H), 1.95 (ddd, J = 14.3, 8.5, 6.2 Hz, 1H), 1.83 
(ddd, J = 15.1, 8.2, 6.3 Hz, 1H), 1.63–1.18 (m, 24H), 0.90 (t, J = 6.6 Hz, 3H);  
13C NMR (126 MHz, Chloroform-d): δ 100.4, 71.9, 66.3, 66.1, 61.1, 58.3, 55.9, 37.4, 
37.3, 36.2, 35.8, 31.9, 29.5, 25.5, 25.54, 25.3, 25.2, 24.7, 22.6, 14.0;  
HRMS: calculated for C20H38NaO5 (M+Na)+ 381.2617; found 381.2074 (TOF MS ES+). 




To a stirred solution of epoxy diol 3.3b (500 mg, 1.39 mmol) in CH2Cl2 (25 mL) 
was added Et3N (0.4 mL, 2.78 mmol), followed by the addition of DMAP (34 mg, 0.278 
mmol) at 0 oC under argon atmosphere. After being stirred for 15 min at the same 
temperature, it was treated with toluene-p-sulfonyl choride (0.53 g, 2.78 mmol). The 
reaction mixture was stirred at room temperature for 15 h. Upon consumption of starting 
material (monitored by TLC), the mixture was cooled to 0 oC and more Et3N (1.0 mL, 
6.95 mmol) was added, followed by the slow addition of acryloyl chloride (282 µL, 3.47 
mmol). The resulting mixture was stirred at room temperature for 1 h (reaction progress 








i. TsCl,  Et3N, DMAP 
CH2Cl2, 0 oC to rt, 15 h
ii. Acryloyl chloride,  Et3N
 0 oC to rt, 1 h 













(10 mL). The organic layer was separated and aqueous phase was extracted with CH2Cl2 
(2 x 15 mL). The combined organic layers were washed with brine (10 mL), then dried 
(Na2SO4), filtered and concentrated in vacuo. The resulting crude oil was 
chromatographed over silica gel (12% EtOAc/Hexanes) to afford the desired product 
3.7.2 (0.68 g, 86% over 2 rxns in one-pot, 93% avg/rxn) as a pale yellow gummy liquid.  
Optical Rotation: [α]D23 +8.8 (c 0.25, CHCl3);  
FTIR (neat): 2931, 2858, 1720, 1579, 1460, 1369, 1190, 979, 812 cm-1; 
1H NMR (500 MHz, Chloroform-d): δ 7.81 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 
6.39 (dd, J = 17.2, 1.5 Hz, 1H), 6.11 (dd, J = 17.2, 10.3 Hz, 1H), 5.81 (dd, J = 10.4, 1.5 
Hz, 1H), 4.95 (tt, J = 7.1, 5.3 Hz, 1H), 4.42 (dd, J = 11.6, 3.1 Hz, 1H), 4.05 (dd, J = 11.6, 
7.4 Hz, 1H), 3.80–3.74 (m, 1H), 3.63 (dt, J = 8.8, 6.4 Hz, 1H), 3.23 (ddd, J = 7.4, 4.2, 3.2 
Hz, 1H), 3.02 (dd, J = 6.7, 4.3 Hz, 1H), 2.46 (s, 3H), 1.84 (ddd, J = 14.7, 8.9, 5.8 Hz, 
1H), 1.69 (ddd, J = 15.4, 9.3, 6.2 Hz, 1H), 1.60–1.45 (m, 8H), 1.44–1.19 (m, 16H), 0.87 
(t, J = 6.5, 3H);  
13C NMR (126 MHz, Chloroform-d): δ 166.1, 145.1, 132.7, 130.2, 129.9 (2), 128.9, 
128.0 (2), 100.3, 74.5, 68.5, 66.2, 65.0, 57.9, 53.7, 36.0, 35.7, 34.1, 31.7, 29.7, 29.4, 25.2, 
25.1 (2C), 24.9, 24.4, 22.5, 21.7, 14.0;  




One-pot Finkelstein substitution, Boord olefination, acetonide deprotection sequential 
protocol to (6R,12R,14S,15R)-12,14,15-Trihydroxyheptadec-16-en-6-yl acrylate 
(3.8.2): 
 
 To a stirring solution of tosylate 3.7.2 (100 mg, 0.176 mmol) in acetone (3 mL) 
was added sodium iodide (526 mg, 3.52 mmol) and the reaction mixture was heated to 
reflux for 12 h. After consumption of the starting material (indicated by TLC), acetone 
was removed under reduced pressure, and EtOH (5 mL) was added to the resulting 
mixture at room temperature, followed by the addition of activated Zn powder (344 mg, 
5.33 mmol). The reaction was heated to reflux for 2 h until TLC indicated the absence of 
the iodo-derivative. The reaction mixture was cooled to room temperature and 
subsequently treated with slow addition of 10% aq. HCl (2.0 mL). Stirring was continued 
for 2 h and the mixture was quenched with saturated aq. NaHCO3 solution (8.0 mL, until 
pH = 5). EtOH was completely removed under vacuo and to the resulting residue was 
added EtOAc (20 mL), followed by and H2O (5 mL). The organic layer was removed and 
aqueous layer was again extracted with EtOAc (2x10 mL). The combined organic layers 
were washed with brine (10 mL), dried (Na2SO4), filtered and concentrated under vacuo. 
















i. NaI, acetone, reflux, 12 h
ii. Zn dust, EtOH, reflux, 2 h
 iii. 10% HCl (aq.), EtOH, rt, 2 h




EtOAc/Hexanes) to provide triol 3.8.2 (49 mg, 79% over 3 rxns in one-pot, 93% avg/rxn) 
as a colorless gummy oil.  Compound 3.8.2 matched the reported material in all respects.7 
Optical Rotation: [α]D23 –2.91 (c 0.3, CHCl3);  
FTIR (neat): 3398, 3361, 2939, 1720, 1404, 1271, 1195, 1045, 983, 808 cm-1; 
1H NMR (400 MHz, Chloroform-d): δ 6.38 (dd, J = 17.3, 1.2 Hz, 1H), 6.11 (dd, J = 17.2, 
10.4 Hz, 1H), 5.91 (ddd, J = 17.2, 10.4, 6.1 Hz, 1H), 5.81 (d, J = 10.4 Hz, 1H), 5.35 (d, J 
= 17.2 Hz, 1H), 5.27 (d, J = 10.5 Hz, 1H), 4.95 (p, J = 6.4 Hz, 1H), 4.14 (t, J = 5.4 Hz, 
1H), 4.02–3.90 (m, 2H), 2.72 (s, 1H), 2.26–2.02 (m, 2H), 1.70 (ddd, J = 14.3, 9.5, 2.8 Hz, 
1H), 1.56–1.49 (m, 6H), 1.48–1.41 (m, 1H), 1.38–1.21 (m, 12H), 0.88 (t, J = 6.8 Hz, 3H);  
13C NMR (126 MHz, Chloroform-d): δ 166.2, 136.4, 130.4, 128.9, 117.6, 76.1, 74.5, 
71.2, 69.3, 37.4, 37.2, 34.1, 34.0, 31.7, 29.2, 25.6, 25.1, 24.9, 22.5, 14.0;  
HRMS: calculated for C20H36NaO5 (M+Na)+ 379.2460; found 379.2400 (TOF MS ES+). 
  
                                                





To a stirring solution of triol 3.8.2 (30 mg, 0.084 mmol) in anhydrous CH2Cl2 (1.5 
mL) under argon atmosphere was added N,N-disopropylethylamine (110 µL, 0.63 mmol). 
After being stirred for 15 min, chloro(methoxy)methane (34 µL, 0.42 mmol) was added 
slowly at 0 oC. The reaction mixture was stirred at room temperature for 15 h; then 
excess N,N-disopropylethylamine (110 µL, 0.63 mmol) and chloro(methoxy)methane (34 
µL, 0.42 mmol) were added at 0 oC. The stirring was continued for another 9 h at room 
temperature (until TLC showed the absence of starting material). Upon reaction 
completion, saturated NaHCO3 (5.0 mL) was added followed by CH2Cl2 (15 mL). The 
organic layer was separated and the aqueous layer was back extracted with CH2Cl2 (2x5 
mL). The combined CH2Cl2 extracts were washed with brine (5.0 mL), dried (Na2SO4), 
filtered and concentrated under reduced pressure. The obtained crude material was 
subjected to silica gel column chromatography (15% EtOAc/Hexanes) to furnish the tri-
MOM protected diene 3.9.1 (40 mg, 97%) as a colorless liquid.  
Optical Rotation: [α]D23 –30.1 (c 0.25, CHCl3);  





















1H NMR (400 MHz, Chloroform-d): δ 6.38 (d, J = 17.2, 1H), 6.11 (dd, J = 17.2, 10.4 Hz, 
1H), 5.84–5.71 (m, 2H), 5.33-5.25 (m, 2H), 4.94 (p, J = 6.2 Hz, 1H), 4.83 (d, J = 6.8 Hz, 
1H), 4.73–4.65 (m, 4H), 4.62 (d, J = 6.7 Hz, 1H), 4.16 (d, J = 7.3 Hz, 1H), 3.87–3.81 (m, 
1H), 3.73–3.65 (m, 1H), 3.42 (s, 3H), 3.38 (s, 6H), 1.65–1.46 (m, 8H), 1.38–1.16 (m, 
12H), 0.88 (t, J = 6.8 Hz, 3H);  
13C NMR (126 MHz, Chloroform-d): δ 166.1, 134.5, 130.2, 129.0, 119.0, 96.9, 96.1, 
94.1, 79.6, 77.1, 75.3, 74.5, 55.9, 55.6, 55.4, 36.3, 35.3, 34.1 (2C), 31.7, 29.8, 25.3, 24.9, 
24.8, 22.5, 14.0;  
HRMS: calculated for C26H48NaO8 (M+Na)+ 511.3247; found 511.3239 (TOF MS ES+). 




To a stirred solution of tri-MOM protected diene 3.9.1 (10 mg, 0.02 mmol) in a 
freshly distilled, freeze-degas-thawed CH2Cl2 (14 mL, 0.0015 M) was added the Grubbs 
2nd generation catalyst (G-II) (1.0 mg, 6 mol%). The reaction was heated to reflux for 6 h 
and cooled down to room temperature to add a second batch of G-II (0.7 mg, 4 mol%). 
The reflux was resumed for 6 h (until the RCM completed by TLC). The solvent was 
reduced to a final volume of approximately 1.0 mL by removing the reflux condenser 
from the reaction flask. The reaction mixture was then cooled to room temperature and 








i. G-II (10 mol%) 








ii. TFA, rt, 36 h









36 h (reaction progress was monitored by TLC) and the volatiles were removed under 
vacuo. The crude residue was chromatographed over silica gel (75% EtOAc/Hexanes) to 
furnish the target natural product, Sch-725674 (3.1f) (5.6 mg, 84% over 2 rxns in one-
pot, 92% avg/rxn) as a colorless solid. Characterization data noted below was compared 
and matched to those reported by Prasad7 and Curran.8 
M.P. Range: 181–183 ºC;  
Optical Rotation: [α]D23 +4.97 (c 0.15, CH3OH), {Reported: [α]D +5.15 (c 0.27, 
CH3OH)};  
FTIR (neat): 3451, 2931, 1708, 1279, 1068, 983, 896, 805 cm-1; 
1H NMR (400 MHz, Methanol-d4): δ 6.87 [dd, J = 15.8, 6.1 Hz, 1H, -CH=CH(C=O)O-], 
6.08 [dd, J = 15.8, 1.5 Hz, 1H, -CH=CH(C=O)O-], 4.98–4.93 [m, 1H, 
CH2CH(OC=O)CH2CH3], 4.51–4.46 [m, 1H, -CH=CHCH-(OH)], 3.99 [p, J = 6.1 Hz, 
1H, -CH2CH(OH)CH2-], 3.85 [dd, J = 6.3, 4.4 Hz, 1H, -CH2CH(OH)CH(OH)-], 1.83 [dt, 
J = 14.7, 6.0 Hz, 1H, -CH(OH)CHaHbCH(OH)-], 1.73–1.51 (m, 5H, aliphatic protons), 
1.40–1.25 (m, 11H, aliphatic protons), 1.23–1.12 (m, 3H, aliphatic protons), 0.90 (t, J = 
6.8 Hz, 3H, CH3);  
13C NMR (126 MHz, Methanol-d4): δ 168.4, 149.3, 123.1, 77.6, 76.0, 72.9, 69.5, 38.3, 
36.8, 36.5, 34.1, 32.9, 29.5, 27.0, 26.4, 25.8, 23.8, 14.5;  
HRMS: calculated for C18H32NaO5 (M+Na)+ 351.2147; found 351.2135 (TOF MS ES+). 
  
                                                
[8]. Moretti, J. D.; Wang, X.; Curran, D. P. J. Am. Chem. Soc. 2012, 134, 7963–7970. 
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phosphabicyclo[4.3.1]dec-4-ene 1-oxide (3.10.3): 
 
To a solution of (S,S)-triene 3.4a9 (500 mg, 2.17 mmol) in a degased CH2Cl2 (434 
mL, 0.005 M) was added HG-II (40 mg, 0.065 mmol, 3 mol%)  and the reaction mixture 
was refluxed for 30 min. After completion of RCM, CH2Cl2 was evaporated under 
reduced pressure. To the crude product was added freshly distilled, freeze-degas-thawed 
1,2-dichloroethane (DCE) (43 mL, 0.05 M), the cross metathesis (CM) partner 3.4b10 
(1.77 g, 2.8 mmol) and HG-II (130 mg, 0.13 mmol, 6 mol%) under argon. The reaction 
mixture was heated at 70 ºC for 5 h and a second portion of HG-II (54 mg, 0.086 mmol, 
4 mol%) and CM partner 3.4b (408 mg, 0.65 mmol) were added to the reaction mixture. 
The reaction mixture was stirred at 70 ºC for an additional 3 h (monitored by TLC). After 
completion of reaction, it was cooled to room temperature and was added o-
nitrobenzenesulfonyl hydrazine (o-NBSH) (4.70 g, 21.7 mmol) and Et3N (9.7 mL, at 2 
mL/g of o-NBSH). The reaction mixture was stirred for 12 h at room temperature. A 
                                                
[9]. For the preparation of (S,S)-8, see: (a) Whitehead, A.; McReynolds, M. D.; Moore, J. D.; Hanson, P. R. 
Org. Lett. 2005, 7, 3375−3378. (b) Thomas, C. D.; McParland, J. M.; Hanson, P. R. Eur. J. Org. Chem. 
2009, 5487−5500. (c) Venukadasula, P. K. M.; Chegondi, R.; Maitra, S.; Hanson, P. R. Org. Lett. 2010, 12, 
1556−1559. 




HG-II  (2 mol%), CH2Cl2
    reflux, 30 min, then
HG-II (10 mol%), DCE
reflux, 5 h, then
3
 o-NBSH, Et3N, DCE, rt, 20 h















second portion of o-NBSH (2.3 g, 10.85 mmol) and Et3N (4.6 mL, at 2 mL/g of o-NBSH) 
were added and the reaction mixture was stirred for an additional 8 h. The progress of 
reaction was monitored by crude NMR, which confirmed the completion of reaction. The 
reaction mixture was diluted with EtOAc (200 mL) followed by addition of saturated 
aqueous solution of NaHCO3 (50 mL). The organic layer was separated and aqueous 
phase was extracted with EtOAc (3x50 mL). The combined organic layers were washed 
with brine (40 mL), dried (Na2SO4), concentrated under reduced pressure, and purified by 
flash chromatography (25% EtOAc/CH2Cl2), which furnished bicyclic phosphate 3.10.3 
as a brownish semi solid (620 mg, 62% over 3 rxns in one-pot, 85.5% avg/rxn).  
Optical Rotation: [α]D23 +57.6 (c 0. 5, CHCl3). 
FTIR (neat): 2929, 2856, 1461, 1359, 1303,1253, 1103, 1070, 973, 835, 773 cm-1.   
1H NMR (400 MHz, Chloroform-d): δ 6.03 (dddd, J = 12.0, 8.9, 5.4, 2.2 Hz, 1H), 5.59 
(ddd, J = 11.8, 4.0, 2.5 Hz, 1H), 5.24–5.14 (m, 1H), 5.00 (ddt, J = 14.7, 5.8, 2.3 Hz, 1H), 
4.64 – 4.47 (m, 1H), 4.37 (ddd, JHP = 27.7, JHH = 14.7, 6.7 Hz, 1H), 3.61 (p, J = 5.7 Hz, 
1H), 2.17 (ddd, J =16.4, 12.0, 6.3 Hz, 1H), 1.79 – 1.63 (m, 2H), 1.61 – 1.45 (m, 2H), 1.42 
– 1.19 (m, 15H), 0.92–0.84 (m, 12H), 0.04 (s, 3H), 0.03 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ 130.1, 128.1, 77.4, 76.9, 72.5, 63.1 (d, JCP = 6.5 Hz), 
37.4, 37.1, 35.9 (d, JCP = 9.5 Hz), 35.1 (d, JCP = 6.4 Hz), 32.3, 29.7, 26.1 [3xC, Si-
C(CH3)3], 25.4, 25.2, 24.8, 22.9, 18.4, 14.3, -4.2 [2xC, Si(CH3)2]. 
31P NMR (162 MHz, Chloroform-d): δ -3.63. 






To a flame dried flask containing CuCN (478 mg, 5.3 mmol) and LiCl (529 mg, 
12.46 mmol), weighted inside the glove box, was added dry THF (35.6 mL, 0.05 M) 
under argon and stirred at room temperature for 15 minutes. A pale green coloration was 
observed. The reaction was cooled to –30 ºC followed by slow addition of a 1 M solution 
of Me2Zn in THF (5.3 mL, 5.3 mmol). The reaction was stirred for 40 minutes at –30 ºC 
and a solution of bicyclic phosphate 3.10.3 (820 mg, 1.78 mmol) in dry THF (35.6mL, 
0.05 M) was added drop wise via cannula to the reaction mixture. The reaction was 
slowly warmed to room temperature and allowed to stir for 3 h. Upon completion of 
reaction, it was quenched with aqueous ammonium chloride (NH4Cl). The reaction was 
stirred for 30 minutes and was added anhydrous Na2SO4 (200 mg) stirred for another 20 
min. The reaction mixture was filtered through a Celite® pad to get rid of salt particles. 
The Celite® layer was washed with excess of EtOAc (3x50 mL) and concentrated under 
reduced pressure, which afforded the crude acid as yellowish colored clear oil, which was 
proceeded to the next reaction without further purification.  
 To a flask containing the crude acid was added THF (22 mL, 0.08 M). The 
reaction mixture was cooled to 0 ºC followed by the addition of a 70% solution of Red-Al 
in toluene (5.4 mL, 6 mmol). The reaction was brought to room temperature and stirred 











 1.  Me2Zn, CuCN, LiCl,
THF, -30 ºC-rt, 3 h
2. Red Al, THF, 0 ºC-rt
12 h, 79% (2 steps)
3.10.3 3.10.5
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quenched with NH4Cl (sat’d aq) and extracted with EtOAc (3x100 mL). The organic 
layer was dried (Na2SO4) and the solvent was evaporated under reduced pressure. The 
crude product was purified via flash chromatography, which afforded TBS-protected diol 
3.10.5 (590 mg, with 79% yield over two reactions) as colorless viscous oil. 
Optical Rotation: [α]D23 –0.54 (c 0. 37, CHCl3); 
FTIR (neat): 3355, 2929, 2856, 1461, 1253, 1081,1053, 1004, 912, 835, 773 cm-1;   
1H NMR (500 MHz, Chloroform-d): δ 5.79 – 5.70 (m, 1H), 5.18 – 5.13 (m, 2H), 4.00 – 
3.87 (m, 1H), 3.75 – 3.68 (m, 1H), 3.62 (p, J = 5.7 Hz, 1H), 2.48 (t, J = 4.1 Hz, 1H), 2.34 
– 2.19 (m, 2H), 1.64 (t, J = 6.3 Hz, 2H), 1.60–1.51 (m, 1H), 1.56 – 1.28 (m, 18H), 1.03 
(d, J = 6.8 Hz, 3H), 0.89 (s, 12H), 0.04 (s, 6H). 
13C NMR (126 MHz, CDCl3): δ 140.7, 117.0, 72.5, 72.2, 69.4, 44.7, 39.4, 37.6, 37.3, 
37.3, 32.3, 30.1, 26.3 [3xC, Si-C(CH3)3], 26.2, 25.5, 25.2, 22.9, 18.4, 16.4, 14.3, -4.2 
[2xC, Si(CH3)2]. 








 To a stirred solution of TBS-protected diol 3.10.5, (200 mg, 0.48 mmol) in 
CH2Cl2 (4.9 mL, 0.1 M) was added DIPEA (496 ml, 2.88 mmol), and DMAP (6.08 mg, 
0.04 mmol) followed by drop wise addition of Chloromethyl methyl ether (MOMCl) 
(108 mL, 1.44 mmol) at 0 ºC under argon. The reaction mixture was stirred at room 
temperature for 2 h. After completion of reaction (monitored by TLC), the solvent was 
evaporated under reduced pressure and was added dry THF (4.8 mL, 0.1 M). To the 
crude reaction mixture was added Tetrabutylammonium fluoride (TBAF, 1 M solution) 
(1.5 mL, 1.43 mmol) and refluxed for 3 h. After completion of reaction (monitored by 
TLC), it was quenched with aqueous ammonium chloride (NH4Cl), extracted with EtOAc 
(3x40 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. The crude 
compound was purified by silica gel chromatography (Hexane/EtOAc 3:1), which 
furnished the MOM-protected alcohol 3.12.1 (176 mg, 89% yield over two reactions, 
94.5% av/rxn) as a colorless viscous liquid. 
Optical Rotation: [α]D23 –17.6 (c 0.5, CHCl3).  






 MOMCl, DIPEA, DMAP
CH2Cl2, 0 ºC-rt, 2 h, then
TBAF, THF, reflux, 3 h






P = MOM 3.12.1
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1H NMR (500 MHz, Chloroform-d): δ 5.83 – 5.75 (m, 1H), 5.12 – 5.01 (m, 2H), 4.70 
(s, 2H), 4.67 (s, 2H), 3.77 – 3.64 (m, 2H), 3.63 – 3.56 (m, 1H), 3.41 (s, 3H), 3.39 (s, 3H), 
2.58–2.47(m, 1H), 1.61 – 1.49 (m, 4H), 1.49 – 1.38 (m, 4H), 1.37 – 1.26 (m, 13H), 1.04 
(d, J = 6.9 Hz, 3H), 0.90 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 140.4, 115.2, 97.0, 96.2, 79.1, 75.7, 72.1, 56.0, 55.9, 
41.5, 37.7, 37.6, 36.7, 35.5, 32.1, 30.1, 25.8, 25.6, 25.2, 22.9, 14.3, 14.5. 





To a stirred solution of TBS-protected diol 3.10.5, (50 mg, 0.12 mmol) in CH2Cl2 
(0.1 M) was added DIPEA (124 mL, 0.72 mmol), and DMAP (1.52 mg, 0.012 mmol) 
followed by drop wise addition of Chloromethyl methyl ether (MOMCl) (27 mL, 0.36 
mmol) at 0 ºC under argon. The reaction mixture was stirred at room temperature for 6 h. 
After completion of reaction (monitored by TLC), the solvent was evaporated under 
reduced pressure and was added dry THF (0.1 M). To the crude reaction mixture was 
added Tetrabutylammonium fluoride (TBAF, 1 M solution) (360 mL 0.36 mmol) and 
refluxed for 1 h under argon. After completion of reaction (monitored by TLC) the 
solvent was evaporated and was added CH2Cl2 (0.1 M) followed by Et3N (67 mL, 0.48 






 MOMCl, DIPEA, DMAP
CH2Cl2, 0 ºC-rt, 2 h, then







DMAP, CH2Cl2, 0º C-rt, 1 h





added acryolyl chloride (29 mL, 0.36 mmol) at 0 ºC. The reaction mixture was stirred at 
room temperature for 1 h. After completion of reaction, it was quenched with ice-coold 
water. Extracted with CH2Cl2 (3x10 mL), dried (MgSO4), concentrated and purified using 
silica gel chromatography (hexane/EtOAc 7:1), which afforded the 3.11.3 (40.7 mg, 72% 
yield over 3 reactions, 90% av/rxn) as a colorless viscous liquid. 
FTIR (neat): 2931, 2860, 1722, 1458, 1404, 1296, 1271, 1195, 1147, 1099, 1035, 916, 
810 cm-1. 
Optical Rotation: [α]D23 = –9.0 (c 0.5, CHCl3).  
1H NMR (500 MHz, Chloroform-d): δ 6.39 (dd, J = 17.3, 1.6 Hz, 1H), 6.12 (dd, J = 17.3, 
10.4 Hz, 1H), 5.83 – 5.72 (m, 2H), 5.10 – 5.04 (m, 2H), 4.95 (tt, J = 7.1, 5.4 Hz, 1H), 
4.70 (s, 2H), 4.66 (s, 2H), 3.72 – 3.63 (m, 2H), 3.40 (s, 3H), 3.38 (s, 3H), 1.63 – 1.44 (m, 
7H), 1.39 – 1.22 (m, 14H), 1.04 (d, J = 6.9 Hz, 3H), 0.89 (t, J = 6.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 166.3, 140.5, 130.4, 129.2, 115.2, 97.0, 96.2, 79.1, 75.7, 
74.8, 56.0, 55.9, 41.5, 36.7, 35.5, 34.3 (2C), 31.9, 30.0, 25.5, 25.2, 25.1, 22.7, 14.2, 14.0. 







To a solution of MOM-protectd alcohol 3.12.1 (70 mg, 0.15 mmol) under argon 
was added PPh3 (83 mg, 0.31 mmol) and DIAD (64 mg, 0.31 mmol). The reaction 
mixture was stirred for 5 min at room temperature and then was added DPPA (90 mg, 
0.33 mmol) at 0 ºC. The reaction mixture was stirred at the same temperature for 2 h 
(monitored by TLC). After completion of reaction, LiAlH4 (12.5 mg, o.33 mmol) was 
added in portions at 0 ºC over 5 minutes and the reaction mixture was stirred at the same 
temperature for 1 h (monitored via TLC, the azide was reduced to the corresponding 
amine). After complete consumption of the starting material the reaction mixture was 
quenched with aqueous saturated NaHCO3 solution (1 mL), stirred for 15 min at 0 ºC and 
diluted with THF (1.2 mL). Acryloyl chloride (29 µL, 0.33 mmol) was added at the same 
temperature and the reaction mixture was stirred for 1 hour at 0 ºC. After completion of 
acrylation reaction indicated by TLC, the reaction mixture was quenched with NH4Cl, 
extracted with EtOAc (3x10 mL), dried (Na2SO4) and concentrated under reduced 
pressure. The compound was purified using silica gel chromatography (Hexane/EtOAc 
4:1), which afforded the acrylamide 3.12.4 (56 mg, 74% over three reaction one-pot, 90% 
av/rxn) as colorless viscous liquid. 
3.12.1
DPPA, DIAD, PPh3
THF, 0 ºC, 2 h, then
LiAlH4, 0 ºC-rt, 1 h, then
sat. NaHCO3 (aq), 0 ºC
acryloyl chloride, 1 h














FTIR (neat): 3272, 2929, 2856, 1654, 1623, 1542, 1147, 1099, 1043, 1916 cm-1. 
Optical Rotation: [α]D23 = –3.2 (c 0.25, CHCl3).  
1H NMR 1H NMR (500 MHz, Chloroform-d): δ 6.28 (dd, J = 16.9, 1.5 Hz, 1H), 6.08 
(dd, J = 16.3, 10.3 Hz, 1H), 5.86 – 5.73 (m, 1H), 5.64 (dd, J = 10.3, 1.5 Hz, 1H), 5.22 (d, 
J = 9.2 Hz, 1H), 5.09–5.04 (m, 2H), 4.72 (s, 2H), 4.68 (s, 2H), 4.10 – 3.94 (m, 1H), 3.82 
– 3.60 (m, 2H), 3.42 (s, 3H), 3.40 (s, 3H), 2.63 – 2.44 (m, 1H), 1.56 – 1.51 (m, 4H), 1.38 
– 1.28 (m, 16H), 1.06 (d, J = 6.9 Hz, 3H), 0.9 (t, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 165.2, 140.4, 131.3, 126.4, 115.2, 96.9, 96.2, 79.1, 77.4, 
75.6, 56.0, 55.9, 49.6, 41.5, 36.7, 35.5 (2C), 32.0, 30.0, 26.1, 25.8, 25.1, 22.8, 14.3, 14.0. 




General procedure A; one-pot sequential RCM/MOM-deprotection.  
 To a flame dried RB was added CH2Cl2 (33 mL, 0.001 M), degased it for 20 
minutes and was added diene (0.05 mmol) and G-II catalyst (10 mol%). The reaction 
mixture was refluxed for 10–12 h (monitored via TLC). After completion of reaction 
(monitored by TLC), the CH2Cl2 was evaporated under reduced pressure. To the crude 
RCM product was added 2 mL mixture of MeOH and HCl (3.0 M) in a ratio of 1:1.5, 
respectively. The reaction mixture was stirred at room temperature for 36–40 h 
(monitored via TLC).  After completion, the reaction mixture was quenched with aqueous 
NaHCO3 (pH ~8), extracted with EtOAc (3x10 mL), dried (Na2SO4), filtered, 
concentrated under reduced pressure, and purified using flash chromatography to furnish 




Following general procedure A, the compound 3.1g was synthesized and purified 
via silica gel column chromatography (Hexane/EtOAc 3:2), 15 mg of 3.13.3 (0.031 
mmol) generated 9.4 mg of 3.1g [85% over 2 rxns in one-pot (92.7% av/rxn)] as a 











G-II ( 10 mol %)
CH2Cl2 (0.001 M)
 reflux, 10 h, then
HCl (3 M), MeOH, rt, 36 h





FTIR (neat): 3400, 2929, 2858, 2358, 1714, 1699, 1456, 1361, 1362 1083, 1037, 987, 
869, 719 cm-1. 
Optical Rotation: [α]D23 = +10.2 (c 0.37, CHCl3).  
1H NMR 1H NMR (500 MHz, Chloroform-d) δ 6.86 (dd, J = 15.7, 10.0 Hz, 1H), 5.87 (d, 
J = 15.7 Hz, 1H), 4.96–4.88 (m, 1H), 4.04–3.94 (m, 2H), 2.84 (bs, 1H), 2.62–2.51 (m, 
1H), 2.10–1.98 (m, 1H), 1.84 (dt, J = 15.5, 4.8 Hz, 1H), 1.75 – 1.60 (m, 4H), 1.59 – 1.49 
(m, 2H), 1.47–1.40 (m, 2H), 1.40 – 1.24 (m, 11H), 1.18 (d, J = 6.9 Hz, 3H), 0.90 (t, J = 
5.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 166.3, 150.4, 123.2, 75.7, 71.7, 69.4, 43.6, 36.7, 35.5, 
35.4, 33.4, 31.9, 28.0, 25.3, 24.7, 23.7, 22.8, 14.3, 13.6. 




Following general procedure A, the compound 3.1h was synthesized and purified 
via silica gel column chromatography (Hexane/EtOAc 1:1), 25 mg of 3.12.4 (0.031 








G-II ( 10 mol %)
CH2Cl2 (0.001 M)
 reflux, 12 h, then
HCl (3 M), MeOH, rt, 40 h








FTIR (neat): 3330, 3286, 2925, 2850, 1662, 1627, 1558, 1541, 1456, 1436, 1269, 1107, 
1078, 983, 869 cm-1. 
Optical Rotation: [α]D23 = +3.6 (c 0.25, CHCl3).  
1H NMR (400 MHz, MeOD): δ 6.64 (dd, J = 15.6, 9.5 Hz, 1H), 5.92 (d, J = 15.6 Hz, 
1H), 3.92–3.80 (m, 2H), 3.77–3.68 (m, 1H), 2.38–2.28 (m, 1H), 1.76–1.60 (m, 2H), 1.48–
1.12 (m, 18H), 1.09 (d, J = 6.7 Hz, 3H), 0.83 (t, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 166.7, 147.0, 124.9, 73.6, 68.6, 56.1, 53.6, 49.2, 44.1, 
35.8, 35.3, 33.0, 31.8, 29.9, 26.0, 23.9, 22.8, 15.5, 14.3. 






To a solution of TBS-protected alcohol 3.10.5 (200 mg, 0.48 mmol) in THF 
(4.8mL, 0.1 M) was added PPh3 (253 mg, 0.96 mmol) and DIAD (290 mg, 1.44 mmol) 
under argon atmosphere. The reaction mixture was stirred for 5 min at room temperature 
and was added DPPA (462 mg, 1.68 mmol) at 0 ºC. The reaction mixture was stirred at 
the same temperature for 2 h (monitored by TLC). After completion of reaction, LiAlH4 






THF, 0 ºC, 2 h, then
LiAlH4, 0 ºC-rt, 1 h, then
sat. NaHCO3 (aq), 0 ºC
(Boc)2O, 1 h
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mixture was stirred at the same temperature for 1 h (monitored via TLC, the azide was 
reduced to the corresponding amine). After complete consumption of the starting material 
the reaction mixture was quenched with aq. saturated NaHCO3 solution (1 mL), stirred 
for 15 min at 0 ºC and diluted with THF (1.2 mL). To the crude reaction mixture were 
added Boc2O (230 mg, 1.05 mmol) and the reaction mixture was stirred for 1 h at room 
temperature. After completion of reaction indicated by TLC, the reaction mixture was 
quenched with NH4Cl, extracted with EtOAc (3x30 mL), dried (Na2SO4) and 
concentrated under reduced pressure. The compound was purified using silica gel 
chromatography (Hexane/EtOAc 4:1), which afforded the Boc-protected alkene 3.13.2 
(238 mg, 80% over three reaction one-pot, 93% av/rxn) as colorless viscous liquid. 
FTIR (neat): 3338, 2956, 2929, 2856, 1716, 1699, 1506, 1456, 1365, 1249, 1174, 1080, 
835, 773 cm-1. 
Optical Rotation: [α]D23 = +13.0 (c 0.4, CHCl3).  
1H NMR (500 MHz, Chloroform-d): δ 5.66 (ddd, J = 17.0, 10.3, 8.4 Hz, 1H), 5.19 – 4.94 
(m, 2H), 4.65–4.53 (m, 1H), 3.61 (p, J = 5.7 Hz, 1H), 3.58–3.46 (m, 2H), 2.45–2.35 (m, 
1H), 1.51 – 1.36 (m, 27H), 1.36 – 1.20 (m, 10H), 1.02 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 
2.3 Hz, 12H), 0.04 (s, 3H), 0.03 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ 155.8, 140.9, 115.9, 79.3, 79.1, 72.6, 51.8, 48.4, 42.9, 
37.32, 37.28, 36.5, 35.5, 32.3, 30.0, 28.7 [3x2C, NHC(O)OC(CH3)3], 26.5, 26.2 [3xC, Si-
C(CH3)3], 25.5, 25.2, 22.9, 18.4, 17.0, 14.3, -4.17, -4.19 [2xC, Si(CH3)2]. 




6-yl acrylate (3.13.3): 
 
To a stirred solution of TBS-protected alcohol 3.13.2 (200 mg, 0.32) in dry THF 
(3.2 mL, 0.1 M) under argon was added TBAF (183 ml, 0.65 mmol) at room temperature. 
The reaction mixture was refluxed for 3 h. After completion (monitored via TLC), the 
solvent was evaporated and CH2Cl2 (3.2 mL, 0.1 M) was added under argon followed by 
Et3N (269 µl, 1.92mmol) and DMAP (4.06 mg, 0.032 mmol). The crude reaction mixture 
was cooled to 0 ºC and added acryloyl chloride (72 µl, 0.8 mmol) drop wise and the 
reaction mixture was stirred at 0 ºC for 1 h. After completion of reaction, it was quenched 
with ice cold water, the organic layer was extracted with CH2Cl2 (3x20 mL), dried 
(Na2SO4), concentrated and purified using silica gel chromatography (Hexane/EtOAc 
5:1), which furnished the acrylate 3.13.3 (156 mg, 86 % over two reactions one-pot, 93% 
av/rxn) as colorless liquid. 
FTIR (neat): 3365, 2931, 2860, 2360, 1716, 1699, 1519, 1506, 1456, 1390, 1245, 1191, 
1174, 1047, 985, 773 cm-1. 
Optical Rotation: [α]D23 = +10.0 (c 0.25, CHCl3).  
1H NMR (500 MHz, Chloroform-d): δ 6.39 (dd, J = 17.3, 1.5 Hz, 1H), 6.12 (dd, J = 










TBAF, THF, reflux, 3 h, then
acryloyl chloride, CH2Cl2, 0 ºC, 1 h




1H), 5.11 – 5.01 (m, 2H), 4.94 (p, J = 6.5 Hz, 1H), 4.65–4.49 (m, 1H), 3.59–3.43 (m, 
2H), 2.44–2.31 (m, 1H), 1.62–152 (m, 3H), 1.49–137 (m, 23H), 1.28 (m, 13H), 1.02 (d, J 
= 6.8 Hz, 3H), 0.88 (t, J = 6.7 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 166.3, 155.9, 155.8, 140.8, 130.4, 129.2, 115.9, 79.3, 
79.1, 74.7, 51.8, 48.4, 42.9, 36.5, 35.4, 34.3, 34.3, 31.9, 29.5, 28.7 [3x2C, 
NHC(O)OC(CH3)3], 26.3, 25.5, 25.2, 22.7, 17.0, 14.2. 





To a solution of Boc-protectd alcohol 3.14.1 (100 mg, 0.20 mmol) in THF (2.0 
mL, 0.1 M) was added PPh3 (5.2 mg, 0.02 mmol) and DIAD (80 mg, 0.40 mmol). The 
reaction mixture was stirred for 5 min at room temperature and then was added DPPA 
(115 mg, 0.42 mmol) at 0 ºC. The reaction mixture was stirred at the same temperature 
for 2 h (monitored by TLC). After completion of reaction, LiAlH4 (22.8 mg, o.6 mmol) 
was added in portions at 0 ºC over 5 minutes and the reaction mixture was stirred at the 
same temperature for 1 h (monitored via TLC, the azide was reduced to the 







THF, 0 ºC, 2 h, then
LiAlH4, 0 ºC-rt, 1 h, then
sat. NaHCO3 (aq), 0 ºC
acryloyl chloride, 1 h










mixture was quenched with aq. saturated NaHCO3 solution (0.8 mL), stirred for 15 min at 
0 ºC and diluted with THF (1.2 mL). Acryloyl chloride (39.8 µl, 0.44 mmol) was added 
at the same temperature and the reaction mixture was stirred for 1 hour. After completion 
of reaction indicated by TLC, the reaction mixture was quenched with NH4Cl, extreacted 
with EtOAc (20x3 mL), dried (Na2SO4) and concentrated under reduced pressure. The 
compound was purified using silica gel chromatography (Hexane/EtOAc 4:1), which 
afforded the acrylamide 3.14.4 (82mg, 75% over three reactions in one-pot, 91% av/rxn) 
as colorless viscous liquid. 
FTIR (neat): 3307, 2929, 2854, 2356, 1699, 1539, 1519, 1456, 1363, 1244, 1172, 895, 
912 cm-1. 
Optical Rotation: [α]D23 = +9.1 (c 0.25, CHCl3).  
1H NMR (500 MHz, Chloroform-d) δ 6.21 (dd, J = 17.0, 1.5 Hz, 1H), 6.03 (dd, J = 16.9, 
10.2 Hz, 1H), 5.68–5.49 (m, 2H), 5.23 (bs, 1H), 5.07–4.87 (m, 2H), 4.67–4.50 (m, 1H), 
3.99–3.86 (m, 1H), 3.50–3.37 (m, 2H), 2.38–2.25 (m, 1H), 1.61–1.47 (m, 4H), 1.43–1.31 
(m, 16H), 1.28–1.16 (m, 18H), 0.94 (d, J = 6.8 Hz, 3H), 0.88 (t, J = 6.7 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 165.3, 156.0, 140.9, 131.4, 126.4, 122.5, 115.9, 79.3 
(2C), 79.1, 51.7, 49.6, 48.3, 42.9, 35.55, 35.48, 35.1, 32.0, 29.5, 28.7 [3x2C, 
NHC(O)OC(CH3)3], 26.0, 25.9, 25.8, 22.8, 16.9, 14.3. 








 To a flame dried RB was added CH2Cl2 (38 mL, 0.001 M), degased it for 20 
minutes and was added diene 3.13.3 (20 mg, 0.038 mmol) followed by G-II catalyst (10 
mol%). The reaction mixture was refluxed for 12 h (monitored via TLC). After 
completion of RCM reaction, the CH2Cl2 was evaporated under reduced pressure. To the 
crude RCM product was added a cooled solution of HCl (1 mL, 4.0 M in dioxane) and 
the reaction mixture was stirred at room temperature for 5 h (monitored via TLC). After 
completion of reaction the dioxane was evaporated completely under reduced pressure. A 
mixure of EtOAc:heptane (6 mL, 1:4 ratio) was added to the above residue and stirred it 
at room temperature for  30 min. The reaction mixture was filtered and the resulting 
solids was washed with the same mixture of solvents (3 mL) and the compound was dried 
at 40–45 oC for 5-6 h, which afforded 7.1 mg of pure amine salt 3.1i in 69% yield (83.9% 
av/rxn, three reactions one-pot) as a pale yellow solid. 
FTIR (neat): 3433, 2929, 2854, 1708, 1602, 1521, 1458, 1265, 1184, 991, 721 cm-1. 
Optical Rotation: [α]D23 = –15.3 (c 0.15, MeOH).  
1H NMR (500 MHz, MeOD): δ 6.74 (dd, J = 15.7, 9.8 Hz, 1H), 5.87 (d, J = 15.7 Hz, 











G-II ( 10 mol %), CH2Cl2 
 reflux, 12 h, then
4M HCl in dioxane, 0 ºC-rt, 5 h
69% (2 rxns one-pot), (83.9% av/rxn)
3.13.3 3.1i
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1.81 (m, 2H), 1.72–1.60 (m, 1H), 1.58–1.08 (m, 17H), 1.04 (d, J = 6.5 Hz, 3H), 0.74–
0.67 (m, 3H). 
13C NMR (101 MHz, MeOD): δ 165.5, 149.2, 124.0, 74.7, 60.2, 51.1, 40.9, 38.3, 32.9, 
31.4, 30.4, 28.6, 25.9, 25.0, 22.7, 22.2, 21.2, 16.9, 12.9. 
HRMS: calculated for C19H37N2O2 (H+ for free-salt) 325.2855; found 325.2853 (TOF 
MS ES+). 
(6R,12S,14R,15R)-12,14-bis((tert-butoxycarbonyl)amino)-15-methylheptadec-16-en-
6-yl acrylate (3.1j): 
 
 To a flame dried RB was added CH2Cl2 (27 mL, 0.001 M), degased it for 20 
minutes and was added diene 3.13.3 (15 mg, 0.027 mmol) followed by G-II catalyst (10 
mol %). The reaction mixture was refluxed for 12 h (monitored via TLC). After 
completion of RCM reaction, the CH2Cl2 was evaporated under reduced pressure. To the 
crude RCM product was added added a cooled solution of HCl (1 mL, 4.0 M in dioxane) 
and the reaction mixture was stirred at room temperature for 5 h (monitored via TLC). 
After completion of reaction, the dioxane was evaporated completely under reduced 
pressure. To the crude reaction mixture was added EtOAc (10 mL) followed by the 
addition of solid NaHCO3 (10 mg) and the reaction mixture was stirred at room 
temperature for 1 h. The solid NaHCO3 was removed via filtration using celite® pad and 
the solid residue was washed with EtOAC (15 mL). The filtrate was evaporated under 
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CH2Cl2 (0.001 M)
 reflux, 12 h, then
4M HCl in dioxane,
 0 ºC-rt, 5 h
 NaHCO3 (solid), EtOAc









MeOH in CHCl3 to furnish the pure cyclic lactone 3.1j (6 mg) in 67% yield (82.2% 
av/rxn) as a colorless gummy liquid. 
FTIR (neat): 3321, 2921, 2856, 2360, 1724, 1546, 1458, 1265, 1184, 991, 721 cm-1. 
Optical Rotation: [α]D23 = –15.3 (c 0.15, MeOH).  
1H NMR (400 MHz, MeOD): δ 4.93–4.85 (m, 1H), 3.29 (dt, J = 12.7, 4.6 Hz, 1H), 2.92 
(t, J = 10.9 Hz, 1H), 2.74 (td, J = 11.3, 4.2 Hz, 1H), 2.54 (t, J = 12.9 Hz, 1H), 2.18 (dd, J 
= 13.1, 4.5 Hz, 1H), 1.93–1.86 (m, 1H), 1.71–1.01 (m, 20H), 0.83 (d, J = 6.9 Hz, 3H), 
0.75 (t, J = 6.7 Hz, 3H). 
13C NMR (126 MHz, MeOD): δ 173.3, 75.6, 55.7, 50.7, 44.8, 40.6, 40.2, 33.9, 32.4, 
31.8, 31.4, 28.2, 25.3, 24.0, 22.6, 22.2, 21.1, 13.6, 13.0. 






 To a flame dried RB was added CH2Cl2 (34 mL, 0.001 M), degased it for 20 
minutes and was added diene 3.14.4 (19 mg, 0.034 mmol) followed by G-II catalyst (10 
mol %). The reaction mixture was refluxed for 12 h (monitored via TLC). After 
completion of RCM reaction, the CH2Cl2 was evaporated under reduced pressure. To the 
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reaction mixture was stirred at room temperature for 6 h (monitored via TLC). After 
completion of reaction, the dioxane was evaporated completely under reduced pressure. 
To the crude reaction mixture was added EtOAc (6 mL) followed by solid NaHCO3 (5 
mg) and the reaction mixture was stirred at room temperature for 1 h. The solid NaHCO3 
was removed via filtration using celite® pad and washed with EtOAC (8 mL). The 
filtrate was evaporated under reduced pressure and the crude product was purified using 
basic alumina using 10% MeOH in CHCl3 to furnish the pure cyclic lactam 3.1k (6 mg) 
in 70% yield (82.2% av/rxn) as a brownish gummy liquid. 
FTIR (neat): 3278, 2931, 2858, 1683, 1676, 1438, 1205, 1184, 1137, 842, 800, 723 cm-1. 
Optical Rotation: [α]D23 = –9.6 (c 0.25, MeOH).  
1H NMR (500 MHz, Methanol-d4): δ 6.51 (dd, J = 15.2, 10.6 Hz, 1H), 6.11 (d, J = 15.2 
Hz, 1H), 4.11 – 3.91 (m, 1H), 3.49 – 3.35 (m, 1H), 3.17 (dt, J = 10.1, 3.4 Hz, 1H), 2.52 – 
2.39 (m, 1H), 2.09 – 1.69 (m, 3H), 1.69 – 1.25 (m, 19H), 1.23 (d, J = 6.5 Hz, 3H), 1.21 – 
1.03 (m, 4H), 0.74 (t, J = 6.4 Hz, 3H). 
13C NMR (126 MHz, MeOD): δ 168.5, 145.9, 127.1, 55.5, 53.1, 42.3, 36.4, 36.1, 35.6, 
34.5, 32.9, 30.9, 28.5, 27.2, 26.8, 23.8 (2C), 18.9, 14.5. 
HRMS: calculated for C19H38N3O (H+) 324.3015; found 324.3008 (TOF MS ES+). 
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 5.2b: 5.2b: A pot-economical approach for the total syntheses of Sch-725674 
analogs (Chapter-3) 
(1S,6S,8R)-8-((R)-6-((tert-butyldimethylsilyl)oxy)undecyl)-2,9,10-trioxa-1-





























































































































































































































































































































5.3: Efforts Towards Asymmetric Total Synthesis of (–)-13-Desmethyl-
lyngbouilloside an Unnatural Analog of Lyngbouillosid (Chapter 4) 
 
(1S,6S,8R)-8-(3-(benzyloxy)propyl)-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-4-ene 
1-oxide (4.8.3):  
 
To a solution of (S,S)-triene 4.9g (400 mg, 1.7 mmol) in a degased CH2Cl2 (347 
mL, 0.005 M) was added HG-II (21.2 mg, 0.034 mmol, 2 mol%) the reaction mixture 
was refluxed for 20 min. After completion of RCM reaction, CH2Cl2 was evaporated 
under reduced pressure. To the crude product was added freshly distilled, freeze-degas-
thawed 1,2-dichloroethane (DCE) (17 mL, 0.1 M), the cross metathesis (CM) partner 
4.8.1 (327 mg, 2.2 mmol) and HG-II (63 mg, 0.06 mmol, 6 mol%) under argon. The 
reaction mixture was stirred at 70 ºC for 5 h and a second portion of HG-II (42 mg, 0.068 
mmol, 4 mol%) and CM partner (75 mg, 0.51 mmol) were added to the reaction mixture, 
and was stirred at 70 ºC for an additional 3 h (monitored by TLC). After completion of 
CM reaction, the reaction mixture was brought to room temperature and was added o-
nitrobenzenesulfonyl hydrazine (o-NBSH) (3.6 g, 17 mmol) and Et3N (7.3 mL, at 2 mL/g 
of o-NBSH), the reaction mixture was stirred for 12 h (Note: The reaction flask was 
wrapped with aluminum foil in order to avoid decomposition of o-NBSH due to light). A 
second portion of o-NBSH (1.8 g, 8.5 mmol) and Et3N (3.6 mL, at 2 mL/g of o-NBSH) 
were added and the reaction mixture was stirred for an additional 8 h at room 








 HG-II (2 mol%), CH2Cl2
 reflux, 20 min, then
(S,S)-triene, 4.9g
o-NBSH, DCE, rt, 18 h








 HG-II (10 mol%) 





complete reduction of the external double bond in the CM adduct 4.8.2. The reaction 
mixture was diluted with EtOAc (150 mL) followed by addition of saturated aqueous 
solution of NaHCO3 (100 mL). The organic layer was separated and aqueous phase was 
extracted with EtOAc (3x100 mL). The combined organic layers were washed with brine 
(50 mL), dried (Na2SO4), concentrated under reduced pressure, and purified with flash 
chromatography (25% EtOAc/CH2Cl2), which furnished 362 mg of bicyclic phosphate 
4.8.3 as a dark brown semi solid in 53% yield over three reactions in one-pot (81% 
av/rxn). 
FTIR (neat): 2929, 2852, 2356, 1470, 1298, 1009, 1506, 1068, 972, 885, 773 cm-1. 
Optical Rotation: [α]D23 = +45.5 (c 1.72, CHCl3).  
1H NMR (500 MHz, Chloroform-d): δ 7.40–7.24 (m, 5H), 5.98 (dddd, J = 12.0, 6.7, 3.3, 
2.1 Hz, 1H), 5.54 (ddd, J = 11.8, 4.0, 2.5 Hz, 1H), 5.23–5.13 (m, 1H), 4.97 (ddt , J = 
14.4, 5.6, 2.7 Hz, 1H), 4.68–4.55 (m, 1H), 4.48 (s, 2H), 4.33 (ddd, JHP = 27.7, JHH 14.7, 
6.7 Hz, 1H), 3.50 (m, 2H), 2.16 (ddd, J = 14.6, 11.8, 6.2 Hz, 1H), 1.88 – 1.63 (m, 5H). 
13C NMR (126 MHz, CDCl3): δ 138.4, 129.9, 128.4 (2), 127.8, 127.6 (2), 127.6, 72.9, 
69.6, 63.0, 62.9, 34.9 (d, JCP = 6.0), 32.7, 32.6, 24.9. 





To a flame dried RB was added CuCN (290 mg, 3.2 mmol) and LiCl (317 mg, 7.5 
mmol) inside the glove box, followed by addition of dry THF (10 mL, 0.05 M) under 
argon and the reaction mixture was stirred at room temperature for 15 minutes. A pale 
green coloration was observed. The reaction mixture was cooled to –40 ºC followed by 
slow addition of a 1 M solution of Me2Zn in THF (3.2 mL, 3.2 mmol). The reaction 
mixture was stirred for 40 minutes at –30 ºC and a solution of bicyclic phosphate 4.8.3 
(350 mg, 1.08 mmol) in dry THF (10 mL, 0.05 M) was added dropwise via cannula to the 
reaction mixture. The reaction was slowly warmed to room temperature and allowed to 
stir for 3 h. Upon completion of reaction (monitored via TLC), the reaction mixture was 
quenched with saturated aqueous ammonium chloride (NH4Cl, 2 mL), stirred for 15 
minutes followed by the addition of anhydrous Na2SO4 (200 mg) stirred for another 30 
min. The crude product was filtered through Celite® pad and washed with excess EtOAc 
(3x50 mL), the filtrate was concentrated under reduce pressure, which afforded the crude 
acid as yellowish viscous oil, which was proceeded to the next reaction without further 
purification.  
 To a flask containing the crude acid was added THF (13.5 mL, 0.08 M). The 
reaction mixture was cooled to 0 ºC and was added 70% solution of Red-Al in toluene 
(1.5 mL, 5 mmol). The reaction mixture was brought to room temperature and stirred for 
4 h. After completion of reaction (monitored by TLC), it was quenched with NH4Cl 
 i. CuCN, LiCl, Me2Zn









0 ºC to rt, 4 h
80%, (over 2-rxn)
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(sat’d aq) and was added (Na2SO4), stirred for 30 minutes, filtered through Celite pad. 
The residue was washed with EtOAc (3x50 mL). The organic layer was dried (Na2SO4) 
and the solvent was evaporated under reduced pressure. The crude product was purified 
via flash chromatography (30% EtOAc/Hexane), which afforded TBS-protected diol 
3.8.4 (240 mg, with 80% yield over two reactions) as colorless viscous oil. 
FTIR (neat): 3458, 2943, 2866, 1718, 1699, 1456, 1390, 1097, 1027, 912, 842, 736, 697 
cm-1. 
Optical Rotation: [α]D23 = 2.1 (c 0.8, CHCl3).  
1H NMR (500 MHz, Chloroform-d): δ 7.42 – 7.29 (m, 5H), 5.84 – 5.72 (m, 1H), 5.20 – 
5.15 (m, 1H), 5.13 (ddd, J = 5.8, 1.9, 0.8 Hz, 1H), 4.55 (s, 2H), 3.99–3.94 (m, 1H), 3.75 
(ddd, J = 6.7, 5.3, 3.2 Hz, 1H), 3.65 – 3.50 (m, 2H), 3.32 (dd, J = 4.0, 1.0 Hz, 1H), 2.47 
(dd, J = 4.0, 1.0 Hz, 1H), 2.36 – 2.19 (m, 1H), 1.95 – 1.72 (m, 2H), 1.73 – 1.57 (m, 4H), 
1.04 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 140.6, 138.1, 128.4 (2), 127.8 (2), 127.7, 116.4, 73.1, 
71.9, 70.6, 69.07, 44.4, 39.5, 34.9, 26.6, 16.1. 






To a solution of 4.8.4 (240 mg, 0.86 mmol) in CH2Cl2 (8.6 mL, 0.1 M) was added 
2,6 lutidine (251 ml, 2.1 mmol). The reaction mixture was cooled to –78 ºC and was 
added dropwise TIPSOTf (254 ml, 0.9 mmol). The reaction mixture was stirred for 30 
min, after completion of reaction (monitored via TLC), it was added N,N-
disopropylethylamine (600 µL, 3.44 mmol) followed by dropwise addition of 
chloro(methoxy)methane (130 µL, 1.72 mmol) and the reaction mixture was stirred for 
12 h. After completion of reaction, it was quenched with saturated aqueous NaHCO3, 
extracted with CH2Cl2, dried (MgSO4), concentrated under reduced pressure. The crude 
product was purified using silica gel column chromatography (5% EtOAc/Hexanes), 
which furnished 394 mg of 4.9f in 95% yield over two reactions in one-pot (97.5% 
av/rxn) as colorless viscous liquid. 
FTIR (neat): 2943, 2866, 2352, 2329, 1693, 1556, 1454, 1348, 1151, 1099, 1041, 916, 
883, 732 cm-1. 
Optical Rotation: [α]D23 = -1.25 (c 1.43, CHCl3). 
1H NMR (500 MHz, Chloroform-d): δ 7.41 – 7.29 (m, 5H), 5.85 – 5.75 (m, 1H), 5.10 – 





CH2Cl2, –78 oC-rt 
95%, (2 rxns one-pot)
(97.5 % av/rxn)
 TIPSOTf, 2,6-Lutidine





Hz, 1H), 3.49 (t, J = 6.4 Hz, 2H), 3.39 (s, 3H), 2.59 – 2.48 (m, 1H), 2.20 (s, 1H), 1.83 – 
1.47 (m, 6H), 1.07 (s, 23H).  
13C NMR (126 MHz, CDCl3): δ 140.2, 138.7, 128.3 (2), 127.5 (2), 127.4, 114.9, 96.7, 
79.7, 72.7, 70.6, 69.8, 55.7, 41.3, 38.4, 34.3, 24.8, 18.3 (6), 14.2, 12.9 (3). 





To a solution of (S,S)-triene 4.9e (394 mg, 1.7 mmol) in a degased CH2Cl2 (347 
mL, 0.005 M) was added HG-II (21.2 mg, 0.034 mmol, 2 mol%) the reaction mixture 
was refluxed for 20 min. After completion of RCM reaction, CH2Cl2 was evaporated 
under reduced pressure. To the crude product was added freshly distilled, freeze-degas-
thawed 1,2-dichloroethane (DCE) (17 mL, 0.1 M), the CM partner 4.9f (975 mg, 2.04 
mmol) and HG-II (63 mg, 0.102 mmol, 6 mol%) under inert atmosphere. The reaction 
mixture was stirred at 70 ºC for 12 h, a second portion of HG-II (21 mg, 0.034 mmol, 2 
mol%) and CM partner (162 mg, 0.34 mmol) were added to the reaction mixture, was 












 HG-II (2 mol%) CH2Cl2





HG-II (10 mol%), CH2Cl2 
24 h, reflux, then
o-NBSH, TEA
DCE, rt, 72 h










CM partner (162 mg, 0.34 mmol) were added and the reaction mixture was stirred for an 
additional 8 h. After completion of CM reaction, the crude product 4.9.1 was subjected to 
chemoselective hydrogenation “H2” reaction using o-NBSH and Et3N (2 mL/1 g of o-
NBSH) at room temperature. It should be noted that for the chemoselective 
hydrogenation of external olefin of the crude CM product 4.9.1, o-NBSH (1.8 g, 8.5 
mmole) and Et3N (3.6 mL, 2 mL/1 g of o-NBSH) were sequentially added after each 8–
12 h and the reaction mixture was stirred for 72 h. Reaction progress was monitored via 
crude NMR, which confirmed the complete reduction of external double bond in the CM 
adduct 4.9.1. The reaction mixture was diluted with EtOAc (100 mL) followed by 
addition of saturated aqueous solution of NaHCO3 (50 mL). The organic layer was 
separated and aqueous phase was extracted with EtOAc (3x100 mL). The combined 
organic layers were washed with brine (50 mL), dried (Na2SO4), concentrated under 
reduced pressure, and purified with flash chromatography (40% EtOAc/Hexane), which 
furnished 362 mg of bicyclic phosphate 4.8.3 as a dark brown semi solid in 47% yield 
over three reactions in one-pot (74% av/rxn). 
FTIR (neat): 2945, 2864, 2351, 1556, 1305, 1245, 1101, 1039, 972, 773 cm-1. 
Optical Rotation: [α]D23 = -24.3.0 (c 0.63, CHCl3). 
1H NMR (500 MHz, Chloroform-d): δ 7.38 – 7.30 (m, 5H), 6.05 (dddd, J = 12.0, 6.8, 
3.2, 2.1 Hz, 1H), 5.59 (ddd, J = 11.9, 3.9, 2.5 Hz, 1H), 5.24–5.15 (m, 1H), 5.02 (dddd, J 
= 14.8, 8.5, 5.0, 2.6 Hz, 1H), 4.70 – 4.62 (m, 2H), 4.61 – 4.54 (m, 1H), 4.52 (s, 2H), 4.38 
(ddd, JHP = 27.7, JHH 14.8, 6.7 Hz, 1H), 4.02–3.96 (m, 1H), 3.65 (dt, J = 8.9, 3.0 Hz, 1H), 
3.50 (td, J = 6.2, 1.8 Hz, 2H), 3.37 (d, J = 5.4 Hz, 4H), 2.23 – 2.13 (m, 1H), 1.90 – 1.78 
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(m, 1H), 1.78 – 1.49 (m, 6H), 1.43 (ddd, J = 14.2, 8.2, 2.8 Hz, 1H), 1.28 (d, J = 3.0 Hz, 
0H), 1.24 – 1.14 (m, 1H), 1.07 (d, J = 6.0 Hz, 25H), 0.92 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 138.6, 129.8, 128.3 (2), 128.0, 127.5 (2), 127.5, 96.9, 
80.1, 72.8, 70.6, 70.1, 63.0 (d, JCP = 6.5), 62.9, 55.6, 37.8, 36.5, 34.7 (d, JCP = 4.1), 34.6, 
33.7 (d, JCP = 6.0), 27.6, 25.1, 18.3 [6C, Si (CH (CH3)2)3], 14.3, 13.0, 12.9 [3C, Si (CH 
(CH3)2)3]. 




To a stirring solution of bicyclic phosphate 4.9d (1.2 g, 1.8 mmol) in dry THF 
(6.1 mL, 0.3 M) under argon was added Cs2CO3 (2.9 g, 9 mmol) and HCO2H (2.23 mL, 
4.8 mmol). Then a solution of 5 mol % Pd(OAc)2 (29 mg, .09 mmol) and PPh3 (47 mg, 
0.18 mmol) in dry THF (1.6 mL) under argon was immediately transferred via cannula to 
the reaction mixture. The reaction mixture was stirred at 60 ºC for 1 h (monitored by 
TLC). After 1 h, the starting materials were consumed (indicated by TLC) and the color 







Pd(OAc)2, HCO2H, PPh3 
Cs2CO3, THF, 62 ºC
 1 h, then
LiAlH4, 0 ºC, 1 h, 51% 

















(Me2SO4) (525µl, 5.4 mmol) was added and the reaction mixture was refluxed for 3 h 
(TLC showed that phosphate acid was completely methylated). The reaction mixture was 
cooled to 0 ºC and LiAlH4  (205 mg, 5.4 mmol) was added portion-wise over a period of 
five minutes. The reaction mixture was stirred at 0 ºC for 1 h. After completion of 
reduction, it was quenched following the Fieser workup11 via slow sequential addition of 
H2O (1 mL/g of LiAlH4), followed by 10% aqueous NaOH (1 mL/g of LiAlH4) and 
finally H2O (3 mL/g of LiAlH4). The ice bath was removed and the reaction mixture was 
stirred for 2 h at room temperature. The reaction mixture was filtered through Celite® 
pad, the solid residue was washed with excess EtOAc and dried (Na2SO4). The resulting 
solution was concentrated under reduced pressure and purified using a short silica gel 
chromatography column (hexane/EtOAc 2:1), which afforded the 550 mg of 1,3-anti diol 
fragment 4.9.4 in 51% yield over 3 reactions in one-pot (83% av/rxn) as a colorless 
viscous liquid. 
FTIR (neat): 3417, 2931, 2864, 1699, 1556, 1454, 1359, 1207, 1095, 1093, 883, 734 cm-
1. 
Optical Rotation: [α]D23 = -1.38 (c 0.95, CHCl3). 
1H NMR (500 MHz, Chloroform-d): δ 7.39 – 7.29 (m, 5H), 5.89–5.79 (m, 1H), 5.22–
5.13 (m, 2H), 4.70–4.65 (m, 2H), 4.53 (s, 2H), 4.01 (td, J = 7.1, 3.6 Hz, 2H), 3.97–390 
(m, 1H), 3.67 (dt, J = 8.9, 3.1 Hz, 1H), 3.49 (t, J = 6.1 Hz, 2H), 3.38 (s, 3H), 2.40 – 2.22 
(m, 4H), 1.89 – 1.78 (m, 1H), 1.78 – 1.55 (m, 6H), 1.55 – 1.43 (m, 3H), 1.10–1.05 (m, 
21H), 0.93 (d, J = 6.8 Hz, 3H). 
                                                
[11]. L. F. Fieser, M. Fieser in Reagents for Organic Synthesis, Vol. 1, Wiley: New York, 1967, pp. 
581−595; b) V. M. Mićović, M. Mihailović, J. Org. Chem. 1953, 18, 1190–1200. 
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13C NMR (126 MHz, CDCl3): δ 138.8, 130.0, 128.5 (Aromatic 2 x CH), 128.2, 127.7 
(Aromatic CH x 2), 127.7, 97.1, 80.3, 73.0, 70.8, 70.2, 63.2, 63.1, 55.8, 38.0, 36.7, 35.4, 
34.9, 33.9, 27.8, 25.3, 18.5 [6xCH3, Si-(CH (CH3)2)3], 14.5, 13.2, 13.1 [3xCH, Si-(CH 
(CH3)2)3]. 




To a stirred solution of 1,3-anti diol fragment 4.9.4 (500 mg, 0.84 mmol) in dry 
THF (10.5 ML, 0.08 M) was added NaH (100 mg, 4.2 mmol), and the reaction mixture 
was stirred for 30 min at room temperature. Then, it was added p-methoxy benzyl 
bromide (675 mg, 3.36 mmol) and tetrabutylammonium iodide (30 mg, 0.08 mmol) and 
the reaction mixture was stirred at 60 ºC for 12 h. After completion of reaction 
(monitored by TLC), it was quenched with saturated aqueous solution of NaHCO3 (10 
mL), extracted with EtOAC (3x100), dried (Na2SO4), concentrated under reduced 
pressure, and purified with flash chromatography (25% EtOAc/Hexane), which afforded 
502 mg of olefin 4.9c in 71% yield as a colorless viscous liquid. 











 TBAI, THF, 5 h




Optical Rotation: [α]D23 = +19.7 (c 0.87, CHCl3). 
1H NMR (500 MHz, Chloroform-d): δ 7.30 – 7.20 (m, 5H), 7.17 – 7.11 (m, 4H), 6.81 – 
6.74 (m, 4H), 5.76 (m, 1H), 5.06 – 4.95 (m, 2H), 4.59 – 4.55 (m, 2H), 4.49 – 4.34 (m, 
4H), 4.16 (dd, J = 18.5, 11.0 Hz, 2H), 3.91 (td, J = 7.3, 3.6 Hz, 1H), 3.76 – 3.72 (m, 1H), 
3.70 (s, 6H), 3.63 (dt, J = 9.2, 4.7 Hz, 1H), 3.58 – 3.51 (m, 2H), 3.40 (td, J = 6.1, 1.6 Hz, 
2H), 3.28 (s, 3H), 2.30 – 2.21 (m, 2H), 1.77 – 1.14 (m, 12H), 1.01–0.95 (m, 23H), 0.81 
(d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 159.0 (Aromatic 2 x CH), 138.7, 134.7, 131.1, 131.0, 
129.4 (Aromatic 2 x CH), 129.3 (Aromatic 2 x CH), 128.3 (Aromatic 2 x CH), 127.5 
(Aromatic 2 x CH), 127.4, 117.2, 113.7 (Aromatic 2 x CH), 96.8, 80.6, 75.4, 74.7, 72.8, 
70.7, 70.6, 70.5, 70.0, 55.7, 55.3, 55.3, 55.2, 39.9, 38.6, 37.5, 37.0, 34.7, 32.1, 27.8, 25.0, 
18.4 [6xCH3, Si-(CH (CH3)2)3], 18.3, 14.1, 13.0 [3xCH, Si (CH (CH3)2)3]. 




hoxymethoxy)-10-methyl-3-oxo-13-((triisopropylsilyl)oxy)hexadecanoate (4.10.2):  
 
To a stirring solution of olefin 4.9c (400 mg, 0.47 mmol) in dioxane-water (3:1, 6 
mL, 0.08 M) were added 2,6-lutidine (109 µL, 0.94 mmol), OsO4 (4% in water, 3 mg, 
0.011 mmol), and NaIO4 (400 mg, 1.88 mmol). The reaction mixture was stirred at room 
temperature and monitored by TLC. After completion of reaction, water (6 mL) and 
CH2Cl2 (12 mL) were added. Both layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (3x15 mL). The combined organic layer was washed with brine 
and dried (MgSO4). The solvent was removed under reduced pressure and the crude 
aldehyde was proceeded in to the next step without any further purification. 
To a solution of crude aldehyde in CH2Cl2 (6 mL, 0.07 M) was added ethyl 
diazoacetate (121 µL, 1.175 mmol), NaHCO3 (197 mg, 2.35 mmol) and SnCl4•5H2O (65 
mg, 0.188 mmol). The reaction mixture was stirred at room temperature for 2 h. After 
completion of reaction, it was quenched with brine (10 mL). The organic layer was 
extracted with Et2O (3x30 mL). The combined organic extracts were washed with brine, 
dried (Na2SO4), and concentrated under reduced pressure. The residue was purified by 
flash chromatography using EtOAc/Hexane (5: 95) to afford β-keto ester 4.10.2 (315 mg, 
69%) as colorless oil and as a mixture of keto and enolic tautomers. 






















FTIR (neat): 2941, 2864, 1743, 1718, 1612, 1514, 1464, 1365, 1301, 1247, 1172, 1037, 
918, 883, 819, 736, 698 cm-1. 
Optical Rotation: [α]D23 = +16.3 (c 0.87, CHCl3). 
1H NMR (500 MHz, Chloroform-d): δ 7.39 – 7.28 (m, 5H), 7.26 – 7.18 (m, 4H), 6.94 – 
6.81 (m, 4H), 4.70 – 4.60 (m, 3H), 4.53 – 4.39 (m, 4H), 4.34 – 4.16 (m, 4H), 4.13 (ddd, J 
= 8.3, 4.1, 2.4 Hz, 1H), 4.02–3.94 (m, 1H), 3.82 (s, 2H), 3.78 (s, 6H), 3.67 – 3.62 (m, 
1H), 3.57 (ddd, J = 7.6, 3.1, 1.5 Hz, 1H), 3.50 – 3.46 (m, 2H), 3.43 (s, 2H), 3.36 (d, J = 
1.5 Hz, 3H), 2.85 – 2.67 (m, 2H), 1.85 – 1.32 (m, 10H), 1.27 (t, J = 7.1 Hz, 3H), 1.06 (m, 
21H), 0.90 (d, J = 6.8 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): δ 201.8, 167.3, 159.3 (Aromatic 2xCH), 138.8, 133.3, 
131.0 (Aromatic 2xCH), 129.5, 128.9, 128.5, 127.7 (Aromatic 2xCH), 114.1 (Aromatic 
2xCH), 113.9, 97.0, 80.7, 75.7, 73.0, 72.7, 71.8, 70.8, 70.4, 70.2, 65.3, 61.5, 60.2, 55.9, 
55.5, 55.5, 55.4, 50.5, 48.9, 40.5, 37.7, 37.2, 34.9, 32.2, 28.0, 25.2, 18. 6, 18.5 [6xCH3, 
Si-(CH (CH3)2)3], 14.3, 13.2 [3xCH, Si (CH (CH3)2)3]. 







To a stirring solution of TIPS-protected alcohol 4.10.2 (300 mg, 0.32 mmol) in 
dry THF (4 mL, 0.08 M) was added TBAF (184 µL, 0.64 mmol) at 0 ºC. The reaction 
mixture was stirred at 40 ºC for 12 h. After completion of reaction (monitored via TLC), 
it was quenched with NH4Cl. The organic layer was extracted with EtOAc (3x20 mL). 
The combined organic extracts were washed with brine, dried (Na2SO4), and 
concentrated under reduced pressure. The residue was purified by silica gel 
chromatography using EtOAc/Hexane (25: 75) to afford alcohol 4.9b (222 mg, 87%) as 
colorless oil. 12 
  
                                                
[12]. Structural characterization data for compound, 4.9bc and 4.9a is not provided as we have only the 






















To a stirring solution of alcohol 4.9a (50 mg, 0.065 mmol) in dry toluene (65 mL, 
0.001 M) was taken in a Dean-Stark apparatus and refluxed for 12 h with azeotropic 
removal of the EtOH as a by-product. After completion of the reaction (monitored by 
TLC), the solvent was removed under reduced pressure. The residue was purified by 
flash chromatography using EtOAc/Hexane (15:85) to afford macrolactone 4.9a (37.5 
mg, 81%) as colorless oil. 
Special Acknowledgment 
The author acknowledges that portions of this chapter, including the chemical 
procedures, spectral data are reprinted, in part, or adapted from the following publications, 
with permission from the corresponding publishers: 
(a) Javed, S.; Bodugam, M.; Ganguly, A.; Torres, J.; Hanson, P. R. Modular Synthesis of 
Novel Macrocycles Bearing α,β-Unsaturated Chemotypes via a Series of One-Pot, 
Sequential Protocols. Chem. Eur. J. 2016, 22, 6755–6758. (b) Bodugam, M.; Javed, S.; 
Ganguly, A.; Torres, J.; Hanson, P. R. A Pot-Economical Approach to the Total 
Synthesis of Sch-725674. Org. Lett. 2016, 18, 516–519. (c) Maitra, S.; Bodugam, M.; 
Javed, S. Hanson, P. R. Efficient Synthesis of the C9–C25 Subunit of Spirastrellolide B. 














































































































































en-2-yl)-9,9-diisopropyl-10-methyl-2,4,8-trioxa-9-silaundecane (4.9c):  
 
  
TIPSO
OMOM
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	 314	
(5R,7S,10R,11S,13R)-ethyl-16-(benzyloxy)-5,7-bis((4-methoxybenzyl)oxy)-11-(met-
hoxymethoxy)-10-methyl-3-oxo-13-((triisopropylsilyl)oxy)hexadecanoate (4.10.2): 
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(5R,7S,10R,11S,13R)-ethyl-16-(benzyloxy)-5,7-bis((4-methoxybenzyl)oxy)-11-(met-
hoxymethoxy)-10-methyl-3-oxo-13-((triisopropylsilyl)oxy)hexadecanoate (4.10.2): 
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